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Abstract 
 
Colorectal cancer (CRC) is the third most common cancer and the second most 
common cause of cancer related deaths in the UK. Research has shown that the five year 
survival rate for patients if diagnosed at an early stage is 83% however, only 11% of cases are 
diagnosed at this stage. The aim of this study was to use proteomic approaches to investigate 
secreted proteins from colorectal cancer cell lines to identify candidate biomarkers for early 
stage diagnosis. Microvesicles (MVs) are a mixed population of vesicles that are released by a 
wide range of cells and are thought to play a role in tumour development and progression. 
Stable Isotope Labeling of Amino Acids in Culture (SILAC) was used to investigate the 
relative abundance of proteins secreted in MVs released by two cell lines that are used as a 
model of early tumour progression. This study identified 86 potential candidates that 
demonstrated increased release and six of these proteins (AGR2, OLFM4, SBP1, HSP90α, 
HSP90β and CEACAM5) were selected for further investigation by Western blot analysis. 
These proteins show potential as markers of early stage CRC and would be suitable for further 
validation in patient serum samples. 
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Chapter 1 : Introduction 
Section 1.1 : Colorectal Cancer and Currently used Biomarkers 
1.1.1. Introduction 
Colorectal cancer (CRC) is the third most common cancer in the UK following breast 
and lung cancer with 38,608 newly diagnosed cases in 2007 (21,014 in men and 17,594 in 
women) (Cancer Research UK). In 2008, there were 16,254 deaths related to colorectal cancer 
(8,758 in men and 7,501 in women) making it the second most common cause of cancer 
related deaths in the UK (see Figure 1.1). Mortality rates increase with age with 69% of the 
total deaths due to colorectal cancer occurring in patients >70 years of age.  
Figure 1.2 outlines the commonly used Dukes’ staging which is used for colorectal 
cancer tumour staging. Dukes’ stage A is early stage cancer with the tumour present in the 
innermost lining of the colon. Dukes’ stage B is when the tumour has started to grow into the 
muscle layer. When the tumour has spread to the lymph nodes, this is known as Dukes’ stage 
C and advanced stage cancer (Dukes’ stage D) is when tumour cells have metastasized to 
distant organs such as the liver. The survival rate is dependent upon the stage of CRC at 
diagnosis with the 5 year survival rate being 83, 64, 38 and 3% for Dukes stage A, B, C and D 
respectively. If diagnosed early (Dukes stage A) the prognosis looks promising however, very 
few cases are diagnosed at an early stage with only 11% of cases diagnosed in 2006 at this 
stage (Figure 1.2e). Studies have shown that detection of CRC at an earlier stage via mass 
screening and intervention can reduce the risk of death from CRC, highlighting the need for 
biomarkers for early stage diagnosis (Hardcastle et al., 1996, Kronborg et al., 1996). 
The symptoms of CRC include rectal bleeding and blood in stools, persistent diarrhea, 
the presence of a lump in the right side of the abdomen or rectum, weight loss, anaemia 
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(b) 
 
UK mortality 2008: The 20 most common causes of death from cancer 
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(c)  
 
UK incidence 2007: the 20 most commonly diagnosed cancers in persons 
 
 
Figure 1. 1 : Cancer Research UK Colorectal Cancer Statistics. 
(a) Number of deaths and age-specific mortality rates, colorectal cancer, by sex, UK, 2006; 
(b) The 20 most common causes of death from cancer in 2008; (c) The incidence of the 20 
most common cancers in the UK in 2007. Statistics taken from the Cancer Research UK 
website http://info.cancerresearchuk.org/cancerstats. 
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(e) 
Dukes’ 
Stage 
UIJCC / 
AJCC Description  # 
Approximate 
frequency at 
diagnosis * 
Appromimate 
5 year 
survival * 
A I 
Tumours invading 
submucosa or muscularis 
propria 
11% 83% 
B II 
Tumours invading 
through muscularis 
propria 
35% 64% 
C III Invasion of tumour  to lymph nodes 26% 38% 
D IV Metastasis to distant sites 29% 3% 
  
Figure 1. 2 : Dukes’ Staging of CRC. 
Figure to show tumour staging according to the Dukes’ system. The stages can also be 
referred to as stage I-IV according to the UICC / AJCC system (UICC – International Union 
Against Cancer, AJCC – American Joint Committee on Cancer). (a) Dukes’ Stage A or Stage 
I – tumour is located in the innermost lining of the colon or rectum only or may have just 
started to grow in the muscle layer. (b) Dukes’ Stage B or Stage II – the tumour has started to 
grow in to the muscle layer of the colon. (c) Dukes’ Stage C or Stage III – tumour cells have 
spread to at least one lymph node in close proximity to the colon. (d) Dukes’ Stage D or Stage 
IV – tumour cells have metastasised to distant organs such as the liver. (e) Table to summarise 
the stages of CRC, the approximate frequency and 5 year relative survival rate if diagnosed at 
each stage. * - taken from http://info.cancerresearchuk.org/cancerstats Diagrams a-d taken 
from http://www.cancerhelp.org.uk/type/bowel-cancer/treatment/dukes-stages-ofbowelcancer.  
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causing tiredness and breathlessness and pains in the abdomen caused by a bowel obstruction 
leading to constipation and vomiting (Cancer Research UK). The risk factors associated with 
CRC include age, obesity, lack of exercise, diet (low in fibre, fruit, vegetables, folate and high 
in red or processed meat), smoking, high alcohol consumption and genetic predisposition 
(Cancer Research UK). 
CRC results from the cumulative effects of sequential genetic alterations in 
oncogenes, tumour suppressor genes and DNA repair genes. In sporadic CRC, these 
alterations are acquired after exposure to exogenous and endogenous carcinogens. In certain 
conditions such as Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis 
Colon Cancer (HNPCC) genetic alterations can lead to a predisposition to malignancy.  
1.1.2. Currently used Biomarkers for Colorectal Cancer 
Biomarker is a term often referring to an indicator of a biological state i.e. biological 
process, pathogenic process or pharmacological response to therapeutic intervention. A 
biomarker for early detection for CRC would require high sensitivity and specificity therefore 
producing a low number of false positives to prevent subjecting patients to unnecessary 
colonoscopies. Other useful biomarkers that could reduce the mortality rate of CRC include 
prognostic markers to predict the outcome of patient’s survival and markers to predict 
response to drugs or treatment. As well as other research approaches, genomic and proteomic 
advances have contributed to our understanding of pathways that control growth, 
differentiation and death of cells. DNA microarray analysis and proteomic methods such as 
2DE and mass spectrometry-based methods are commonly used to evaluate the expression 
profiles of genes and proteins in cells, tissues and body fluids (Faca et al., 2007, S. Y. Kim 
and Hahn, 2007). Biomarker discovery will be further discussed in Section 1.4. 
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1.1.2.1. Faecal Markers 
Faecal Occult Blood Test (FOBT) is the least expensive and invasive screening 
method for CRC and detects faecal haemoglobin enzymatically or immunologically. 
Enzymatic FOBT (the guaiac test) measures the peroxidase-like activity of haemoglobin that 
originates from any source (i.e. both colorectal and upper gastrointestinal bleeding). 
Immunological FOBT uses antibodies to detect the globin moiety in haemoglobin. FOBT 
screening has been shown to reduce the incidence of advanced stage CRC and related 
mortality by 20% and 16% respectively (C. S. Huang et al., 2005a) and has been 
recommended as a screening test for early stage CRC in patients >50 yrs old alongside 
flexible sigmoidoscopy, colonoscopy and double contrast barium enema (Duffy et al., 2003). 
The advantages of FOBT screening include: ability to examine the entire colorectal 
tract, non-invasive, inexpensive, requires no patient preparation and sample collection can be 
carried out in the privacy of the patient’s home. However, the FOBT test does have its 
limitations demonstrating low sensitivity and specificity for both adenomas and carcinomas. 
Also, the ingestion of certain foods (red meats, fruits and vegetables) and certain medication 
(non-steroidal anti-inflammatory drugs) can yield false-positive results with the guaiac-based 
assay (limits don’t apply to the immunochemical FOBT assay). The test also relies on 
multiple stool samples analysed annually to increase chances of detecting intermittent 
bleeding. 
Various genes and epigenetic markers can also be used as markers of CRC in patients 
stool samples. Colonocytes (colon cells) that are shed into the faecal stream can provide 
material for the detection of genes and epigenetic markers in faeces. They are shed 
continuously but occur more frequently in CRC compared to normal colon. Faecal 
colonocytes are assessed by analysing DNA mutations in target genes such as K-ras, p53 and 
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APC by analysing epigenetic markers such as microsatelite instability (MSI) or by measuring 
un-fragmented long form DNA (L-DNA). 
After a review of the literature, Haug and Brenner showed that DNA marker panels 
detected CRC with a specificity of >95% and a sensitivity 60-90% (Haug and Brenner, 2005). 
In comparison with FOBT, DNA marker panels identified more cases of invasive CRCs and 
neither test detected the majority of neoplastic lesions but the DNA panel showed a higher 
sensitivity than FOBT without reducing specificity (Albaugh et al., 1992). However, faecal 
DNA markers exhibit a low sensitivity in asymptomatic patients and the assay is relatively 
expensive and complex, so it is unlikely to replace FOBT for general screening. 
1.1.2.2. Serum or Blood Markers 
1.1.2.2.1. CEA 
Carcinoembryonic antigen (CEA) was first described by Gold and Freeman as an 
antigen detected in both foetal colon and colon adenocarcinoma and appeared to be absent in 
healthy adult colon (Gold and Freedman, 1965a). It was later shown to be present in certain 
healthy tissues but was 60-fold higher in tumours compared with non-malignant tissue (Gold 
and Freedman, 1965b). Thomson et al then described increased concentrations of CEA in the 
serum of  35 out of 36 patients with CRC (Thomson et al., 1969). High levels of CEA were 
not found in ‘normal’ patients, pregnant women, patients with non-gastrointestinal cancers or 
patients with miscellaneous benign gastrointestinal diseases. These results were not confirmed 
in other studies but nevertheless prompted the widespread use of CEA as a marker of CRC. 
CEA can be detected in biopsies but is usually measured in serum. A high CEA level 
is associated with cancer progression and levels are expected to fall following surgery (Duffy, 
2001). However in the absence of cancer, high levels of CEA can be observed in other 
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conditions such as hepatitis, inflammatory bowel disease, pancreatitis and obstructive 
pulmonary disease. Other factors that affect CEA levels include: 
Tumour Stage. One study investigated the reoccurrence rates in 348 CRC patients and 
demonstrated that the proportion of these patients with an elevated CEA (>2.5µg/L) were 
28%, 45%, 75% and 84% for Dukes’ stage A, B, C and D respectively. These values are 
greatly reduced when the cut-off is increased to >5µg/L with 3, 25, 45 and 65% for Dukes’ 
stage A, B, C and D respectively (Wanebo et al., 1978). 
Tumour Grade. Serum concentrations of CEA tend to be higher in patients with well 
differentiated tumour compared to those with poorly differentiated tumours (Goslin et al., 
1981).  
Liver Status. Liver is the primary site for the degradation/removal of CEA and benign 
liver diseases impair liver function and thus the clearance of CEA. Therefore CEA can be 
increased in patients’ serum with non-malignant liver disease (Begent, 1984, Thomas et al., 
1990). 
Tumour Site within Colon. Patients with tumours on the left side of the colon tend to 
have higher CEA levels than those on the right (Slater et al., 1979, Wanebo et al., 1978). 
Presence or Absence of Bowel Obstruction. Bowel obstruction can lead to increased 
CEA levels in patients with colorectal malignancy (Sugarbaker and Wilson, 1976). 
Smoking. Smoking appears to double the serum levels of CEA (Rognum, 1986). 
 
CEA doesn’t provide sufficient sensitivity and reliability for the detection of early 
stage cancer. Using a cut-off of 2.5ng/ml, it has been reported that CEA can detect early stage 
CRC (Dukes’ A, B) with a low sensitivity of 30-40% and a specificity of 87% (Duffy et al., 
2003). Therefore, the NIH does not recommend CEA is used in screening programmes for the 
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detection early stage of CRC. Instead, the potential value of the CEA test is as a prognostic 
marker once CRC has been diagnosed (with higher levels of CEA being indicative of greater 
disease severity and poor prognosis) (Cancer Research UK). 
CEA is mainly used to monitor patients following curative resection for primary 
cancer (Duffy et al., 2003). Studies have shown that intensive follow up including regular 
serum CEA determinations results in a modest but statistically significant improvement in 
outcome compared with a minimal follow up strategy. Using CEA during follow-up is 
relatively inexpensive compared to other follow up strategies such as radiology and 
endoscopy and also causes minimal inconvenience for the patients. 
CEA can also be used for the early detection of metastatic disease in candidate 
patients for liver resection (Duffy et al., 2003). Liver metastasis usually occurs within 5 years 
of initial diagnosis but curative resection is only suitable in ~25% of cases. In these patients, 
serum CEA should be determined every 2-3 months for at least the first 3 years after 
diagnosis. Two studies have demonstrated that serial CEA determination is useful in detecting 
liver metastasis and an increased CEA could detect liver metastases with a sensitivity of 94% 
and 100% and a specificity of 96% (Arnaud et al., 1980, Pietra et al., 1998). 
CEA can also be used to monitor patient’s response to chemotherapy. Patients who 
exhibit a decrease in serum CEA whilst on chemotherapy have been shown to exhibit an 
improved survival rate compared to those whose CEA levels failed to decrease ((no-authors-
listed), 1996, Begent, 1984, Sugarbaker and Wilson, 1976). An increase in CEA in patients 
receiving chemotherapy predicts progressive disease. 
1.1.2.2.2. CA19-9 
Glycoprotein CA19-9 is the second most investigated gastrointestinal tumour marker 
and is the best marker available for diagnosing pancreatic adenocarcinoma however, it 
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demonstrates a lower sensitivity than CEA for CRC and is also less useful for monitoring 
patients once diagnosis has been made (Duffy, 1998). Other glycosylated proteins have been 
studied including CA 50, CA195, CA 242, CA M26, CA M25, CA M43 and CA 72-4 but 
have been shown to not be useful detection markers for CRC (Hundt et al., 2007). 
1.1.2.3. Tissue-Based Markers for CRC 
Thymidylate Synthase (TS) is involved in the conversion of 
deoxyuridinemonophosphate (dUMP) to deoxythymidine monophosphate (dTMP). It 
provides a source of thymidylate for DNA synthesis and has been investigated as a prognostic 
and therapy predictive marker of CRC. Protein levels of the TS enzyme is the target of many 
currently used chemotherapeutic agents such as 5-fluorauracil (5-FU). Only 20% of patients 
respond to 5-FU and a predictive marker that could indicate whether a patient is likely to 
respond preventing patients suffering from unnecessary side effects. Several studies have 
investigated the levels of TS in patients being treated with 5-FU, although the results of theses 
appear to be conflicting (Edler et al., 2002, Prall et al., 2007, Soong et al., 2008). Therefore, 
TS is not currently recommended for routine prognosis determination or predicting response 
to therapy. 
1.1.2.4. Other Potential Protein Biomarkers for CRC 
There are many proteins identified using a variety of mass spectrometry and antibody-
based proteomic studies that have been reported as potential markers for colorectal cancer. In 
many of these studies, the candidate biomarkers are compared to CEA and although it is not 
an ideal marker it is the most commonly used biomarker for CRC (see Section 1.1.2.2.1). 
Table 1.1 shows a few examples other protein biomarkers for CRC. 
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Protein Investigation Ref
TIMP-1 Blood marker shown to be higher in patients with colon and rectal cancers. 1, 2
Five serum marker
panel
Five proteins (Spondin-2, DcR3, Trail-R2, RegIV, MIC 1) 
shown to be elevated in CRC patients compared to normal 
controls and benign tumours. 3
NNMT and PSME2
Shown to be elevated in CRC tissue samples compared to 
matched normal tissue. Validated in serum of CRC patients. 4, 5
CRMP2
Elevated in CRC patient sera compared to normal controls. 
CRMP-2 alone showed increased sensitivity (61%) but decreased 
specificity (65%) compared to CEA (sensitivity 4% and 87% 
specificity if used alone). When used in conjunction with CEA, 
CRMP-2 showed 6
Six SELDI peak
panel
six peaks corresponding to four proteins, apolipoprotein C1, 
complement C3a-desArg, a1-antitrypsin and transferrin. Used to 
classify CRC patients with 95% sensitivity and 91% specificity 
compared to CEA alone (54% sensitivity and 93% specificity). 7
a-Defensins 1,2 and
3 (HNP-1, HNP-2
and HNP-3 
Two separate SELDI-TOF studies identified these proteins to be 
elevated in CRC pateint sera compared to normal controls.  
HNP1-3 showed a sensitivity of 69% and a specificity of 100% 
in one of these small studies. 8, 9
MIF
Significantly increased in sera from CRC patients. Demonstrated 
increased sensitivy for early stage CRC compared to CEA 
(47.3% and 29.5% respectively). 10
Prolactin
Could be used to distinguish CRC from normal healthy controls 
with a sensitivity of 77% and a specificity of 89%. 11  
Table 1. 1: Other Potential Protein Biomarkers for CRC. 
Table to show a few examples of other potential protein biomarkers for CRC reported in the 
literature. References: 1 - (Holten-Andersen et al., 1999), 2 - (Sorensen et al., 2008), 3 - 
(diaDexus-Inc., 2007), 4 - (Roessler et al., 2006), 5 - (Roessler et al., 2005), 6 - (C. C. Wu et 
al., 2008), 7 - (Ward et al., 2006c), 8 - (Habermann et al., 2006), 9 - (Melle et al., 2005), 10 - 
(H. Lee et al., 2008), 11 - (Soroush et al., 2004). 
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Section 1.2 : Mass Spectrometry-based Proteomics 
1.2.1. Introduction 
Proteomics is the study of peptides and proteins within a biological system i.e. the 
proteome. Traditionally, Edman degradation has been used to sequence proteins by 
chemically cleaving amino acids one at a time from the amino terminus (Edman, 1949). The 
technique is not always completely successful and requires a high level of expertise (Steen 
and Mann, 2004). More recently, advances in mass spectrometry (MS) has allowed the 
development of methods which are more sensitive and are not hindered by modifications or 
by a blocked N-terminus, as is the case with Edman degradation. MS-based proteomics is 
now the most commonly used technology for identifying proteins in a single spot or gel band 
slice from a simple experiment and is increasingly being used to identify as many proteins in 
a single experiment as possible. This is known as shotgun proteomics. 
In order to identify proteins, they can be enzymatically cleaved using proteases and 
the resulting peptides are analysed by MS. Figure 1.3 outlines the general workflow of a 
typical shotgun proteomics experiment. Proteins are commonly digested using trypsin which 
cleaves proteins at the C-terminal side of arginine and lysine residues. Other proteases used 
include Lys-C and Glu-C which cleave at the C-terminus of lysine and glutamate residues 
respectively and Asp-N which cleaves at the N-terminus of aspartate residues. Digesting 
proteins to produce peptides overcomes problems that protein analysis presents such as 
solubility and instability under the conditions required for MS. However, sequence coverage 
is sacrificed and is not sufficient for complete protein characterisation but can be sufficient for 
unambiguous protein identification. 
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Figure 1. 3 : Tandem MS/MS based shotgun proteomics. 
Diagram to show the typical workflow of a tandem MS/MS based proteomics study. Proteins 
are extracted from cell lines, tissues or body fluids and are then fractionated using various 
methods e.g. 1D or 2D gel electrophoresis. The proteins are digested in-gel or in solution with 
a proteolytic enzyme (typically trypsin). These peptides are then analysed by LC MS/MS to 
generate hundreds or thousands of spectra. This is then followed by the data analysis 
involving database searching and statistical approaches. 
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Typically, the peptides generated from a protein digest are not directly injected into a 
mass spectrometer but are first loaded onto a high-performance liquid chromatography 
(HPLC) column. Often, these columns contain a reversed-phase stationary phase that resolves 
peptides based on hydrophobicity and can be coupled directly or indirectly to the mass 
spectrometer. Peptides are eluted from the column using an increasing organic solvent 
gradient with hydrophilic peptides eluting at the start of the gradient.  
HPLC columns provide one dimension of separation which may not be sufficient for 
some complex samples and an additional level of separation prior to analysis may be required. 
Protein fractionation can be achieved by one or two dimensional (1D or 2D) gel 
electrophoresis followed by in-gel digestion of protein bands or spots. This also has the added 
advantage of providing additional information about the mass of the protein that the digested 
peptides originated from adding confidence that the correct protein assignment has been made 
by a database search (see Section 1.3). 
Multidimensional Protein Identification Technology (MudPIT) allows the separation 
of peptides by charge and relative hydrophobicity using strong cation exchange (SCX) and 
reverse phase (RP) liquid chromatography coupled to MS (Liu et al., 2002a). This has been 
shown to identify thousands of peptides in a sample, enhances the protein coverage and 
allows the identification of low-abundance and membrane proteins that are often difficult to 
detect using gel based methods (Kislinger et al., 2005). MudPIT has been utilised in cancer 
secretomics (Mbeunkui et al., 2006, Sardana et al., 2007) and to investigate the low molecular 
weight (LMW) proteome (Hu et al., 2006). The study of the LMW proteome has identified 
cytokines, chemokines, peptide hormones and proteolytic fragments of larger proteins and is 
often referred to as peptidomics. Petricoin et al have demonstrated that these protein 
fragments or peptides can be detected using accurate instruments such as the Orbitrap mass 
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spectrometers with or without trypsin digestion (Petricoin et al., 2004). BRCA2, a cancer-
related low abundant protein, is found in the serum as fragments bound to albumin 
highlighting the importance of the LMW proteome in biomarker discovery (Lowenthal et al., 
2005). 
1.2.2. Tandem Mass Spectrometry 
Mass spectrometers produce mass spectra that plots mass-to-charge (m/z) ratio on the 
X-axis against relative abundance on the Y-axis regardless of the instrument type or ionisation 
mode (Rifai et al., 2006). Proteins are enzymatically digested to generate peptides and the 
sequence of these peptides can be determined using tandem mass spectrometry (MS/MS) and 
the appropriate database search algorithm. Parent ions are fragmented by collision with a gas 
(such as nitrogen or helium) to produce daughter fragment ions. The masses and abundances 
of these product ions are recorded and used to search against in silico theoretical digests of 
proteins in a database of known protein sequences. The identified peptides are then assigned 
various correlation and scoring factors based upon how close the obtained spectra matches the 
theoretical spectra. 
For ion trap instruments (see section 1.2.3 for description of types of instruments), 
tryptic peptides are often doubly charged and designated (M + 2H)2+ therefore a peptide with 
a mass of 1232.55 would generate a peak at 617.28 (1232.55 + (2 x 1.0073))/2). Higher 
charge states are seen in peptides with more than 15 amino acids. The charge state can be 
calculated from the isotope cluster of peaks that can be found with each signal. These peaks 
are separated by 1.0073 and are caused by 12C atoms being replaced with a 13C isotope atom 
which occurs at a ~1% probability rate. Therefore a peak with a mass of 617.28 with an 
isotope peak at 618.28 must have a charge of 1 (Steen and Mann, 2004). Evaluating the 
isotope peaks can indicate the resolution of the mass spectrometer. Ion trap instruments are 
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unable to efficiently separate the isotope peaks of doubly charged species however, the 
FTICR-MS demonstrates the highest resolution for separating isotopic peaks. 
1.2.2.1. Fragmentation Methods 
In order to identify peptides, their ions need to be fragmented by the mass 
spectrometer to acquire MS/MS spectra that can be searched against a database using a search 
algorithm. This can be achieved by isolating the desired ions (precursor or parent ion) and 
fragmenting them further by collision with an inert gas such as nitrogen, argon or helium to 
generate the product or daughter ions. This is known as collision-induced dissociation (CID). 
The masses of these ions are determined and the fragmentation pattern (the MS/MS spectra) is 
used to determine the amino acid sequence. Other precursor fragmentation methods include: 
Electron-Capture Dissociation (ECD) which involves gas phase ions being fragmented by 
introduction of low energy electrons and is commonly used in fourier transform-ion cyclotron 
resonance instruments (FT-ICR) instruments only; and Electron-Transfer Dissociation (ETD) 
which induces fragmentation of cations (e.g. peptides or proteins) by the transfer of electrons. 
ETD involves protonated peptides being fragmented by electron transfer from a radical anion 
(such as fluoranthene) to cleave N-C bonds of the peptide backbone to produce c- and z- type 
ions. ETD allows the analysis of larger peptides and post translational modifications (PTMs) 
and can be used in ion trap instruments. 
‘Bottom-up’ proteomics describes the process of digesting proteins and analysing the 
peptide mixture by MS. The studies carried out in this thesis used CID to fragment the peptide 
ions by cleavage of the backbone amide bonds to produce b- and y- type ions. The precursor 
ions are fragmented at the amide bonds between amino acids and the product ions that retain 
the charge at the N-terminus are called b-ions and those that retain the charge at the C-
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terminus are known as y-ions (Figure 1.4). This fragmentation method was traditionally used 
for smaller molecules but is now used for larger intact molecules. 
‘Top-Down’ proteomics refers to identifying proteins by ionising the large intact 
molecule rather than the smaller fragments generated from a proteolytic digest. Each of these 
fragments differ by the mass of one amino acid and the observed mass differences can be used 
to predict the amino acid sequence. This is often complicated by incomplete MS/MS 
fragmentation patterns and accurate data analysis is dependant on the quality of the spectra as 
well as the mass accuracy and resolution of the instrument used. The obtained MS/MS spectra 
may not be complete but may be sufficient to accurately match the fragmentation pattern with 
a theoretical pattern in a database. This is carried out using an algorithm to search databases 
for the closest match for example Sequest and Mascot (Eng, 1994, Perkins et al., 1999). See 
Section 1.3 for description of data analysis methods for shotgun proteomics. 
1.2.3. Quantitative Proteomics 
Many studies require quantification of peptides and proteins as well as their 
identification. For quantitative proteomics, relative abundances of proteins can be studied 
using labeling methods such as stable isotope labeling by amino acids in culture (SILAC), 
isotope-coded protein labels (ICAT) and isobaric tags for relative and absolute quantization 
(iTRAQ) or label free methods such as absolute quantification (AQUA) and multiple reaction 
monitoring (MRM). Peak intensity is affected by experimental factors (such as incomplete 
protein digestion and peptide solubility) and mass spectrometry specific factors (such as 
ionisation efficiency and ion suppression). These factors are all reproducible so the peak 
height of the corresponding peaks of the light and heavy peptides can be used to determine 
relative abundance of proteins between two samples. 
 
Chapter 1  Introduction 
36 
 
 
 
 
 
 
Figure 1. 4: Ion Fragmentation of Peptides. 
Diagram to show the nomenclature of the fragmentation of amide bonds between amino acids 
known as the Roepstorff-Fohlman-Bieman nomenclature exhibited using CID (Biemann, 
1988, Roepstorff and Fohlman, 1984). (R1, R2, R3 and R4 represent the amino acid R 
groups). 
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1.2.3.1. Stable Isotope Labeling of Amino Acids in Culture (SILAC) 
SILAC is a relative quantification method used for the proteomic analysis of cell lines 
to investigate the expression levels of proteins between two or more samples. Figure 1.5 
outlines the basic workflow of a proteomic experiment using SILAC. 
 The technique was first described by Oda et al in 1999 for labeling simple salts and 
modified for labeling of amino acids by Chen et al in 2000 (Chen et al., 2000, Oda et al., 
1999). The method was then adapted to analyse complex protein mixtures by Ong et al in 
2002 (Ong et al., 2002). Two cell lines are cultured in media depleted of arginine or lysine 
which is then supplemented with ‘heavy’ or ‘light’ isotopically labeled amino acids (e.g [13C6] 
or [12C6]  labeled lysine or arginine) and dialysed foetal bovine serum (FBS) to ensure there is 
no contamination from free amino acids or peptides. They are cultured for a minimum of six 
population doublings to ensure >98% labeling efficiency.  
Samples are harvested from both cell lines (cell lysates, conditioned media or 
subcellular fractions) and mixed in a 1:1 ratio at a very early stage of the experiment such that 
both samples are treated identically in subsequent steps ensuring that the abundance ratios are 
maintained throughout and are not affected by experimental errors. The sample is then 
prepared for MS/MS analysis. 
Stable isotope labeling using SILAC offers several advantages (Ong et al., 2002): 
• Does not require any changes to routine tissue culture methods already used in 
the laboratory. 
• Does not require peptide labeling steps or protein purification steps after 
harvesting the proteins. This is important when your starting material for the 
cell models is limited. The number of manipulations are minimised to reduce 
loss of sample. 
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Figure 1. 5 : Stable Isotope Labeling by Amino acids in Culture (SILAC) 
Diagram to demonstrate the experimental overview of using SILAC for relative quantification 
of proteins in cell based models as first described by Ong et al in 2002 (Ong et al., 2002). 
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• The labeling strategy is universal throughout the protein sequence therefore 
several peptides can be used to calculate the relative abundance. 
• Allows the quantification of most proteins as the method does not rely on 
labeling of single residues that occur infrequently as other previously reported 
labeling strategies. Arg and Lys residues should be present in all peptides 
resulting from a trypsin digest except the C-terminal peptide (unless it contains 
an Arg or Lys residue).  
1.2.3.2. 18O labeling 
18O labeling was developed for use in comparative shotgun proteomic strategies by 
Yao et al (Yao et al., 2001). Most shotgun strategies involve digesting proteins to generate 
peptides and 18O labeling combines both the digestion and labeling steps. It involves digesting 
two sample pools in parallel; one digested using H216O (light) and the other with H218O 
(heavy). Two heavy oxygen molecules are incorporated into the C-terminus of each peptide 
generated resulting in a mass difference of four. These two pools are mixed in a 1:1 ratio and 
analysed by mass spectrometry. As the peptides are labeled at the C-terminus, the y-ions in 
the MS/MS spectrum appear as labeled or unlabeled doublets with the b-ions remaining 
unlabeled. The 18O labeling strategy has also been used in a post-digestion protocol  
(Bantscheff et al., 2004). 
Due to the small mass differences observed between the heavy and light labeled 
peptides in 18O labeling, this strategy was originally thought only to be possible using high 
resolution and high mass accuracy instruments such as FTICR-MS. However, this labeling 
strategy has been shown to be possible using low resolution instruments such as ion traps 
(Heller, 2003). 
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18O labeling is simple and does not rely on the presence of specific amino acids as is 
the case with other labeling techniques however, it cannot be used to compare more than two 
samples and incomplete labeling can occur (Ye et al., 2009). 
1.2.3.3. Isotope-Coded Affinity Tag (ICAT) 
The ICAT reagent consists of an iodoacetamide residue, a linker region containing the 
heavy or light label and a biotin residue to allow enrichment of the labeled peptides using 
affinity chromatography (Figure 1.6a). Samples are incubated with either the ‘light’ or 
‘heavy’ label which binds to the thiol groups of cysteine resides via the iodoaceatmide region 
of the ICAT molecule. The samples can then be mixed and digested followed by enrichment 
of the cysteine-containing peptides using affinity chromatography by binding of the biotin 
label to avidin coated stationary phase.  
Originally the linker was tagged with H or D2 (Figure 1.6a) however, the D2 labeling 
affected the hydrophobicity causing the heavy labeled peptide to elute later. More recently, an 
ICAT reagent with a cleavable biotin molecule has been utilised that uses a [12C] and [13C] 
labeled linker (Figure 1.6b) (Qu et al., 2006). The ‘light’ and ‘heavy’ peptides are then 
analysed by LC-MS/MS to determine the relative abundance of the peptides using the 
intensities or the area under the respective peaks. ICAT demonstrates high specificity and 
sensitivity and is applicable to samples of all origins such as cells, tissues and fluids. ICAT 
labeling also decreases sample complexity and simplifying data interpretation but does not 
allow the comparison of proteins that do not contain cysteine residues. Also, data analysis 
requires high quality spectra with high search scores as often only a single cysteine-containing 
peptide for each protein is isolated. However, the absolute requirement for a cysteine residue 
in the peptide sequence does permit greater stringency in the database search. 
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Figure 1. 6 : Examples of Chemical Tags used for Quantitative Proteomics 
(a) The structure of the Isotope-Coded Affinity Tag (ICAT) Diagram taken (Kraj, 2008). (b) 
The structure of cleavable ICAT (cICAT). Diagram taken (Qu et al., 2006). (c) Isobaric Tags 
for Relative and Absolute Quantification (iTRAQ). Diagram taken (Kraj, 2008). 
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1.2.3.4. Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 
iTRAQ is a method that uses tags of the same molecular weight (isobaric) that 
produce different ions during fragmentation. It allows the simultaneous comparison of four or 
eight samples and consists of a reporter group, a balance group and a peptide reactive group. 
The masses of the reporter groups differ but with the addition of the balance group keeps the 
total mass of the tag constant (Figure 1.6c). The differences between the tags are seen after 
fragmentation of the labeled peptides during MS/MS with characteristic peaks at 114, 115, 
116, and 117 m/z from the reporter groups. The peak intensity of these ions is used to 
determine the relative abundance of the proteins in the samples. 
iTRAQ is not suitable for ion-trap analysers as they have a lower mass exclusion limit 
during fragmentation which excludes the characteristic peaks being present in the spectrum.  
1.2.3.5. Absolute quantification (AQUA) and Multiple Reaction Monitoring (MRM) 
AQUA can be achieved using an internal standard of a known quantity of a stable 
isotope-labeled standard proteotypic peptide allowing a comparison of the mass spectrometric 
signals of standard labeled peptide and corresponding endogenous peptide in a digest. This 
method utilises multiple reaction monitoring/stable isotope dilution MS (MRM/SID-MS) 
using triple quadrapole mass spectrometers which monitors for a specific intact peptide and its 
various fragments based on retention times, peptide mass and fragment masses to eliminate 
ambiguities in peptide identification and quantification. Coupling the MRM method with 
protein enrichment by immunodepletion or peptide enrichment by antibody capture may allow 
the measurement of plasma/serum proteins in a high throughput manner for biomarker 
validation (Bantscheff et al., 2007, Z. Hu, Hood, L. and Tian, Q., 2007).  
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MRM is a high throughput method that offers greater sensitivity and accuracy than 
methods used in the discovery phase and has the potential to target 30-100 candidate markers 
within the same assay (Rifai et al., 2006). When the appropriate standards are used, MRM can 
provide absolute quantification as well as relative quantification and demonstrates a high 
specificity for the sample. A fragment of interest is isolated in the first quadrapole and 
fragmented by collision with a neutral gas in a collision cell (the second quadrapole) and the 
mass of the resulting product ion is analysed in the third quadrapole. Multiple ion-product 
transitions can be monitored in a single assay when coupled to a liquid chromatographic 
elution method. 
SID-MS can increase the reliability of the quantification by comparing the signal from 
an endogenous species with a known concentration of an exogenous stable isotope species. 
This method has been successfully used to measure human growth hormone and prostate 
specific antigen in serum or plasma (Barnidge et al., 2004, S. L. Wu et al., 2002) and also 
been used to quantify the levels of 53 high-abundance proteins in plasma (L. Anderson and 
Hunter, 2006). To detect lower abundance proteins, depletion of the high abundance proteins 
is required. For those proteins that are at too low a level to detect by MRM, stable isotope 
standards and capture by anti-peptide antibodies (SISCAPA) can also be used to capture 
isotopically labeled  and unlabeled target peptides to improve sensitivity and specificity (N. L. 
Anderson et al., 2004). Labeled and unlabeled peptides both bind to the antibodies therefore 
quantification is still possible. 
1.2.4. Mass Spectrometers 
Two of the main components of a mass spectrometer are the ionisation source and the 
mass analyser. 
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1.2.4.1. Ionisation Sources 
Within the ionisation source, the sample is ionised and desorbed into the gas phase 
using various techniques. Ionisation is the conversion of a molecule to an ion by the addition 
of or the removal of electrons to become positively or negatively charged. Desorption is the 
process of releasing ions from liquid phase to gas phase. 
Some ionisation techniques can cause extensive fragmentation to produce fragment 
ions (ions derived from the fragmentation of a parent ion) and others are softer and only 
produce molecular ions (ions derived from a neutral molecule by loss or gain of an electron). 
Two common ionisation methods used in proteomics are electrospray ionisation (ESI) (Fenn, 
1988) and matrix-assisted laser desorption ionisation (MALDI) (Karas, 1987). Though they 
can both be used to analyse large proteins, they have been mainly used for peptide analysis 
from proteolytic digests of proteins. The ability to directly link the mass spectrometer with a 
separation method such as HPLC has allowed the development of high-throughput methods 
for the analysis of biological molecules. 
For liquid phase ion sources, such as electrospray ionisation (ESI) and atmospheric 
pressure chemical ionisation (APCI), the sample is in solution and is sprayed as droplets in to 
the mass spectrometer. For solid state ion sources, such as matrix-assisted laser desorption 
laser ionisation (MALDI) the sample is incorporated into a solid or viscous fluid matrix which 
is then irradiated by energetic particles that desorbs the ions close to the surface of the matrix. 
An electric field is then applied to extract the ions and focus them towards a mass analyzer.  
1.2.4.1.1. Electrospray Ionisation (ESI) 
ESI works by applying a strong electric field in a vacuum to a liquid passing through a 
capillary tube. This induces an accumulation of charged ions at the liquid surface at the end of 
the capillary tube which in turn causes the formation of highly charged droplets. When a 
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liquid passes through a thin capillary to which a voltage is applied, a cloud of small droplets 
(or a spray) is formed. The liquid leaves the capillary in a cone shape (known as a Taylor 
cone) and charged ions accumulate on the surface of the droplets.  
 These ions can be negatively or positively charged but in the case of peptides and 
proteins, these ions typically carry a positive charge due to additives such as formic acid 
which are added to the solvents to act as proton donors. The sample is then desorped of any 
solute before entering the mass analyser. Desorption occurs either by passing the sample 
through a heated capillary or through a curtain of drying gas (such as nitrogen) to evaporate 
the solvent from the sample (also known as desolvation). This process occurs under 
atmospheric pressure however, the mass analyser is maintained under a vacuum. It is this 
pressure differential that draws the ions into the mass analyser. The ions are then separated 
according to their mass by a mass analyser (Figure 1.7a). 
ESI is particularly suited to the study of large biological molecules (such as proteins) 
due to its ability to produce multiply charged species. The number of charges on a molecule is 
dependant on factors such as size and the number of basic residues present. Peptides 
commonly carry a single (+1), double (+2) or triple (+3) charge. As trypsin is the most 
common protease used to digest proteins in proteomic studies, peptides are typically +1 and 
+2 charged due to the presence of basic Arg or Lys residues at the C-terminus. 
Typically in an ion source, only 1% of the introduced sample is ionised. This is mainly 
influenced by the initial diameter of the droplets formed in the ESI needle and the flow rate. 
The ionisation yield (i.e. the sensitivity) can be increased by using a nanoelectrospray needle 
which has a diameter of 1-20µm. Nanoelectrospray requires lower voltages than ESI (as the 
delivery needle is usually positioned much closer to the transfer capillary) and uses lower 
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Figure 1. 7 : Ionistion Methods used in Proteomics 
Diagram to demonstrate the basic principles of the two most commonly used ionisation 
methods used in proteomics. (a) Electrospray Ionisation (ESI). The sample in solution is 
passed through a capillary to which a high positive potential is applied resulting in positively 
charged droplets to leave the capillary. These droplets then travel towards the mass 
spectrometer under atmospheric pressure. The solvent within the droplets evaporate and the 
desolvated ions are drawn towards the low pressure of the mass analyser. (b) Matrix Assisted 
Laser Desorption Ionisation (MALDI). The sample is co-crystallised with an excess of matrix. 
Short pulsed laser shots are focused on the sample spot causing the sample/matrix mixture to 
become volatile and fly towards the vacuum of the mass analyser. (Diagram modified from 
(Veenstra, 2006)). 
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volumes of samples due to the decreased flow rate. The droplets that are formed are much 
smaller increasing the ionisation efficiency. 
1.2.4.1.2. Matrix-Assisted Laser Desorption Laser Ionisation (MALDI) 
MALDI produces ions by irradiating a solid mixture of sample dissolved in an organic 
matrix compound with a pulsed laser beam (usually UV or IR) (Figure 1.7b). This results in 
the sample molecules being both ionised and desorbed from the solid mixture. The solid 
mixture is usually prepared by mixing a sample with a saturated solution of matrix prepared in 
solvents such as water, acetonitrile, acetone or tetrahydrofuran. The matrix is a small 
conjugated organic molecule that is able to absorb energy in the UV region. Typically used 
matrices are α-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid (DHB) 
and 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) and the choice of matrix used is 
dependant upon the type of molecule being analysed. The matrix must be capable of 
dissolving in the same solvent as the sample, be stable in a vacuum, able to absorb the laser 
wavelength used, be able to co-crystalise with the sample and promote ionisation. 
Microliter amounts of matrix are spotted onto a MALDI target plate (can be pre-mixed 
with sample or spotted after the sample) and dried to allow the formation of a crystal lattice 
structure incorporating the sample molecule. The plate is then inserted into the source where 
the laser is applied to the plate. As with ESI, the mass analyser is maintained at low pressure 
and the source at a higher pressure therefore the pressure differential draws the ions into the 
mass analyser. MALDI sources can be maintained at atmospheric pressure allowing them to 
be coupled to mass analysers such as ion traps, and quadrapole time-of-flight (TOF) analysers 
(see Section 1.2.4.2). 
MALDI can produce both positive and negative ions but as with ESI, positive ions are 
typically generated during peptide and protein analyses. Positive ions are formed by the 
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acceptance of a proton from the matrix solvent. Most samples accept a single proton therefore 
predominantly generating ions with a (+1) charge and large mass-to-charge (m/z) ratios. 
Therefore, MALDI is commonly coupled to mass analysers with large m/z ranges such as 
TOF, TOF-TOF and QqTOF instruments which are capable of tandem mass spectrometry.  
1.2.4.2. Mass Analysers 
The mass analyser guides the gas-phase ions to the detector where the m/z ratio is 
determined. The most common types of mass analysers used in proteomics are time-of-flight 
(TOF), quadrapole, ion trap and ion cyclotron resonance mass analysers. Three important 
characteristics of a mass analyser are:  
• Upper mass limit. The highest m/z ratio that can be measured. 
• Transmission. The ratio between the number of ions reaching the detector and 
the number of ions produced in the source. 
• Resolution. This refers to the instrument’s ability to produce distinct signals 
from two ions with a small mass difference. 
1.2.4.2.1. Quadrapole Mass Spectrometer 
A quadrapole is made up of four metal rods arranged in parallel to which a voltage and 
radiofrequency (rf) is applied to guide and manipulate ions through the mass analyser (Figure 
1.8a). The voltage can be altered to allow ions with specific m/z ratios to pass through. Single 
quadrapole instruments are not commonly used in proteomics as they are unable to perform 
tandem MS however, triple quadrapole instruments are capable of performing MS/MS 
analysis when a collision cell is placed between two quadrapoles (Figure 1.8b). 
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(d) 
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Figure 1. 8 : Mass Analysers 
(a) Diagram of a linear quadrapole, Diagram taken from (Burlingame, 2005). (b) 
Schematic a triple quadrapole mass analyser. IS = Ion Source; Q1 = quadrapole 1; q2 = 
quadrapole 2; Q3 = quadrapole 3; DET = detector, Diagram taken from (Agnieszka and 
Silberring, 2008). (c) Ion Trap Mass Analyser. Schematic diagram to illustrate the basic 
principles of an ion trap mass analyser. Diagram taken from (Burlingame, 2005). (d) 
Schematic diagram to illustrate the basic principles of linear Time-of-Flight mass analyser 
(TOF) and reflectron (e) TOF mass analyser. Diagram taken (Kraj, 2008). 
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Triple quadrapole mass spectrometers used in conjunction with ESI are one of the 
most commonly used mass analysers in proteomics as they are able to switch between two 
different scan modes. In the first mode (or full scan mode), ions with a broad range of m/z 
ratios are allowed to pass through the first quadrapole. In this mode, the ions are then free to 
pass through the remaining two quadrapoles to be measured by the detector. In the second 
mode (or MS/MS mode), the first quadrapole only allows ions in a narrow m/z ratio range to 
pass through to the second quadrapole where they are subjected to fragmentation by collision 
with an inert gas. The fragmented ions then pass through the third quadrapole to be measured 
by the detector. 
1.2.4.2.2. Ion-Trap Mass Spectrometer 
Ion trap mass spectrometers became commonly used for proteomic studies when new 
developments were made in the ability to manipulate trapped ions. Stafford et al developed 
the mass instability mode which allowed ions with different m/z values to be ‘trapped’ over a 
period of time and ejected sequentially into a detector (Stafford, 1984). The resolution of the 
instrument was improved by using helium to cluster ions of the same m/z value in the ion trap 
and eject them faster and more efficiently than diffuse clouds of ions (Figure 1.8c). 
Ion traps cycle through rounds of collecting, storing and ejecting ions from the trap 
and during which it can isolate and fragment peptide ions from complex mixtures and is 
therefore well suited for proteomic analyses.  The ion trap selects and traps specific ions and 
then adjusts its trapping voltage to eject all other ions from the trap. The applied voltages are 
then increased to cause the energy of the remaining ions to increase. This in turn causes the 
ions to collide with helium and fragment. These fragmented ions (daughter ions) are trapped 
and ejected from the ion trap sequentially according to their m/z value. 
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Ion trap mass spectrometers are often thought of as ‘work horses’ of global proteomic 
studies and are commonly used to analyse complex mixtures of peptides. During these studies 
the ion traps work in a data-dependant MS/MS mode i.e. each full MS scan is followed by a 
specific number of MS/MS scans. The full scan identifies the m/z ratio of all the ions in the 
trap at that time and selects the pre-defined number of the most abundant ions for further 
fragmentation. Some instruments are also able to trap daughter fragments and subject them to 
further fragmentation (MS/MS/MS or MSn). This is not commonly used to identify proteins in 
complex mixtures but is useful for identifying peptides with post-translational modifications 
such as phosphorylated peptides. 
1.2.4.2.3. Time-of-Flight Mass Spectrometer 
Time-of-Flight (TOF) mass spectrometers measure the m/z ratio of ions based on the 
time taken to move through the mass analyser to the detector. The time taken is proportional 
to the m/z ratio with smaller ions reaching the detector faster than larger ones (Figure 1.8d).  
1.2.4.2.4 Matrix-Assisted Laser Desorption Time-of-Flight (MALDI-TOF) 
MALDI-TOF instruments are relatively simple to operate and robust making them 
extremely useful for generating peptide fingerprints for individual proteins. MALDI-
TOF/TOF instruments are also able to perform tandem MS by having two TOF analysers 
separated by a collision cell. Peptide ions are generated in the source and accelerated through 
the first TOF tube and become dissociated by colliding with an inert gas (such as air or 
nitrogen) in the collision cell. The ions are then fragmented and the daughter ions are 
accelerated through the second TOF tube to the detector. This allows proteins to be identified 
through peptide fingerprinting and confirmed by MS/MS analysis of specific peptides. 
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1.2.4.2.5. Quadrapole Time-of-Flight Mass Spectrometer (QqTOF) 
The quadrapole time-of-flight mass spectrometer (QqTOF) combines the ion 
selectivity and sensitivity of a quadrapole with the high mass accuracy and resolution of a 
TOF instrument (Shevchenko et al., 2000). This instrument has the potential to perform de 
novo sequencing and can utilise either ESI or MALDI ionization methods to analyse samples 
(Loboda et al., 2000). 
QqTOF instruments usually comprise of two quadrapoles, the first acts as an rf only 
quadrapole that provides collisional dampening, the second acts as a standard quadrapole 
which is followed by a reflecting TOF mass analyser (Figure 1.8e). MS measurements are 
taken in rf-only mode where all ions are allowed to pass through to the TOF tube resulting in 
high resolution and high mass accuracy spectra. For MS/MS spectra, only specified ions are 
allowed to pass through to the collision cell where they are fragmented after colliding with a 
neutral gas. The resulting fragments are highly charged with energy and need to be 
collisionally cooled before being accelerated and focused towards the field-free drift space of 
the TOF analyser where they are separated according to their m/z ratio and detected. 
Due to its high resolving power and its ability to perform tandem MS, the QqTOF is 
often used in quantitative studies using isotopic internal standards and isotopic labeling 
strategies that require measuring small mass differences e.g 18O labeling (see Chapter 1.2.3.2). 
1.2.4.2.6. Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR) 
The fourier transform ion cyclotron resonance mass spectrometer (FTICR-MS) was 
developed over thirty years ago by Comisarow and Marshall and is increasingly being used to 
generate high-quality proteomics data (Comisarow and Marshall, 1974). The FTICR-MS 
consists of an ion trap-like analyser within a high strength magnetic field. The magnetic field 
causes the ions trapped within the analyser to resonate at their cyclotron frequency. An 
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electric field is applied which is at or near the cyclotron frequency of the trapped ions which 
in turn are excited into a larger orbit pattern. The cyclotron frequency is measured by detector 
plates on opposite sides of the trap and uses fourier transformation to convert the frequencies 
to m/z ratios. Adjusting the applied electric field can be used to dissociate the ions or eject 
them from the trap. 
These analysers have demonstrated the highest resolution, mass accuracy and 
sensitivity for peptide and protein analysis compared to all other mass analysers available and 
whilst they are relatively expensive, they are fast becoming more commercially available. 
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Section 1.3 : Data analysis for Shotgun Proteomic Approaches for Biomarker Discovery 
1.3.1. Introduction to Data Analysis for Proteomics 
The analysis of proteomic data is complicated due to the effect of multiple factors 
such as the diversity of methods and technologies available, the effects of biological artefacts, 
loss of data during data handling and the complexity of biological systems. The analysis of 
large datasets produced by shotgun proteomic approaches requires automated programs or 
algorithms to search and filter the data as manual data analysis is not feasible. Bioinformatics 
provides a key support for building proteomic knowledge databases. The management, 
analysis and interpretation of large amounts of raw and processed data require various 
bioinformatic technologies e.g. databases, sequence comparison, predictive and statistical 
models.  
For biomarker discovery, multiple samples such as healthy vs disease or pre- or post-
therapy are compared to produce patterns of protein expression and modifications. Software is 
used to identify peaks and the relative changes involving the normalisation of the raw data 
from consecutive runs against internal or external standards. Proteomic techniques produce 
large amounts of data to provide information on biological systems. The cost of proteomic 
experiments can often lead to poor experiment design including low number of replicates and 
insufficient controls leading to poor reproducibility (Brusic et al., 2007). 
1.3.2. Factors that Affect Proteomic Profiling Experiments 
1.3.2.1. Individual Variation 
Genetic studies have identified potential variations associated with more than 1000 
hereditary diseases and cancer. Large-scale studies of identical twins have failed to establish a 
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dominant role of direct genetic factors in uterine carcinoma and inherited breast cancer with 
only a small proportion of patients with major mutations in genes linked with breast cancer 
such as BRCA1, BRCA2 and TP53 (T. M. Mack et al., 2002, Thomsen et al., 2006). Subtle 
genetic changes in gene factors or their binding factors can lead to altered regulation of the 
cancer associated gene (Yan and Zhou, 2004).  
Individual diversity amongst clonal populations of cells can lead to phenotypic and 
behavioural variation. One study showed that melanoma cells grown in 3-dimensional 
cultures exhibited distinct expression profiles and an increased number of differentially 
expressed genes compared to the same cells grown in 1-dimensional cultures (Ghosh et al., 
2005).  
Individual variation can also arise from experimental factors such as sample collection 
and pipetting or dilution errors. Differences in collection, handling, storage and profiling 
techniques used, complicates comparisons between studies. The techniques involved require 
standardisation to overcome these issues (Schrohl et al., 2008). Individual variation adds 
another level of complexity to the analysis of proteomic data making it difficult to distinguish 
between individual and disease specific variation which may involve sophisticated statistics 
and machine learning (Larranaga et al., 2006). 
1.3.2.2. The immune system and disease 
The host’s response to a disease could be a potential source of useful biomarkers. The 
immune system plays a complex role during cancer development and progression involving 
interactions between the immune cells and its mediators with all cells and components of the 
tumour microenvironment. The innate immune response involves microbial recognition and 
clearance, inflammation and cell death which when stimulated, initiates the production of pro-
inflammatory cytokines. This in turn activates the adaptive immune system. 
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Immune surveillance is among the most important defenses against cancer. Antigen 
processing and presentation include antigen degradation by proteases, transport to the site 
where they bind to MHC molecules, stabilization of MHC molecules and the display of 
MHC/peptide complexes on the cell surface. Cancer escape from immune recognition 
involves mechanisms such as the down-regulation of human leukocyte antigen expression, 
up-regulation of oncogenes and down-regulation of tumour suppressor genes. Cancer cells 
can also affect immune function in dendritic cells, macrophages and T-cells and inhibit 
immune recognition (Brusic et al., 2007). For example, differentiation and maturation of 
myeloid dendritic cells is blocked by tumour environmental factors such as vascular 
endothelial growth factor (VEGF) (Carmeliet and Jain, 2000, Kryczek et al., 2005). These 
immune responses reduce the effectiveness of the host’s anti-tumour activity. 
Proteins that do not originate from the tumour itself but from the host’s immune 
response due to the presence of a tumour could also play an important role in biomarker 
discovery. 
1.3.2.3. Biological Change 
The dynamics of change of biological systems brings another level of complexity to 
the interpretation and understanding of proteomic data. Diagnostics, therapy and monitoring 
will increasingly depend upon comparisons with large datasets from an extensive range of 
prior studies. Modeling the data will require sophisticated methods for analysis (Brusic et al., 
2007). 
1.3.3. Data Analysis Methods 
A single tandem MS/MS experiment generates hundreds of thousands of spectra for 
interpretation and analysis. This involves assigning peptide sequences to the MS/MS spectra, 
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identifying the proteins from which they originated from and potentially quantifying the 
peptides and proteins. The data analysis of tandem MS/MS experiments is a complex 
computational and statistical challenge (Nesvizhskii et al., 2007). 
1.3.3.1. Assigning MS/MS spectra to peptide sequences 
This is the first and most critical step in any large-scale proteomics experiment. This 
can be achieved using any one of the following three methods: 
1.3.3.1.1. Database Searching 
Database searching software such as Sequest or Mascot compares the acquired 
MS/MS spectra to theoretical peptide fragments from databases of known protein sequences 
downloaded from online sources such as the National Centre for Biotechnology Information 
(NCBI) (National Center for Biotechnology Information) and International Protein Index (IPI) 
(IPI - International Protein Index). Restrictions are set by user-specified criteria such as mass 
tolerance, enzyme cleavage and post translational modifications (Nesvizhskii et al., 2007). 
The search generates a list of MS/MS spectra that has been assigned to a peptide sequence 
accompanied by a correlation score to indicate the degree of similarity between the acquired 
and the theoretical fragment ion spectra. These correlation scores can be arbitrary values such 
as Xcorr (used with Sequest) or converted to a statistical measure such as the expectation 
value (Evalue, used with Mascot). The Evalue refers to the expected number or peptides with 
scores equal to or better than observed scores under the assumption that peptides are matching 
the experimental spectrum by random chance. 
Database search engines will make assignments regardless of the quality of the 
acquired mass spectra therefore a selection or filtering process (manual or automated) is 
required to have confidence in the reliability of the assignments. Statistical validation of the 
assignments also adds confidence that the correct peptide and protein sequences have been 
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identified. The need for guidelines for the use of database search engines and the publication 
of proteomic data was first recognized, reported and developed in 2005 in Molecular and 
Cellular Proteomics (Bradshaw, 2005) and was extended to the publication of clinical 
proteomic studies in 2008 (Celis, 2008). 
The Sequest algorithm utilises a technique called autocorrelation to determine the 
overlap between the theoretical spectra contained within a database and the observed spectra 
generated from a proteomic experiment. This overlap is measured by many scoring criteria 
but the main scores are Xcorr (measure of the correlation between theoretical and observed 
spectra) and Delta Cn (the difference in Xcorr scores between the top candidate and the next 
best matching peptide sequence). Sequest is quite robust and is ideal for low signal-to-noise 
spectra and is also useful for low-resolution data. 
The Mascot search algorithm utilises probability-based matching. The theoretical 
spectra in the database are matched to the observed spectra in a top-down fashion by starting 
with the most intense b and y ions. The probability of these matches being random is 
calculated and assigned an identification score. 
Every single amino acid substitution in a peptide will produce a different mass (with 
the exception of Leucine/Isoleucine) so even proteins with low sequence coverage (i.e 
percentage of protein sequence represented by identified peptide sequences) have the potential 
to identify different isoforms of the same protein. However, this can prove to be difficult 
especially for identifying alternatively spliced variants or post translational modifications 
where the affected peptide is not identified. Many different isoforms of proteins contain 
identical peptide sequences and distinguishing between these can be difficult. The ideal 
database would be non-redundant with each gene and all its spliced variants represented. 
NCBI databases can be large databases, containing many protein entries which claim to be 
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spliced variants or isoforms but are all actually the same protein sequence i.e. a high degree of 
redundancy. IPI databases are more suited to proteomics experiments as they contain reported 
protein sequences, translated cDNA sequences and also information on predicted genes (Steen 
and Mann, 2004).  
1.3.3.1.3 Spectral Libraries 
Another method used to assign peptide sequences to acquired MS/MS spectra is 
spectral matching. Spectral libraries are compiled from a large collection of experimentally 
observed MS data of correctly identified peptides. The acquired spectra are then searched 
against this database to identify the closest match. Spectral matching tools include SpectraST, 
X!P3 and Biblispec. Compared to database searching, this method is quicker and exhibits 
decreased error rates and increased sensitivity however is not suitable for unknown or novel 
proteins in a sample, i.e. peptides cannot be correctly identified if they are not represented in 
the spectral library (Nesvizhskii et al., 2007). 
1.3.3.1.3. De Novo Sequencing 
This is a method that directly reads the amino acid sequence from the fragment ion 
spectrum. This was originally performed manually but now software tools are available to 
assist in the process such as the PEAKS software (PEAKS software). The method allows 
sequencing of peptides not represented in a database, peptide sequences not previously 
observed and sequences containing polymorphisms or modifications. De novo sequencing is 
mainly used for species with limited genome information or for identifying modifications but 
requires high quality MS/MS spectrum and is computationally intensive. 
1.3.3.1.4. Hybrid Approaches 
These approaches combine elements of database searching and de novo sequencing 
approaches (Mann and Wilm, 1994). It starts with inference of short sequence tags (partial 
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sequences) from MS/MS spectra followed by an error-tolerant database search to allow one or 
more mismatches between acquired spectra and those in the database. By limiting the search 
space to those only containing the sequence tag extracted from the spectrum, the search time 
is significantly reduced. This approach has proved to be useful for identifying post-
translational modifications. 
1.3.3.1.5. Estimation of False Positive Rates 
There are many cases of the incorrect peptide sequences being assigned to MS/MS 
spectra in a database search due to factors such as low quality spectra, the presence of 
contaminants, simultaneous fragmentation of peptides with similar m/z values and an 
incorrect determination of charge state or peptide mass (Nesvizhskii et al., 2007). Manual 
inspection of MS/MS spectra and database search results will give confidence that the correct 
peptide sequence has been assigned. However, this requires a degree of experience and isn’t 
viable for large datasets as it is incredibly time consuming and subjective depending upon the 
users expertise. The data can be filtered using cut-off values for the threshold parameters used 
by the database search software but these need to be determined for all experiments as the 
error rates will vary from one experiment to the next. A high through-put method is required 
to statistically measure the confidence of peptide assignments and estimate the error rates.  
Two of the approaches used to calculate false positive rates are: 
(1) Target-Decoy Searching. 
This approach involves searching the acquired MS/MS spectra against a decoy-target 
database and optimising the cut-off score for each dataset. The target-decoy database contains 
a randomised or reversed (decoy) sequence of every protein represented in the database as 
well as the correct sequences. This approach assumes that matches to decoy sequences and the 
correct sequences follow the same distribution pattern. The false-positive rate can be 
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determined by calculating the percentage of peptides assigned to decoy sequences. The 
peptide assignments can then be filtered using cut-off scores optimised to maintain a low 
false-positive rate. This approach is relatively simple but does double the database search time 
(Elias and Gygi, 2007). 
(2) Empirical-Bayes Approach. 
This method has been used by Keller et al to develop software known as Peptide 
Prophet (A. Keller et al., 2002a). It is reported to be a robust and accurate statistical model to 
assess the validity of peptide identifications made by MS/MS and database searches. Peptide 
sequences assigned to spectra are evaluated with respect to all other assignments in the 
dataset, including some incorrect assignments. Database search scores and the number of 
tryptic termini of the assigned peptides is employed using machine learning techniques to 
distinguish correctly from incorrectly assigned peptides in the dataset. The algorithm then 
computes a probability score for each peptide assignment. 
Experimental factors to consider when deciding if the correct peptide sequence has  
been assigned to the acquired MS/MS spectra include the mass accuracy of the instrument 
used, separation of observed peaks (retention time is important for quantification 
experiments) and the presence of modifications (may have been utilised in purification 
methods). 
1.3.3.2. Assigning Protein Identifications to Peptide Assignments 
The aim of most shotgun proteomic experiments is not to identify peptides but to 
identify the proteins present in a sample prior to enzyme digestion which can be challenging 
for large datasets. Many correctly identified peptides tend to group to a small number of 
proteins and many incorrectly assigned peptides with high search scores tend to group to a 
large number of proteins. This can make the identification of low abundance proteins difficult. 
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Also, shared peptide sequences in multiple protein entries in a database due to the presence of 
homologous proteins, alternative spicing variants and the presence of redundant protein 
entries in the database can add complications to the analysis (Nesvizhskii et al., 2007). It can 
be difficult in shotgun proteomic studies to differentiate between different protein isoforms. 
Protein identifications are determined by the identified peptide sequences from the 
acquired MS/MS spectra and grouping these into proteins. How protein identifications are 
reported and the confidence levels of peptide/protein assignments used differ from one study 
to the next. Some studies report all proteins identified with at least one unique peptide using 
defined filter criteria, however, these results often have a high false positive rate. Commonly, 
only proteins with multiple peptides identified are reported for increased confidence the 
protein is a true identification. Other studies report a representative protein among isoforms 
and homologs. The most common method is to use algorithms to determine the smallest 
number of proteins that can account for all the observed peptides with single-hit peptides 
carrying a low confidence score. This provides a consistent and concise method of reporting 
the results of proteomic experiments. 
The identified peptides and proteins are scored using differing criteria (depending on 
software used) to enable the user to determine how well the observed spectra matched spectra 
from the database. Multiple peptide matches from a single protein increases the confidence of 
that protein being present in a sample however these peptides need to be acceptable matches 
with high scores. Also, only peptides that are ‘full’ tryptic peptides (i.e peptides with an 
arginine or lysine residue at its C-terminal end and preceding the N-terminal residue) should 
be counted. For a protein assignment using only a single peptide, a very high score using the 
chosen criteria is required and is only really possible if the spectra is of high quality with high 
signal-to-noise ratio using instruments with high mass accuracy. 
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Proteomic experiments producing small datasets, i.e. where only a few proteins need 
to be identified from single gel bands or spots, it is possible to manually inspect all spectra to 
determine the quality of the data and analyse the protein identities responsible for differential 
staining observed between two samples. The analysis of larger datasets involving hundreds or 
even thousands of proteins from a single experiment is far more challenging where manual 
inspection of all spectra is time consuming. These large datasets tend to have quite high error 
rates without appropriate filtering of the raw data. The number of incorrectly identified 
peptides and proteins (false positives) can be decreased by increasing the threshold of the 
scoring criteria excluding a large proportion of the assignments leading to a risk of missing 
true peptides (false negatives). 
Several strategies have been developed to overcome these problems. Multiple rounds 
of tandem MS have been used to determine false positive and false negative rates using 
various threshold criteria for peptide identification (A. Keller et al., 2002b). The target-decoy 
approach can also be used for protein identification as well as peptide identifications as 
described in Section 1.3.3.1.5. Nesvizhskii et al have also used a method known as Protein 
Prophet by which the peptide identification scores were plotted against their frequency 
(Nesvizhskii et al., 2003). This produces two Gaussian-shaped distributions, one for low 
scores which is caused by random matches and one for high scores which is caused by true 
matches. These distributions can be used to determine a probability score for correct 
identification. All peptide identifications are then grouped into protein identifications and a 
protein probability score is determined. The individual peptide probability scores are 
increased if there are other peptides found for the same protein or decreased if no other 
peptides are assigned to the same protein to produce an adjusted probability score. It allows 
the data to be filtered according to protein probability score or false positive rates. The 
Chapter 1  Introduction 
65 
advantage of this method is that it allows a standard method of analysis using multiple file 
formats from various instruments across many laboratories allowing comparisons between 
studies. 
The absence of a protein in a database search from a large-scale proteomics 
experiment is not proof that the protein isn’t present. Peptides from the protein may have co-
eluted with higher abundances peptides and therefore may not have been selected for further 
fragmentation and identification. This situation is more problematic because of the 
phenomenon known as ion suppression where an abundant ion suppresses the ionisation of 
low abundance ions that are co-eluting. Peptides derived from the most abundant proteins can 
cause significant ion suppression of peptides from the lower abundance proteins masking the 
signals of ions with similar retention times. Therefore the abundant proteins can limit the 
amount of sample that can be used in a single LC-MS/MS run (Rifai et al., 2006). 
1.3.4. Data Analysis for Quantitative Proteomics 
1.3.4.1. Chemical and Stable Isotope Labelling 
Chemical tags such as ICAT and iTRAQ and metabolic labeling strategies such as 
SILAC introduce a mass difference to the MS spectra allowing the relative abundance to be 
calculated using the relative intensity or area under the corresponding peaks. In the case of 
calculating the relative abundance, the label should not affect the chemistry of the peptide and 
therefore the ‘heavy’ and ‘light’ peptides should elute within the same time window also 
adding confidence that both peaks are results of the same peptide sequence. 
1.3.4.2. Spectral Counting 
Two samples are analysed in separate LC MS/MS runs using the same data acquisition 
protocol. A separate list of proteins is generated for each sample and the lists are compared to 
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identify differentially expressed proteins. Protein abundance is estimated from the number of 
MS/MS spectra identified corresponding to each protein normalised to account for protein 
length or expected number of tryptic peptides. One variation of this method is to also consider 
peak intensity but this is difficult to apply to low abundance proteins with only one or two 
peptide identifications. Spectral counting is not used very often and less accurate than isotope 
labeling but has been utilised in several studies (Ishihama et al., 2005, Old et al., 2005, 
Zybailov et al., 2005). 
1.3.4.3. Spectral Feature Analysis 
This is a label-free strategy that does not require identification of peptide sequences 
prior to quantification. Biological samples are analysed in separate LC MS/MS runs and 
computational tools are used to correlate the spectral features across the runs with minimal 
information from the MS/MS spectra (Radulovic et al., 2004, H. Zhang et al., 2005a). This 
method allows high through-put analysis and could be applied to profiling multiple biological 
samples required for biomarker discovery studies. However there are disadvantages, the 
computational complexity is greatly increased due to the number of spurious spectra, the 
background noise and the requirement for increased stringency in the robustness and 
reproducibility (Listgarten and Emili, 2005, Qian et al., 2006). This approach often requires a 
targeted workflow to verify the presence of features and abundance (L. Anderson and Hunter, 
2006). 
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Section 1.4 : Cancer and Biomarker Discovery 
1.4.1. Introduction 
Cancer is a complex disease resulting from multiple changes and mutations 
accumulating in the cell. Histological classification distinguishes the five major types of 
cancer, i.e. carcinoma, leukaemia, lymphoma, myeloma and sarcoma and various subtypes. 
The molecular signature of a tumour varies with its subtype, shape, size, host characteristics 
and effects of the therapies. Biomarker discovery can encompass all aspects of tumour 
biology. It was proposed by Hanahan and Weinberg that normal cells need to acquire a 
number of the following six properties for the malignant process to begin: 1) uncontrolled 
growth; 2) insensitivity to anti-growth signals; 3) evasion of apoptosis; 4) unlimited potential 
to replicate; 5) ability to form and sustain new blood vessels (angiogenesis) and 6) invasion 
and metastasis to distant sites (Hanahan and Weinberg, 2000). 
Proteomic and genomic studies could contribute to the understanding of the 
mechanism by which each of the six hallmarks of cancer impacts upon individual cancers. 
Full understanding of the pathways involved in normal and disease states and their response 
to various therapies is essential to determine effective treatments across a variety of cancers.  
Carcinogenesis is initiated by alterations in the genome of a target cell caused by 
many factors including genetic, environmental, dietary and immune factors. These alterations 
include single point mutations, deletions, amplifications, translocations, chromosomal 
rearrangements, DNA methylation and other factors causing activation of oncogenes or 
inactivation of tumour suppressor genes (Martinkova et al., 2009). Genes shown to be 
associated with tumour progression are involved in a variety of cellular processes and disrupt 
signalling pathways and cellular communication. Many of these processes are mediated by 
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growth factors, hormones and cytokines via their receptors. Studies have also shown that as 
well as abnormalities in cancer related genes/proteins, the epigenetic regulation of genes 
(mediated by modifications to the DNA and/or histones without alteration to the nucleotide 
sequence of the gene) is also critical in carcinogenesis. Such modifications include DNA 
methylation and covalent modifications such as acetylation, methylation, phosphorylation and 
ubiquitination of specific amino acid residues of the N-termini of the core histones (Smith et 
al., 2007). It has been shown that cancer is accompanied by a genome wide histone 
hypoacetylation and histone deacetylase inhibitors have been shown to exhibit anti tumour 
activity (Hake et al., 2004, Pan et al., 2007). 
Cancer was once thought to be caused by alterations in a small number of genes 
known as oncogenes and tumour suppressor genes and the identifications of these alone 
would lead to ways of preventing and treating cancer. More recently, studies have shown that 
tumours are far more complex and heterogeneous and involve alterations in multiple 
pathways and factors. Genes can be significantly amplified in a tumour without altering the 
RNA levels of that gene therefore the amplification is not represented at the protein level and 
vice versa. 
Currently, studies are able to identify large numbers of differentially expressed genes 
using gene microarray techniques which does not reflect the changes in protein expression or 
proteins arising from alternative splicing and post-translational modifications. Proteomics 
combined with enrichment/ fractionation protocols, has the potential to identify these spliced 
variants and modified proteins that cannot be analysed by gene microarray analysis. 
1.4.2. Cancer Proteomics 
Many advances in research have contributed to our understanding of the molecular 
basis of cancer but increased knowledge of the processes involved in tumour progression and 
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development will lead to improved strategies for early diagnosis and therapy. Proteomics 
involves large-scale identification and characterisation of protein expression levels under 
specific conditions in defined samples. Proteomic techniques can be utilised in various aspects 
of cancer research including: profiling of cell lines, tumour tissue, subcellular components 
and biological fluids; biomarker discovery for diagnosis and early detection; identifying novel 
therapeutic targets and identifying markers for monitoring therapeutic strategies. Changes in 
the molecular mechanisms that occur within the tumour cell can be disease causing and 
therefore could be targets for therapies or may be a host response that is a consequence of the 
disease. 
Clinical proteomics most commonly involves the following studies: 
• Comparing healthy versus cancer tissue or biological fluids (using controls that 
eliminate markers of other diseases or other factors that may interfere) 
• Comparison of protein expression levels pre- and post-treatment 
• Comparison of tissues at various stages of disease 
 
These studies usually result in lists of differentially expressed proteins generated by 
semi-quantitative analysis of relative abundance. Many candidates at this discovery level may 
be false positives due to factors such as the low abundance of potential biomarkers in complex 
proteomes, instrument sensitivity and detection limits all of which can potentially yield 
artificial differences. Therefore in order to have greater confidence that a particular protein is 
present or differentially expressed in your biological model, great care must be taken at the 
data analysis stage to eliminate as many false positives as possible without losing any true 
identifications. The biological model also needs to be robust to ensure that any interesting 
results can be validated in replicate experiments and using other methods. 
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1.4.3. Biomarker Discovery 
As described in Section 1.1.2, a biomarker can be described as a measurable indicator 
of a biological state and usually refers to the presence of and/or stage of disease (Rifai et al., 
2006). The discovery of new cancer biomarkers could improve the early detection of the 
disease, increase accurate prognosis, predicting patient response to treatment and be useful for 
monitoring patients during treatment. These markers could originate from the tumour itself or 
come from the host’s response to the tumour and could be detectable in body fluids such as 
plasma/serum, cerebrospinal fluid and urine However, it is worth noting that the final 
concentration of biomarkers in the bloodstream is considerably lower compared to interstitial 
fluids due to the dilution of the proteins in the total blood volume. Proteins are released into 
the interstitial fluid surrounding the tissue which then passes through the lymph vessels before 
being released into the bloodstream but blood tests for biomarkers would often be the most 
applicable option in a clinical setting. 
There is a vast amount of cancer research that focuses on improving current treatments 
and discovering novel treatments for advanced disease as the majority of patients are 
diagnosed at an advanced stage. Although the survival rates for all colorectal cancer cases 
have improved over the last 20yrs, the prognosis for patients diagnosed with advanced stage 
disease still remains relatively poor (Etzioni et al., 2003). In general, the survival rates for 
patients with early stage cancers at diagnosis are relatively good and considerably improved 
in comparison with late stage cancers. Therefore reliable biomarkers for the detection of early 
stage cancer would be vital to ensure patients receive treatment as soon as possible. 
Any screen for early detection must be able to accurately distinguish between healthy 
and cancer patients with low false-negative (proportion of cancer patients that test negative) 
and false-positive rates (proportion of healthy patients that test positive). Ideally the screen 
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should also distinguish lesions that require treatment and those that are not aggressive and do 
not require treatment. 
The development of a screen for the early detection of cancer involves the discovery, 
development and evaluation of potential biomarker. It was suggested by Pepe et al that there 
should be five phases of biomarker discovery (Pepe et al., 2001). These phases include: (1) 
pre-clinical exploratory studies to identify potential candidates; (2) assay development and 
validation; (3) retrospective studies to investigate the assay in patient samples prior to 
diagnosis; (4) prospective screening studies in asymptomatic patients including follow-up and 
(5) cancer control studies to investigate the impact of the assay on morbidity and mortality 
rates (Etzioni et al., 2003, Pepe et al., 2001). 
1.4.3.1. What makes a good biomarker? 
Biomarkers need to exhibit high sensitivity and specificity and exhibit a low false 
positive rate for a particular disease state. They also need to be robust, i.e. can be easily 
identified in samples collected and processed in a controlled environment such as a research 
lab as well as in a clinical setting where sample collection and processing is much more 
variable (Lescuyer et al., 2007). Proteomics based biomarker studies in serum/plasma samples 
need to be designed to identify proteins with real potential as biomarkers before proceeding to 
costly, time-consuming clinical trials. Such studies should include a discovery and a 
validation phase.  
Many single cancer markers currently used for cancer screens exhibit low sensitivity 
and specificity and using a panel of multiple markers specific for a cancer type could increase 
sensitivity and specificity of these screens (S. Hu et al., 2006). Many proteins identified in 
biomarker discovery studies are acute phase proteins that are common amongst different 
cancer types. These are relatively abundant and overexpressed in other types of diseases such 
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as autoimmune disease. Many groups believe that a single biomarker is unlikely to be 
sufficient as a diagnostic tool. For example, an ovarian cancer study identified four proteins 
(leptin, prolactin, osteopontin and insulin-like-growth factor-II) whose expression levels were 
measured in a simple blood test and was able to distinguish between disease free and early 
ovarian cancer with a specificity and sensitivity of 95% when used in combination. However, 
each of the markers showed very poor specificity and sensitivity when used separately 
(Kumar et al., 2006). 
New proteomic technologies are being used to attempt to improve these studies to 
identify low abundance proteins that are cancer type specific. Table 1.2 shows examples of 
potential biomarkers identified in various cancer types using proteomic methods. 
1.4.4. Potential Sources of Biomarkers 
1.4.4.1. Body Fluids 
1.4.4.1.1 Blood 
Cancer initiation and progression does not just involve the tumour cells themselves but 
also other processes that occur within the tumour microenvironment (Radisky and Bissell, 
2004). Blood collection is a relatively non-invasive procedure and it is accepted that tissues 
release proteins into the surrounding biological fluids. Biomarkers released by both the 
tumour and the micrenvironment (by secretion or leakage) could be expected to be present in 
the interstitial fluid and blood therefore it is expected that proteomics could have an important 
role to play in blood based biomarker discovery. The pattern or the amount of the proteins 
released may be altered in disease states and these disease-associated markers could be 
measured in body fluids such as blood. This hypothesis has proved to be true as demonstrated 
by the discovery of Prostate Specific Antigen (PSA) as a marker of prostate cancer 
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Cancer Type Techniques Identified Markers Ref
Monitoring anti-cancer therapy
SELDI-TOF MS 
(tissues)
High levels of cytosolic ubiquitin and low levels of 
ferritin light chain associated with good prognosis during 
therapy.
1
MALDI-TOF MS 
(cell lines)
Elevated 14-3-3σ associated with drug resistance in 
MCF7 / AdVp3000 cells.
2
2-DE and 
MS/MS (tissue)
2-DE (tissue)
Nasopharyngeal 
carcinoma 
SELDI-TOF MS 
(serum)
2 isoforms of serum amyloid A protein useful for 
monitoring relapse
5
Diagnosis
Bladder 2-DE and 
MS/MS (tissue)
annexin V, heat shock protein 27, lactate dehydrogenase, 
annexin I, galectin-1, lysophospholipase, 15-
hydroxyprostaglandin
6
Breast ICAT and 
MS/MS (NAF)
Alpha2-HS-glycoprotein,lipophilin B, beta-globin, 
hemopexin, vitamin D-binding protein precursor
7
Immunoblotting 
and tissue 
microarray 
(tissue)
ANXA3, BMP4, LCN2, SPARC, MMP7, MMP11 8
2-DE and 
MS/MS (tissue)
secretagogin 9
Oesophageal 2D-DIGE (tissue) periplakin 10
2-DE and 
MALDI-
TOF/TOF 
(serum)
Pro-apolipoprotein, alpha2-HS glycoprotein, 
apolipoprotein A-IV precursor, PRO1708/PRO2044 (C-
terminal fragment of albumin), leucine-rich alpha2-
glycoprotein, alpha1-antitrypsin
11
2D-DIGE 14-3-3γ 12
Lung 2-DE and 
MALDI-
TOF/TOF 
(serum)
Immunoglobulin lamda chain, transthyretin monomer, 
haptoglobulin-alpha 2, 2 isoforms of serum amyloid 
protein, fragment of apolipoprotein A-1
13
Nasopharyngeal 
carcinoma
2-DE and image 
analysis (tissue)
Ceruloplasmin (confirmed in serum by ELISA) 14
Ovarian MALDI-TOF MS 
(serum)
Haptoblobulin precursor, transferrin precursor 
(confirmed by western blotting)
15
Pancreatic 2-DE and 
MS/MS (serum)
Fibrinogen γ 16
Hepatocellular 
carcinoma
Colorectal
Lymphoma Hsp27 over-expression and down-regulation of 
thioredoxin peroxidise 2 and protein disulphide isomerise 
associated with decreased survival times in B cell 
chronic lymphocytic leukemia
4
Breast
Hepatocellular 
carcinoma
Elevated levels of chaperone proteins such as Hsp27, 
Hsp70 and glucose-regulated protein 78 associated with a 
stressful cancerous microenvironment to enhance tumour 
growth and metastasis
3
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Table 1. 2 : Potential Biomarkers Identified in MS-based Proteomic Studies. 
Table to show examples of proteomic studies investigating markers for monitoring cancer 
therapy and diagnosis of cancer. References: 1 - (Granger et al., 2005), 2 - (Huang et al., 
2005b), 3 - (Petricoin et al., 2004), 4 - (Lowenthal et al., 2005), 5 - (Wang et al., 2005), 6 - 
(Doustjalali et al., 2006), 7 - (Ahmed et al., 2005), 8 - (Bloomston et al., 2006), 9 - (Fields 
and Chevlen, 2006), 10 - (Wang et al., 1981), 11 - (Amacher, 1998), 12 - (Antman et al., 
1996), 13 - (Hsich et al., 1996), 14 - (Simpson et al., 2008), 15 - (Radisky and Bissell, 2004), 
16 - (Latterich et al., 2008). 
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(Wang et al., 1981), liver transaminases for liver cell destruction (Amacher, 1998) and 
Troponin I and T for acute myocardial infarction (Antman et al., 1996).  
Plasma samples can be obtained from blood if collected in the presence of anti 
coagulants (EDTA, sodium citrate or heparin) and centrifuged to remove blood cells (S. Hu 
et al., 2006). Serum samples are obtained from blood collected in the absence of anti-
coagulants by centrifugation following blood clotting. Blood collection protocols can differ 
between clinics which may result in differences in protein profiles between studies. The 
timing between the blood collection and serum/plasma preparation and how the samples are 
stored may affect the protein concentration and its proteomic profile due to proteolysis of 
proteins by proteases in the circulation (Latterich et al., 2008). Therefore, there is a 
requirement for a uniform method for blood collection, processing and storage for proteomic 
studies (Schrohl et al., 2008). 
One challenge of using serum/plasma for biomarker discovery is due to the dynamic 
range of protein abundances present e.g. albumin is present at ~ 40mg/ml and cytokines can 
be present at levels as low as ~5x10-9 mg/ml (Simpson et al., 2008). There are 22 proteins 
(including albumins, immunoglobulins, alpha-1-antitrypsin and fibrinogen) that account for 
99% of the protein content of serum/plasma making it difficult to detect and identify less 
abundant proteins therefore highlighting the need for fractionation. One strategy that has 
been employed is to deplete the abundant proteins using a variety of approaches including 
immunological and/or bio-specific depletion (Bjorhall et al., 2005). Immunoaffinity depletion 
columns are commercially available from (Agilent, Palo Alto, CA, USA, Beckman Coulter 
Fullerton, USA and Sigma, USA). These techniques are able to remove ~99% of these 
proteins however, their remaining concentrations can still remain high enough to pose a 
problem e.g. albumin can still be detected at ~5x10-3 mg/ml which is 104 and 106 fold higher 
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concentration than CEA and IL-6 respectively. Therefore additional strategies are still 
required to detect lower abundance proteins by MS. There is also the risk that these low 
abundance proteins could be removed along with the most abundant proteins as these are 
thought to act as carriers for smaller molecules as shown by the loss of some physiologically 
important cytokines when albumin was removed (Granger et al., 2005). This can be 
overcome by disrupting the binding between the LMW proteome and the carrier proteins by 
adding 5% acetonitrile (final concentration) to serum. 
One study has addressed the problem of the high dynamic range in blood using 
orthogonal three-dimensional protein separations (Wang et al., 2005). Immunodepletion was 
followed by three dimensions of separation based on charge, hydrophobicity and mass 
however such approaches are be difficult to perform reproducibly. 
Another approach that could be used to fractionate serum/plasma samples is to use a 
targeted strategy to investigate subproteomes such as glycosylated proteins. Many proteins in 
serum/plasma are glycosylated and their glycosylation state can be linked to cancer and other 
diseases (S. Hu et al., 2006). Lectin-affinity columns (LAC) can be used to enrich the 
glycoproteome prior to MS analysis as demonstrated by Bunkenborg et al with the 
identification of 86 N-linked glycosylation sites in 77 proteins (Bunkenborg et al., 2004). The 
glycosylation state of proteins is known to change in cells during cancer development 
therefore serum glycomics is an emerging approach in biomarker discovery. Many studies 
investigate glycosylated proteins using antibody based immunochemical tests in various 
cancers: ovarian (CA125); breast (CA27.29, CA15-3); pancreatic, gastric and colorectal 
(CA19-9).  
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1.4.4.1.2. Urine 
Urine is a relatively non-invasive biological sample to obtain from patients and a 
potential source of biomarkers in some types of cancer. However, there are many issues to 
overcome when using urine for proteomic studies. Typically, urine has a low protein 
concentration, contains high levels of salts and interfering compounds and also demonstrates 
a high level of variation between patients suffering with the same disease and between 
samples collected from the same patient (Domon and Aebersold, 2006). 
Urine is most commonly used in biomarker studies for bladder and renal cancer 
however, has also shown potential in prostate, lung, ovarian and colorectal cancer 
(Tantipaiboonwong et al., 2005, Theodorescu et al., 2005, Ward et al., 2008a, Ye et al., 
2006). Sample preparation can include desalting, dialysis or precipitation using solvents such 
as acetone, acetic acid or acetonitrile (Hu et al., 2006). Some studies have also used 
immunodepletion of the abundant proteins to identify the low abundant proteins or used pre-
fractionation methods such as molecular weight cutoff columns. Two-dimensional 
electrophoresis has also been used to investigate the urinary protein excretion patterns in 
healthy men compared with men with kidney disease (Lafitte et al., 2002). 
One study has also shown the presence of exosomes in urine that are a rich source for 
biomarker discovery. Pisitkun et al identified 295 proteins in urinary exosomes many of 
which are known to be associated with renal and systemic diseases (Pisitkun et al., 2004). 
1.4.4.1.3 Other Body Fluids 
Cerebospinal fluid (CSF) has been used to investigate markers of neurodegenerative 
and CNS disorders. Typically, it has a very low protein concentration and the most abundant 
proteins originate from blood plasma masking the less abundant proteins in proteomic studies 
(Hu et al., 2006). CSF has been used in proteomic studies to investigate markers for 
Chapter 1  Introduction 
78 
neurological diseases such as Creutzfeldt-Jakob disease (CJD) and Amyotrophic lateral 
sclerosis (ALS) (Davidsson et al., 2002, Ranganathan et al., 2005). 
Saliva has also been used in biomarker discovery due to the ease and non-invasive 
sample collection with very little cost. Proteins found within saliva can be used as markers of 
oral and systemic disease but has been used to investigate markers of breast cancer as well as 
oral cancer (Fingleton et al., 2004, Streckfus et al., 2000). 
Bronchoalveolar lavage fluid (BALF) contains secreted pulmonary proteins and is 
used to investigate the components of the epithelial lining to study lung disorders (such as 
sarcoidosis andiopathic pulmonary fibrosis) and the molecular structure of the lung (Rottoli 
et al., 2005).  
Synovial fluid (SF) can be found in the cavities of synovial joints and reduces friction 
between cartilage and other tissues and is often used to investigate the cause of acute 
arthritis. Biomarkers in SF for rheumatoid arthritis (RA) and osteoarthritis (OA) have been 
studied using proteomic methods (De Ceuninck and Berenbaum, 2009, Wilson et al., 2009). 
Nipple aspirate fluid (NAF) contains cells and proteins and can be collected non-
invasively. It can be used to study the presence of malignant cells and markers for breast 
cancer and has been the focus of many proteomic studies (Alexander et al., 2004, Sauter et 
al., 2005, Varnum et al., 2003). 
1.4.4.2. Tumour Tissue 
Many studies have used tumour tissues to identify candidate biomarkers in various 
cancer types including HCC, pancreatic, gastric and lung (Lee et al., 2005, Li et al., 2004a, Li 
et al., 2006, Li et al., 2004b, Nishigaki et al., 2005, Shen et al., 2004, Yokoyama et al., 2004) 
. As there are numerous challenges when using blood for biomarker discovery, other studies 
are concentrating on tissue biopsies under the hypothesis that potential markers are at their 
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highest concentrations in the tumour microenvironment compared to the bloodstream. Laser 
capture microdissection (LCM) reduces heterogeneity by allowing the selection of specific 
cell types from tumour tissue (Emmert-Buck et al., 1996). This method has been used 
alongside DIGE to identify potential tumour markers in pancreatic adenocarcinomas (Sitek et 
al., 2005). 
1.4.4.3. Cell-based Models 
Although tumour cell lines do not represent the heterogeneity of cells within a 
tumour, they are commonly used to investigate protein changes during various stages of 
carcinogenesis such as epithelial-mesenchyml transition (EMT) in TGF-β treated lung cancer 
cells (Honda et al., 2005), p53-induced apoptosis in colorectal cancer cell lines (Gu et al., 
2004) and the differences between androgen-dependant and androgen-independent prostate 
cancer cells (Lin et al., 2005). 
Another strategy for biomarker discovery is to investigate secreted proteins from cell 
lines. Such proteins include growth factors, extracellular degrading enzymes, cell motility 
factors, cytokines and bioactive molecules involved in essential processes such as 
differentiation, invasion, metastasis, angiogenesis and regulation of cell-to-cell or cell-to-
extracellular matrix interactions (Xue et al., 2008). It is possible that many of these proteins 
can enter and be detected in body fluids such as blood and urine. 
Proteomic methods have been used to investigate novel secreted proteins or proteins 
with differential patterns of secretion in colon, prostate, breast and lung cancers (Kulasingam 
and Diamandis, 2007, Pereira-Faca et al., 2007, Sardana et al., 2007, Volmer et al., 2005). 
These methods include gel-based techniques such as 2DE / 2D-DIGE (Huang et al., 2006b, 
Khwaja et al., 2006, Volmer et al., 2005), gel-free methods (Kislinger et al., 2005, Mbeunkui 
et al., 2006, Sardana et al., 2007), SELDI-TOF MS (Xue et al., 2008) and quantitative 
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methods such as ICAT, iTRAQ and SILAC (Chenau et al., 2009, Gronborg et al., 2006, 
Martin et al., 2004).  
One example of a cancer secretome study identifying a potential novel biomarker 
used a gel-based method to investigate the secretome of two nasopharyngeal carcinoma 
(NPC) cell lines (NPC-TW02 and NPC-TW04) (C. C. Wu et al., 2005). They identified three 
metastasis-related proteins (fibronectin, Mac-2 binding protein and plasminogen activator 
inhibitor I) with increased secretion in NPC which were then shown to be elevated in serum 
from NPC patients compared to healthy controls using an ELISA based assay. A study 
investigating novel biomarkers in renal cell carcinoma (RCC) identified pro-matrix 
metalloproteinase-7 (pro-MMP7) as a candidate marker with elevated levels in serum 
compared to healthy controls (Sarkissian et al., 2008). Another study investigated proteins 
secreted in lung cancer primary cultures and identified a panel of 4 proteins (CD98, fascin, 
polymeric immunoglobulin receptor/secretory component and 14-3-3ŋ) that demonstrated a 
higher sensitivity and specificity in plasma compared to single markers (Xiao et al., 2005). 
All these studies demonstrate the importance of investigating the secretome as a source of 
candidate biomarkers in cancer research. 
Secretome analyses have not just been used for biomarker discovery but have also 
been used to investigate molecular mechanisms. One study used proteomics to analyse the 
secretome from two UV-induced fibrosarcoma cell lines to investigate tumour formation 
mechanisms and identified 28 differentially secreted proteins to suggest possible mechanisms 
involved (Shi et al., 2007). Secretome analysis has also been used to understand gene 
function. Khwaja et al used 2-DE to investigate the secretome of p53-null tumour cells in the 
presence and absence of wt-p53 in order to characterise the role that tumour suppressor p53 
plays within the tumour microenvironment (Khwaja et al., 2006). 
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1.4.4.4. The future of MS-based cancer screening assays 
Currently used biomarkers are assayed using immunoassays which target single 
biomarkers. Similar assays could be optimised for other biomarkers but those that could 
detect multiple biomarkers simultaneously using MS or antibody array methods could prove 
to be effective assay for cancer diagnosis. This can be achieved using an electrospray LC-
MS/MS multiple reaction monitoring (MRM) assay to detect and quantify tryptic peptides 
from selected proteins (see section 1.2.3.5 for description). Anderson and Hunter 
demonstrated that 12 abundant proteins in serum including albumin (40mg/ml) and 
fibronectin (300µg/ml) and L-selectin (670ng/ml) could be detected in a single assay (L. 
Anderson and Hunter, 2006). 
1.4.5. Biomarker Discovery and commonly used Proteomic Techniques 
Once suitable samples have been collected, proteomic approaches to biomarker 
discovery include: 1) sample preparation which may include sample enrichment strategies 
such as phosphoproteins, glycosylated proteins or sub-cellular fractionation; and 2) protein 
separation strategies such as 1D or 2D gel electrophoresis, a gel free approach using 2D 
HPLC or a combination of these techniques. The advantages and disadvantages of commonly 
used proteomic techniques used for biomarker discovery are discussed below. 
1.4.5.1. Two-dimensional polyacrylamide gel electrophoresis (2D PAGE) 
Two-dimensional polyacrylamide gel electrophoresis (2D PAGE) or two-dimensional 
electrphoresis (2DE) was first described by O’Farrell et al in 1975 and was the first technique 
used to profile protein expression patterns in cancer (O'Farrell, 1975). It was first used to 
analyse human plasma proteins by Anderson and Anderson 1977 to separate 300 distinct 
protein spots upon staining (L. Anderson and Anderson, 1977). 
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Proteins are separated by charge in the first dimension using isoelectric focussing 
(IEF). Proteins will have a positive, negative or neutral charge depending upon the pH of the 
environment they are in. Every protein has a pH at which they carry a neutral overall net 
charge known as its isoelectric point (pI). Proteins are positively charged at a pH below its pI 
value and negatively charged at a pH above its pI value. IEF involves placing proteins in a 
medium with a pH gradient and subjecting the medium to an electric field. The proteins will 
then start to migrate through the pH gradient towards the electrode of the opposite charge. 
During the migration, the proteins will gain or lose protons and its net charge and mobility 
will decrease therefore slowing down the proteins migration. The protein will stop migrating 
once it reaches the pH which is equal to its pI (the pH at which the protein is uncharged). If 
the proteins then diffuse either side of this region, they will lose or gain a proton and migrate 
back to its pI region. In this way proteins are focused to the region of the pH gradient 
corresponding to their pI value and can remain there until the electric field is removed.  
The proteins are then separated in the second dimension based on their molecular 
weight (MW) by gel electrophoresis. As proteins migrate through the pores in the gel, they 
become coated in dodecyl sulphate proportional to their MW and migrate with a uniform 
charge-to-mass ratio. The percentage of the acrylamide in the gel determines the pore size of 
the gel, the higher the percentage of the gel, the smaller the pore size. Gels are available as 
single-percentage gels or gradient gels. Single-percentage gels give good resolution of 
samples within a narrow MW range whereas gradient gels allow the analysis of proteins over 
a wide MW range in a single experiment. The percentage of acrylamide increases from the 
top to bottom with proteins migrating from larger pores to smaller ones. Gradient gels are 
more popular for complex mixtures of proteins as they allow large and small proteins to be 
resolved simultaneously however they do not match the resolution of single percentage gels. 
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Traditionally, complex protein samples (such as whole cell lysates, tissues or 
biological fluids) were solubilised and separated by 2DE and the proteins were stained using 
a silver staining protocol. The approach is limited as only the most abundant proteins are 
identified but did prove useful in a number of studies. IEF was originally carried out in 
polyacrylamide gel rods formed in glass or plastic tubes containing ampholytes that form pH 
gradient in an electric field. The development of immobilised pH gradients (IPGs) increased 
the potential utility of 2D PAGE (Bjellqvist et al., 1982). IPGs enabled stable, reproducible 
pH gradients to be formed capable of focusing acidic and basic proteins on a single gel (Issaq 
and Veenstra, 2008). The carrier ampholytes are attached to acrylamide molecules and cast 
into gels to form a fixed pH gradient. Fixing the gradient prevents drift in the gel and allows 
them to be cast in an efficient and reproducible manner. The pH range is immobilised within 
an acrylamide matrix and allows the production of gels that cover defined pH ranges 
allowing proteins with similar pI values to be separated with high resolution (Hoving et al., 
2002, Langen et al., 2000).  
It has also been well documented that 2DE does have its difficulties and limitations 
(Rabilloud, 2002, Roessler et al., 2006). These include:  
• Dynamic range of proteins in samples can make it difficult for good 
separation of all proteins. 
• Moderate reproducibility. 
• Suboptimal resolution of proteins. 
• Difficulty of spot matching between different gels. Gels must be run in 
duplicate or triplicate and imaging software can be used to identify differences 
although even the most advanced software requires manual intervention to 
assist the correct matching. 
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• Spot overlapping (i.e. presence of multiple proteins in single spots on smaller 
gels). If differences in staining intensity are observed in a spot between two 
gels, identification of the protein responsible for the difference would be 
difficult to identify due to the presence of multiple proteins. This could be 
overcome using larger gels to resolve the proteins further. 
• Some proteins are difficult to resolve on a 2D gel such as very basic proteins, 
small proteins and hydrophobic proteins such as membrane proteins. 
• Proteins exhibit a decreased solubility at their pI and therefore can prove 
difficult to resolve on a 2D gel. 
More recently, 2D differential in-gel electrophoresis (2D DIGE) has been used to 
separate two distinct protein mixtures each labeled with different fluorescent dyes on the 
same 2D gel to quantify differences in protein expression (Kondo, 2008, Maurya et al., 
2007). It was developed to attempt to overcome spot alignment problems (Unlu et al., 1997). 
It has been used to identify and quantify the differences in protein expression between 
oesophageal carcinoma cells and normal epithelial cells (Zhou et al., 2002). 
Each protein mixture is covalently labeled with a cyanine fluorescent dye (Cy3 and 
Cy5) with different excitation and emission wavelengths (550nm and 650nm respectively). 
The samples are mixed in equal amounts of total protein and separated together using a 
single IPG strip and 2D gel. Identical proteins in both samples should migrate to the same 
region of the 2D gel at the same speed therefore there is no need for complex data analysis to 
match the spots. The gel is scanned at the specific excitation wavelengths of each dye using a 
fluorescent imager. These are merged and the fluorescent intensity is used to determine the 
relative abundance of all protein spots which can then be excised for identification. 2D DIGE 
allows the direct comparison of two samples without complicated spot matching between 
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samples in the same experiment and uses less 2D gels compared to 2D PAGE. However, the 
fluorescent dyes makes 2D DIGE are more costly than 2D PAGE. 
The cyanine dyes first used in 2D DIGE involves labeling lysine residues and the 
average protein has approximately 30 lysine residues per protein which causes a large mass 
shift in the proteins which can compromise their solubility. Also, smears in the 2D gel can 
occur if the labeling efficiency is less than 100%. A new saturation labeling strategy uses the 
next generation of dyes which label cysteine residues, these occur less frequently than lysine 
residues resulting in a much smaller mass shift. Compared with lysine residue labeling, 100% 
labeling of cysteine residues is more easily achieved and is suitable for investigating low 
abundance proteins or when starting material is limited. DIGE labeling is rapid, sensitive 
(can detect <12amol using saturation labeling) and allows the detection of post-translational 
modifications and alternative splicing products but doesn’t efficiently resolve large proteins 
or integral membrane proteins (Minden, 2007). 2D-DIGE has been used to compare cell 
lysates from oesophageal cancer and normal cells to identify 58 up-regulated spots and 107 
down-regulated spots (Zhou et al., 2002). It has also been to used to profile 64 ovarian tissues 
with the aim of classifying them into four subtypes (Bengtsson et al., 2007). 
Despite theses improvements to 2D gel techniques, it still remains a low throughput 
approach that requires a relatively large amount of protein which is a problem when sample 
is limited which can be the case with clinical tissue samples.  
1.4.5.2. Surface Enhanced Laser Desorption Ionisation (SELDI) 
SELDI pre-fractionates samples based on capturing different types of proteins on 
chips coated with various chromatographic surfaces such as hydrophilic, hydrophobic or 
ionic surfaces and can also be coated with antibodies or ligands. It uses MALDI technology 
to measure low molecular mass proteins/peptide fragments (<20kDa) and larger proteins. 
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SELDI is often used to compare the peptidome or LMW proteome profile resulting from in 
vivo proteolytic cleavage of plasma or tumour derived proteins. The intensities of the 
polypeptide peaks with differing m/z ratios between two or more populations (e.g healthy vs 
cancer) can be compared. Petricoin et al demonstrated the use of SELDI to compare serum 
from ovarian cancer patients and healthy individuals (Petricoin et al., 2002). Algorithms were 
used to compare peak patterns and identified five m/z peaks that could discriminate cancer 
patients from controls with high sensitivity and specificity. The proteins responsible for these 
peaks were subsequently identified and found to originate from high-abundance host 
response serum proteins rather than tumour derived proteins. 
There are many SELDI based biomarker discovery studies reporting peak profiles 
that improve on the sensitivity and specificity of the currently used biomarkers. These 
potential biomarkers show potential and require validation in larger studies before they can 
be transferred to the clinic. One such multi-centre study identified five m/z peaks originating 
from four proteins to be differentially expressed in ovarian cancer. These peaks were shown 
to improve the detection of early stage ovarian cancer compared to CA-125 alone. It was 
hypothesized that this test could be used in conjunction with the measurement of CA-125 
could detect early stage ovarian cancer (Kozak KR, 2005). 
SELDI has been used to study body fluids in many types of cancer such as gastric, 
hepatocellular carcinoma (HCC), colorectal cancer and pancreatic (Honda et al., 2005, Mohri 
et al., 2009, Ward et al., 2006a, Ward et al., 2006b, Ward et al., 2008b, Ward et al., 2006c). 
Studies using SELDI require a lot of thought into the experimental design to eliminate data 
analysis problems and to ensure no biases are introduced due to blood collection, processing 
and storage (Diamandis, 2004, Ransohoff, 2005). One limitation of these surveys is the low 
mass accuracy of the mass spectrometer used making it difficult to positively identify 
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peptides or proteins responsible for the differential peak patterns. This is essential to 
investigate the biological relevance of these differences and for these assays to be moved to a 
clinical setting. Emerging technologies will improve upon peptide profiling and although 
these studies have not yet lead to the development of clinical assays, SELDI based 
techniques may still prove to be a useful tool for biomarker discovery. 
1.4.5.3. Profiling Arrays 
Protein profiling arrays are a sensitive high-throughput method that requires relatively 
small amounts of sample. Antibody arrays are the most common and have been used to 
detect proteins in serum. There are two main types: (i) direct labeling and (ii) dual antibody 
sandwich arrays (S. Hu et al., 2006). The direct labeling method involves labeling proteins in 
a complex sample with a tag followed by incubation with a corresponding antibody to detect 
those proteins. A two-colour rolling-circle amplification (RCA) method allows two samples 
to be compared by labeling with different tags such as biotin and digoxigenin to investigate 
relative abundances. A sandwich array allows the capture of proteins in a complex sample 
using a panel of antibodies. Antibody arrays have been used to profile serum proteins in 
prostate, lung, pancreatic, ovarian and liver cancers (Gao et al., 2005, Miller et al., 2003, Z. 
Sun et al., 2004). However, protein profiling arrays are not yet as comprehensive as those 
investigating the transcriptome and require new candidate targets for efficient unbiased 
profiling (Rifai et al., 2006). 
1.4.5.4. Other Methods 
More recently, MALDI imaging allows the detection of proteins in situ using tissue 
sections. The large number of mass spectra is evaluated using hierichial clustering to classify 
and interpret complex human tissue (Deininger et al., 2008). 
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Serum and tissue samples from cancer patients can be used in other ways to discover 
tumour-related peptides and proteins that could be used as markers. As well as tumour 
secreted proteins, autoantibodies to tumour–related antigens can be found in the circulation. 
Western blotting techniques utilising 2-DE gels of lung adenocarcinoma cell lines have been 
used to identify autoantibodies in patients’ serum (Brichory et al., 2001). The 
immunoreactive spots are excised and the proteins are identified by MS. The assay identified 
annexin I and annexin II autoantibodies to be present in the serum from lung cancer patients 
however, these results are yet to be extended for clinical evaluation. 
A similar approach replaces 2-DE with a combined two-dimensional liquid 
chromatography separation and protein microarrays. The proteins from prostate cancer cell 
line LNCaP cell lysates were separated in to 1760 fractions and each of these fractions were 
then spotted onto microarray slides and incubated with patient serum. The patterns of 
immunoreactive spots for cancer vs normal were plotted on a heat map and upon comparison 
were able to distinguish between organ-confined and metastatic prostate cancer (Bouwman et 
al., 2003). 
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Section 1.5 : Microvesicles 
1.5.1. Introduction 
Communication between cells was thought to be mediated only by neurotransmitters 
and hormones (secreted or cell surface) but electron microscopy showed the presence of small 
discrete vesicles in the intercellular space (Beaudoin and Grondin, 1991). It has since been 
shown that these vesicles may play various specific roles (Lakkaraju and Rodriguez-Boulan, 
2008). Microvesicle (MV) is a term used to refer to a mixed population of vesicles released by 
cells whose composition varies depending upon cell type and status or condition. 
There are two types of vesicles and processes used to release them from cells: (i) 
exocytosis of multivesicular bodies (MVBs) with the release of exosomes (<100nm) and (ii) 
the budding of small vesicles from the plasma membrane referred to as shedding vesicles 
(100-1000nm).  
Exosomes were first identified as vesicular structures segregated within a membrane-
bound organelle known as MVB’s by electron microscopy and were thought to be involved in 
late stage maturation of endosomes to lysosomes. The membranes of theses MVB’s were later 
shown to fuse with the plasma membrane of the cell and release its contents into the 
extracellular space. It was observed that these exosomes were released as a result of specific 
processes and in response to specific intracellular signals (Fevrier and Raposo, 2004, 
Lakkaraju and Rodriguez-Boulan, 2008, Schorey and Bhatnagar, 2008). 
Media collected from ‘healthy’ exponentially growing cell lines and analysed by 
FACS shows the presence of small particles often referred to as cell debris. Electron 
microscopy has confirmed that this cell debris is enriched in shedding vesicles (Beaudoin and 
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Grondin, 1991). Shedding vesicles are more heterogenous in shape and larger than exosomes 
and have been shown to be released from various cell types under different conditions. 
1.5.2. MV Secretion from Cells 
MV secretion has been shown in a wide range of cell types in vivo and in vitro such as 
epithelial, fibroblast, haematopoetic, immune, placental and tumour cells (Chaput et al., 2004, 
Pap et al., 2008, Valenti et al., 2006, Valenti et al., 2007, VanWijk et al., 2003, Wieckowski 
and Whiteside, 2006). Cells constitutively release MVs and release increases in rapidly 
growing cells compared to slow growing cells and in response to a stimulus (e.g. cell 
activation, hypoxia, irradiation, oxidative injury, exposure to shearing stress and exposure to 
proteins from an activated complement cascade). Many studies have investigated MV release 
in specific cell types during a particular process e.g. fibroblasts under mechanical stress (T. L. 
Lee et al., 1993), platelets and macrophages during coagulation (Sims et al., 1988) and 
extracellular matrix (ECM) digestion with increased cell motility for tumour and endothelial 
cells (Ginestra et al., 1998, Gutwein et al., 2003, Taraboletti et al., 2002). 
Many names are given to MVs depending on the cell type they have been secreted 
from including microparticles (MP) from platelets (George et al., 1982), ectosomes from 
neutrophils and firoblast (Hess et al., 1999), shedding vesicles from tumour cells, exovesicles 
for neurotransmitter vesicles and MVs released during tissue development from basolateral 
membrane of cells are known as argosomes (Greco et al., 2001).  
MVs are released into the extracellular space and are either broken down within 
minutes at the site of discharge or others are able to travel some distance via body fluids such 
as blood. Vesicular structures have also been detected in other body fluids such as urine and 
cerebrospinal fluids. They are normal constituents of blood plasma and are secreted by 
leukocytes, endothelium, platelets and erythrocytes. In normal serum, the abundance of MVs 
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are platelet (80%), endothelial (10%) and leukocyte (10%) derived (Caby et al., 2005, George 
et al., 1982). The number of MVs in the peripheral blood increases during cell injury, 
inflammation, thrombosis and platelet activation (Barry and FitzGerald, 1999, Barry et al., 
1998, Horstman et al., 2004, Hugel et al., 2005, VanWijk et al., 2003). MVs have also been 
shown to be released by neoplastic cells and to circulate at higher levels in the peripheral 
blood of cancer patients (Ginestra et al., 1998, H. K. Kim et al., 2003, Shedden et al., 2003). 
MVs have the potential to be a good source of diagnostic markers for a variety of conditions. 
1.5.3. MV Composition 
MVs contain a variety of molecules both enclosed within the vesicle and in the 
membrane. The size and composition of these vesicles is dependent upon the cell they 
originated from and their condition (Coleman et al., 2001, Distler et al., 2005). Shedding 
vesicles have been shown to contain ubiquitous proteins such as β1 integrins which have been 
identified on the cell surface of many vesicles from various cell types (Del Conde et al., 2005, 
Dolo et al., 1998). It has been reported that shedding vesicles from tumour cells are enriched 
with metalloproteinases and other proteolytic enzymes important for digestion of ECM which 
is important for inflammation and tumour growth (Gasser et al., 2003, Giusti et al., 2008, 
Gutwein et al., 2003, Millimaggi et al., 2006, Mochizuki and Okada, 2007). MP’s are 
enriched with integrins, the plasma membrane glycoproteins GP1b and GP11b-111a, P-
selectin, all important for coagulation (Del Conde et al., 2005, Ginestra et al., 1998, Heijnen 
et al., 1999). Macrophage derived vesicles are enriched with PSGL1 which is important for 
binding with platelets (Del Conde et al., 2005). They have also been shown to contain mRNA 
(Baj-Krzyworzeka et al., 2006, Ratajczak et al., 2006b), infectious particles such as HIV virus 
or prions (Fevrier et al., 2005, Pelchen-Matthews et al., 2004, Robertson et al., 2006, 
Rozmyslowicz et al., 2003) and even organelles such as mitochondria (Spees et al., 2006). 
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The membrane of MVs consists of typical markers (proteins and lipids) of the cell line 
they were secreted from. In the case of exosomes, all proteins analysed to date originate from 
the cytosol and plasma membrane. They do not contain nuclear, mitochondrial, golgi or ER 
proteins suggesting an endocytic origin of these vesicles but they do not contain ATPases or 
lysosomal proteases indicating that their formation through MVBs deviate from the lysosomal 
pathway (S. Keller et al., 2006, VanWijk et al., 2003). Exosomes secreted from antigen 
presenting cells such as B-lymphocytes and dendritic cells have membranes enriched in 
MHC-I, MHC-II and in co-stimulatory molecules. 
Tumour cell MVs are rich in pre-apoptotic molecules such as Fas-ligand (FasL) or 
TRAIL (TNF related apoptosis inducing ligand) (Andreola et al., 2002, Huber et al., 2005, 
Valenti et al., 2006). Some proteins are commonly found in MVs from various cell types such 
as chaperone protein HSP70 and tetraspanin proteins (Aoki et al., 2007, Fritzsching et al., 
2002, Hegmans et al., 2004). 
MVs have also been found to contain nucleic acids (mRNA, miRNA and DNA) (Unlu 
et al., 1997, Zhou et al., 2002) and infectious particles such as HIV or prions (Kramer et al., 
2005, Ratajczak et al., 2006b). MicroRNAs are known to control gene expression by 
regulating mRNA turnover and the transfer of RNA between cells has been shown to occur in 
vesicles from progenitor cells of differentiation and tumour cells (Baj-Krzyworzeka et al., 
2006, Deregibus et al., 2007, Hunter et al., 2008). 
1.5.4. MV Formation 
There are two distinct processes involving vesicle production and release. Exosomes 
are released via exocytosis when MVBs leave the lysosomal pathway and fuse with the 
plasma membrane. The sorting process of direct particular proteins into vesicles within the 
MVB is not very well understood. 
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Larger vesicles (100-1000nm) are released by reverse budding. Multiple pathways 
may lead to vesicle formation but the following two appear to be the most relevant. 
(1) The elevation of intracellular Ca2+ concentration. 
Vesicle shedding has been shown to increase in resting cells upon elevation of 
intracellular Ca2+with small structures observed protruding from the plasma membrane using 
time lapse confocal microscopy (Bianco et al., 2005, Pizzirani et al., 2007). Increasing 
intracellular Ca2+ alters phospholipid distribution in the plasma membrane. The phospholipids 
found on the inner membrane are phosphatidylserine (PS) and phosphatidylethanolamie (PE), 
the balance of these are maintained by the enzymes scramblase, floppase and translocase. 
Increasing cytoplasmic Ca2+ inhibits translocase and activates scramblase resulting in PS and 
PE not being returned to the inner side of the membrane. MVs display a large amount of PS 
on their outer surface of their membrane allowing the binding of AnnexinV. MV formation 
has been shown to be regulated in a Ca2+ dependant manner in monocytes, platelets, red blood 
cells, endothelial cells, T-cells and in mast cells (Piccin et al., 2007, Redman and Sargent, 
2007, Thery et al., 2001). 
(2) The re-organisation of the cytoskelen 
The reorganisation of the cytoskeleton leads to the detachment of the plasma 
membrane from the cortical actin. This can be initiated by many processes. 
Phosphatidylinositol 4,5-biphosphate (PIP2) plays an important role in the attachment of the 
membrane to the cortical cytoskeleton. In platelets, incubation with PIP2 inhibited MV 
formation and decreasing PIP2 increases MV formation (Flaumenhaft, 2006). Calpain and 
gelsolin are cytosolic proteases which are activated by Ca2+ ions. Calpain cleaves talin and 
activin and gelsoin (specific to platelets) cleaves actin capping proteins. Both of these lead to 
the disruption of the cortical cytoskeleton allowing budding to occur (Redman and Sargent, 
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2007, Valenti et al., 2007). During the early stages of apoptosis, MV formation is associated 
with cortical myosin-actin movement. It starts with GTP-bound Rho proteins activating Rho-
associated kinase 1 (ROCK-1) which in turn activates (by phosphorylation) myosin light 
chain kinase. This allows exchange between myosin and actin leading to detachment of the 
cytoskeleton from the plasma membrane and MV release (Coleman et al., 2001, Distler et al., 
2005). 
The formation of shedding vesicles starts with the budding of small cytoplasmic 
protrusions which then detach by fission from the plasma membrane (Cocucci et al., 2007, 
Dolo et al., 2000, T. Kobayashi et al., 1984). Accumulation of proteins in the membrane and 
within the vesicle has been found in these buds using confocal and electron microscopy 
immunocytochemistry (Cocucci et al., 2007, Schorey and Bhatnagar, 2008).  How proteins 
are sorted in the proximity of the site of vesicle release is still largely unknown but studies 
with inhibitors of cholesterol synthesis have suggested a role for cholesterol rich micro 
domains of the plasma membranes known as lipid rafts which has also been suggested to be 
involved in exosome biogenesis (Del Conde et al., 2005, Pilzer et al., 2005, Stein and Luzio, 
1991). The process of vesicle shedding involves a small portion of the plasma membrane 
being removed from the cell surface. When this occurs at a low constitutive rate, the missing 
membranes are replaced by the constitutive traffic of membranes rich in vesicle specific 
molecules (Morris and Homann, 2001). When the rate of vesicles shedding is increased (upon 
stimulation), the replacement of the membranes lost from the cell membrane occurs by a 
process known as regulated exocytosis of non-secretory vesicles (which is not yet fully 
understood) (Chieregatti and Meldolesi, 2005). 
Many vesicles do not remain intact in the extracellular space once secreted from the 
plasma membrane but release their contents immediately. In cancer, this is required for cancer 
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development. For example, secretion of metalloproteinases along with EMMPRIN by tumour 
cells in MVs is essential for ECM digestion to increase their mobility and allow them to 
invade neighbouring tissue and enter the bloodstream (Sidhu et al., 2004). The breakdown of 
vesicles upon shedding also appears to be important for the release of signalling molecules 
e.g. IL1-β, caspase1, caspase 3 and cathespin D from dendritic cells and macrophages 
(Cocucci et al., 2009). 
 
1.5.5. Microvesicle Function 
Information transfer by MV secretion plays a role in many physiological and 
pathological processes e.g. immune modulation, inflammation blood coagulation, cancer and 
during pregnancy. Mechanisms by which MVs influence the biology of target cells include: 
1. Stimulation of other cells by surface expressed ligands acting as signalling 
complexes 
2. Transfer of cell surface receptors. MP’s can transfer CD41 antigen from 
platelets to endothelial cells (VanWijk et al., 2003). MP’s are also able to 
transfer platelet adhesion molecules to tumour cells to increase both the 
adhesion of lung cancer cells to the endothelium. (Janowska-Wieczorek et al., 
2005). 
3. The delivery of proteins, lipids and mRNA to target cells. In mouse models, 
MVs derived from murine embryonic stem cells contribute to epigenetic 
reprogramming of target cells. In serum free culture, MVs significantly 
enhanced the survival and improved expansion of murine hematopoietic 
stem/progenitor cells. This occurred by upregulating the expression of markers 
for early pluripotent (Oct4, Nanog, and Rex-1) and early hematopoeitic stem 
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cells (HoxB4, CATA2) and also inducing the phosphorylation of 
MAPKp42/44 and Ser/Thr kinase AKT. MVs from ES cells also express Wnt-
3 protein and are highly enriched in mRNA for several pluripotent 
transcription factors (Ratajczak et al., 2006a). 
4. The transfer of infectious particles. HIV receptors may be transferred between 
cells rendering those cells susceptible to HIV infection (M. Mack et al., 2000, 
Rozmyslowicz et al., 2003). 
5. Delivery of organelles e.g. mitochondria. Cells defective in aerobic respiration 
have been shown to receive mitochondria and mitochondrial DNA transferred 
from other cells via MVs (Spees et al., 2006). 
 
1.5.5.1. Tumour cell-derived MVs and their role in Tumour Progression  
MVs are thought to play an important role in tumour development and progession and 
the number of circulating MVs in peripheral blood has been shown to be increased in cancer 
patients correlating to increased metastasis and a poor prognosis (Ginestra et al., 1998). The 
tumour microenvironment is rich in vesicles from proliferating cells, macrophages and 
neutrophils comprising proteases on the surface of vesicles involved in the digestion of 
intercellular matrix (matrix and ADAM metalloproteinases and cathespin D) and proteins 
within the vesicles involved in stimulating migration and metastasis of tumour cells (Ginestra 
et al., 1998, Giusti et al., 2008, Gutwein et al., 2003, Kim et al., 2003, Millimaggi et al., 2006, 
Mochizuki and Okada, 2007). Angiogenesis is then stimulated by matrix digestion and tissue 
factor (TF) generation which is upregulated by the proangiogenic factor vascular endothelial 
growth factor (VEGF) (Bluff et al., 2008, Janowska-Wieczorek et al., 2005, Taraboletti et al., 
2002). 
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MVs expressing TF on their surface are a strong inducer of VEGF secretion and 
stimulators of angiogenesis (Osterud, 2003). Tumour-derived MVs stimulate the secretion of 
several pro-angiogenic factors by stromal fibroblasts, chemoattract and increase the 
proliferation of endothelial cells to promote angiogenesis (Janowska-Wieczorek et al., 2005). 
The formation of new blood vessels is crucial for the migration of metastatic cells and 
malignant cell survival (Bluff et al., 2008). The transfer of mRNA and miRNA via vesicles 
shed from tumour cells (glioblastoma) to endothelial cells have been shown to have a pro-
angiogenic effect (Skog et al., 2008). Shedding vesicles can also contribute to tumour cell 
growth by inducing Fas-dependent apoptosis of activated lymphocytes (Albanese et al., 1998, 
Kim et al., 2005). 
In a lung cancer model, human and murine lung cancer cell lines secrete MVs in 
response to non-apoptotic doses of hypoxia, irradiation and chemotherapy (Albanese et al., 
1998). They also activated the phosphorylation of MAPKp42/44 and AKT in these stromal 
cells. They also induced expression of LIF (leukaemia inhibitory factor), IL-11, VEGF and 
MMP9 in bone marrow and lung derived fibroblasts.  
Evidence suggests that MV from activated tumour cells can modulate the function of 
tumour infiltrating lymphocytes e.g. MVs from melanoma cells may express Fas ligand on 
their surface which becomes biologically active upon binding to CD95 on T-lymphocytes and 
then induce apoptosis. This could be a mechanism for cancer cells to elude tumour infiltrating 
T lymphocytes (Zwaal and Schroit, 1997). Conversely, MVs secreted by tumour cells may 
have a beneficial effect by increasing the survival of tumour infiltrating monocytes by 
interacting with them to alter their immunophenotype (transfer of CCR6 and CD44v7/8 to 
monocytes can prevent apoptosis) (Baj-Krzyworzeka et al., 2006). 
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The evidence described above highlights that MV secretion is essential in cancer 
progression therefore they could be a potential source of clinically useful biomarkers in the 
detection and diagnosis of various cancers. 
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Section 1.6 : Aims and Objectives 
As previously described, early detection can greatly reduce the risk of death due to 
CRC and patients have a much greater 5-year survival rate if diagnosed at an early stage. 
Unfortunately, the currently used biomarkers are insufficient for wide scale mass screening to 
detect the presence of early stage CRC. Previous studies in our group have focused on 
biomarker discovery in urine and serum from patients with CRC using SELDI and MALDI 
techniques (Ward et al., 2008a, Ward et al., 2006c) as well as studies to investigate other 
cancer types such as hepatocellular carcinomas (HCC) and gastric cancers (Mohri et al., 2009, 
Ward et al., 2006a). 
The aim of the work outlined in this thesis is to identify novel candidates for the early 
detection of CRC using a cell model. Proteomic methods will be used to identify differentially 
secreted proteins in conditioned media (CM) from two cell lines that will be used as model for 
early tumour progression. Initially, two-dimensional electrophoresis will be used to analyse 
proteins secreted by the RG/C2 and PRG/C2 cell lines and this will be followed by the use of 
quantitative methods such as stable isotope labeling of amino acids in culture (SILAC) to 
investigate the relative abundance of the secreted proteins identified. 
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Chapter 2 : Materials and Methods 
2.1 Cell Culture 
2.1.1. Basic Media 
DMEM (41965-039): Purchased from GIBCO Ltd (Invitrogen Corporation). Supplied 
as a liquid (1x) in 500ml sterile bottles, supplemented with L-glutamine and adjusted to pH 
7.4. Media was stored at 4ºC. 
2.1.2. Other sterile solutions and supplements 
Penicillin/Streptomycin (15140-163): Purchased from GIBCO Ltd. Supplied as a 
liquid (10,000 units/ml penicillin and 10,000µg/ml streptomycin) and stored at -20ºC. 5ml 
was added to a 500ml of DMEM. 
Fetal Calf Serum (FCS – 1009-148): Purchased from GIBCO Ltd. Supplied as a liquid 
in 500ml bottles and stored at -20ºC. 
Insulin (I0516): Purchased from SIGMA-ALDRICH. Supplied as a 10mg/ml liquid 
and stored at 4ºC. 380µl was added to 500ml DMEM. 
Hydrocortisone (H6909): Purchased from SIGMA-ALDRICH. Supplied as a 50µM 
liquid and stored at -20ºC in 680µl aliquots. 1 aliquot was defrosted and added to 500ml 
DMEM. 
Trypsin, 0.25% (1X) with EDTA (25200-056): Purchased from GIBCO Ltd. Contains 
2.5g/L of Trypsin (1:250) and 0.38g/L of EDTA•4Na in Hanks' Balanced Salt Solution 
without CaCl2, MgCl2 • 6H2O, and MgSO4 • 7H2O, contains phenol red. 
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10% DMSO / FCS solution: DMSO (D4540 99.5%) was purchased from SIGMA-
ALDRICH. 10% DMSO / FCS solution was prepared by adding 2ml of DMSO to 18ml of 
FCS. 
2.1.3.  Maintenance of Cell Lines 
The media was prepared by adding the following to 500ml of DMEM: 5ml 
penicillin/streptomycin (final concentration - 100 units/ml penicillin and 100µg/ml 
streptomycin): 120ml of FCS (final concentration – 20%); 380µl of insulin (final 
concentration – 7.6µg/ml) and 680µl of hydrocortisone (final concentration – 68nM). This 
will be referred to as supplemented DMEM. Cells were grown to ~80% confluency in tissue 
culture coated plastic T75 flasks at 37ºC supplied with 5% CO2. All solutions were incubated 
at 37ºC for at least 20mins. Cells were washed with sterile PBS and treated with 2ml trypsin 
until cells had detached from the flask. 8ml of supplemented DMEM was added to the flask 
and 5ml of cell suspension was added to fresh flasks along with another 5ml of supplemented 
DMEM and incubated at 37ºC in 5% CO2. 
2.1.4. Cryopreservation of Cell lines 
Cells were grown to ~80% confluency in tissue culture coated plastic T75 flasks at 
37ºC in 5% CO2. All solutions were incubated at 37ºC for at least 20mins. Cells were washed 
with sterile PBS and treated with 2ml tissue culture grade trypsin until cells had detached 
from the flask. 8ml of supplemented DMEM was added and then transferred to a 50ml tube. 
The cells were centrifuged for 5mins at 1,000rpm at 4ºC. The cell pellet was re-suspended in 
PBS and the centrifugation step was repeated. The cell pellet was then re-suspended in 1ml of 
10% DMSO/FCS solution per T75 flask and transferred to 1ml cryovials to be frozen at -20ºC 
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overnight in a ‘Mr Frosty’ freezing container (Nalgene) for a freezing the cells at -1ºC/min. 
Frozen aliquots of cells were then stored in the gas phase of liquid nitrogen at -140ºC. 
2.1.5. Recovery of cryopreserved cell lines 
All solutions were incubated at 37ºC for at least 20mins. 1ml aliquots of cells were 
defrosted at 37ºC and then added to 5mls of supplemented DMEM and centrifuged at 
1,000rpm for 5mins. The cell pellet was re-suspended in 5mls supplemented DMEM and 
transferred to a T25 flask and incubated at 37ºC in 5% CO2 until 80% confluent. 
2.1.6. Cell Lines 
RG/C2 and PRG/C2: Both cell lines were provided by Professor C Paraskeva from the 
University of Bristol. The RG/C2 is a non-tumorigenic cell line that was derived from a 
sporadic colonic adenoma (1-2cm in diameter) isolated from a 59 year old female (Paraskeva 
et al., 1989). The PRG/C2 cell line was isolated from the RG/C2 cell line following in vitro 
transformation by treatment with gamma radiation and represents a transformed adenoma 
(unpublished data, C. Paraskeva). Together, these cell lines will be used as a model of early 
tumour progression in one clonal cell. 
2.2 Harvesting MVs from Conditioned Media (CM) 
Cells were grown to 80% confluency and then washed three times with serum free 
(SF) DMEM. The cells are then incubated for 24hrs in 6mls SF DMEM (per T75 flask) at 37 
ºC in 5% CO2. The CM was transferred to a 50ml tube and centrifuged twice at 1,500rpm for 
10mins to remove cell debris. The CM was then centrifuged at 150,000g for 1h at 4ºC (rotor 
and centrifuge pre-chilled at 4ºC, with brake off). The supernatant was collected and labeled 
remaining conditioned media (REM CM). The barely visible pellet was re-suspended in PBS 
and a protein concentration was determined using BCA protein assay. The proteins from the 
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REM CM fraction were extracted by acetone precipitation as follows. Five times volume of 
acetone (pre-chilled at -20ºC) was added to the REM CM and incubated at -20ºC for 16 hrs. It 
was then centrifuged at 12,000xg for 20mins at 4ºC. The supernatant was discarded and the 
pellet was re-suspended in 500µl of water. 2.5mls of acetone was added and then incubated at 
-20ºC at least 1 hr and centrifuged at 12,000xg for 20mins at 4ºC. The supernatant was 
discarded and the pellet was re-suspended in PBS for protein concentration determination 
using BCA protein assay. 
2.3 Sucrose Density Gradient Ultracentrifigation 
Sucrose Gradient: A sucrose stock solution (2.6M) was prepared; 44.5g of sucrose 
was added to 50mls of 20mM HEPES and warmed in a beaker of hot water for 10-15mins. 
This stock solution was used to prepare 8 different concentrations of sucrose in 20mM 
HEPES as described in Table 2.1. 
Concentration 
(M) 
Dilution Factor Volume of 2.6M 
sucrose stock solution 
(ml) 
Volume of 20mM 
HEPES (ml) 
2.00 1 : 1.30 7.70 2.30 
1.75 1 : 4.80 6.70 3.30 
1.50 1 : 1.73 5.80 4.20 
1.25 1 : 2.08 4.80 5.20 
1.00 1 : 2.60 3.80 6.20 
0.75 1 : 3.46 2.90 7.10 
0.50 1 : 5.20 1.90 8.10 
0.25 1 : 10.40 0.96 9.04 
0.00 - 0.00 10.00 
 
 
Table 2. 1 : Sucrose Density Gradient Ultracentrifugation Fractions 
Table to show the composition and concentration of each sucrose fraction utilised in the 
Sucrose Density Gradient Ultracentrifugation protocol 
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An MV fraction was prepared form CM from RG/C2 cells as described in Section 2.2 
(10 x T75 flasks). The MVs were re-suspended in 4ml of a 2.6M sucrose stock solution. 1ml 
of each solution was carefully layered on top of the MV fraction starting with the densest 
(2.60M) and ending with the 20mM HEPES only solution. This was centrifuged at 100,000xg 
for 15hrs (no brake). Each sucrose layer was collected, diluted in PBS and centrifuged at 
150,000xg for 1hr (no brake). The pellet from each fraction was re-suspended in 40µl of 1 x 
SDS-SB and stored at -20ºC. 
2.4 Harvesting Cell Lysates and Subcellular Fractionation 
Lysis buffer: 20mM Tris-HCl pH 7.4, 10mM MgCl2, 10mM CaCl2, 1 protease 
inhibitor cocktail Tablet per 50ml. 
Cells were grown to 80% confluency and then washed three times with SF DMEM. 
The cells are then incubated for 24hrs in 6mls SF DMEM (per T75 flask) at 37 ºC in 5% CO2. 
The cells were washed three times with ice-cold PBS and then lysed in 1ml of ice cold 
hypotonic lysis buffer (per T75 flask) for 20mins at 4°C. The cells were then scraped into a 
1.5ml tube and sonicated in a sonicating water bath for 5mins twice (allowing lysate to cool 
on ice between sonications). The lysates were then centrifuged at 2,000rpm for 5mins at 4°C. 
The supernatant was transferred to a fresh tube (A) and the pellet was re-suspended in 1ml 
lysis buffer. The pellet was washed twice and final pellet (nuclear fraction) was stored in lysis 
buffer at -20ºC. Supernatant (A) collected in previous step was centrifuged at 13,000rpm for 
30mins at 4°C. The supernatant was transferred to a fresh tube (B) and the pellet was washed 
twice. The pellet (heavy membrane fraction) was stored in lysis buffer at -20ºC. Supernatant 
B (cytosolic/light membrane fraction) was acetone precipitated and stored in lysis buffer at -
20ºC. The protein concentration for all fractions was determined by BCA protein assay. 
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2.5 BCA Protein Assay 
BCA protein assay kits: Purchased from Pierce (Thermo Scientific) as two reagents (A 
and B). Both were stored at room temperature. Reagent A (cat no 23223). Reagent B (cat no 
23224). 
For 1 x 96-wellplate: 25mls of reagent A was mixed with 0.5mls reagent B to make a 
working reagent (WR). 25µl of each sample was added to a well of a 96-wellplate.  Then add 
200µl of WR to each well and incubate at 37ºC for 30 minutes. The plate was allowed to cool 
to room temperature then the absorbance was measured at 562nm using a UV 
spectrophotometer. 
2.6 Two-Dimensional Electrophoresis (2-DE) 
2.6.1. Sample Preparation 
Rehydration Buffer: 8M urea, 50mM DTT, 4% CHAPS, 0.2% carrier ampholytes, 
0.0002% bromophenol blue. Stored at -20ºC. 
2D Quant Kit (80-6483-56): Purchased from GE Healthcare and stored at 4ºC. 
Components: Precipitant (renders proteins insoluble); Co-precipitant (contains reagents that 
co-precipitate with proteins and enhances their removal from solution); Wash buffer (used to 
remove non-protein contaminants from the protein precipitate); Wash additive (contains a 
reagent that promotes rapid and complete re-suspension of the sample proteins). 
2D Clean Up Kit (80-6484-51): Purchased from GE Healthcare and stored at 4ºC. 
Components: Precipitant (renders proteins insoluble); Co-precipitant (contains reagents that 
co-precipitate with proteins and enhances their removal from solution); Copper solution: 
(precipitated protein is re-suspended with this solution); Colour reagent A: (this solution is 
mixed with colour reagent B to prepare the colour reagent used to measure unbound copper 
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ion); Colour reagent B (this solution is mixed with colour reagent A to prepare the colour 
reagent used to measure unbound copper ion); Bovine serum albumin standard solution: (this 
solution is used to prepare a standard curve). 
All samples were collected in rehydration buffer and a protein assay was carried out 
using the 2D Quant kit as manufacturer’s instructions. 500µl of precipitant was added to each 
sample (3µl) and BSA standards (0, 10, 20, 30, 40, 50µg), mixed and incubated for 2-3mins at 
room temperature. 500µl of co-precipitant was added to each tube and mixed by inverting 
tube. The tubes were centrifuged at 10,000 x g for 5mins and the supernatant was removed 
immediately. The pellet was briefly centrifuged again and the residual supernatant was 
removed. 100µl of copper solution and 400µl of de-ionised water was added and vortexed to 
dissolve pellet. 1ml of working colour reagent (prepared by mixing 1 part reagent B with100 
parts reagent A) was added and then incubated at room temperature for 15-20mins. The 
absorbance of each sample was read at 480nm using water as a reference sample and a 
standard curve was generated using the BSA standard samples to determine concentration of 
test samples. 
Once protein concentration was determined the samples were de-salted using the 2D 
Clean Up kit as manufacturer’s instructions. 100µg (1-100µl) of sample was added to 300µl 
of precipitant, vortexed and incubated at 4º for 15mins. 300µl of co-precipitant was added and 
then centrifuged at 12,000 x g for 5mins. The supernatant was carefully removed, the pellet 
was centrifuged again briefly and the residual supernatant was removed. Without disturbing 
the pellet, 40µl of co-precipitant was layered on top of pellet and then incubated at 4ºC for 
5mins. The pellet was the centrifuged again for 5mins and the supernatant was removed. 
Without disturbing the pellet, 25µl of de-ionised water was layered on top of pellet and 
vortexed for 5-10secs to disperse pellet (not dissolve). 1ml of wash buffer (pre-chilled at -
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20ºC) followed by 5µl of wash additive was added, vortexed and incubated at -20ºC for 
30mins (vortexing every 10mins). The tubes were centrifuged at 12,000 x g for 5mins and the 
supernatant was removed. The pellet was then air dried for 5mins and resuspended in an 
appropriate volume of rehydration buffer. 
2.6.2. Isoelectric Focusing 
Running buffer - 10x Tris/Glycine/SDS Buffer (161-0732): Purchased from BIO-RAD. 
Diluted 1:10 with water and stored at room temperature. 
IPG STRIPS – Ready Strip IPG strips 11cm pH 3-10NL 12pack (163-2016): 
Purchased from BIO-RAD and stored at -20ºC. 
Equilibration buffer: as rehydration buffer with either DTT or iodoacetamide 
2D Gels - Criterion Precast Gel  12.5% Tris-HCl, 1.0mm. IPG+1 well comb, 11cm 
(345-0102): Purchased from BIO-RAD and stored at 4ºC.  
200µl of sample (~200µg) was added into 1 lane of the IEF focusing tray in one 
continuous line. The protective cover of the IPG strip was removed and laid gel side down 
over the sample with the ‘+’ over the anode. 1ml of mineral oil was then used to cover the 
strip and sample to prevent drying out. The Isoelectric focusing was then carried out using the 
PROTEAN IEF CELL instrument at 20ºC with a maximum current of 50µA/IPG strip for 
12hrs. For 11cm strip the following program was used: start voltage 0V, end voltage 8,000V, 
volt hours 20-35,000 V-hr, Ramp – rapid. The IPG strip was then removed from the IEF 
focussing tray carefully using forceps and the gel was placed gel side up into a clean, dry 
disposable rehydration/equilibration tray and incubated at room temperature with 
equilibration buffer/DTT (100mg of DTT in 10ml rehydration buffer) for 15mins. Remove 
the equilibration/DTT, overlay strip with equilibration buffer/iodoacetamide (200mg of 
iodoacetamide in 10ml rehydration buffer) and incubate for 15mins at room temperature. The 
Chapter 2                                                                                                  Materials and Methods 
109 
strip was then loaded onto a Criterion pre-cast gel for electrophoresis (200V constant, starting 
current: 90-120mA/gel, final current: 35-55mA/gel for 55mins). Following electrophoresis, 
the gel was stained with CBB G250. 
2.7 Separation of Proteins by SDS-PAGE 
SDS-SB: Made up at a 5X concentration (0.3125M Tris-HCl pH 6.8, 10% SDS, 50% 
glycerol, 0.01% bromophenol blue) and stored in 500µl aliquots at -20ºC. This stock solution 
was diluted 1:5 and DTT was added immediately prior to use (7.7mg to 1ml) to give a final 
concentration of 50mM. 
MOPS running buffer: 50mM MOPS, 50mM Tris base, 0.1% SDS, 0.1mM EDTA (pH 
7.7) 
TBST: 150mM NaCl, 100mM Tris pH 7.5, 0.1% TWEEN 20. 
NuPAGE Transfer Buffer: (Made fresh each time). 25mM Bicine, 25mM Bis-Tris, 
1mM EDTA, 20% methanol. 
NuPAGE Novex 4-12%Bis-Tris gels 1.0mm x 10 wells (NP0321BOX): Purchased from 
Invitrogen Corporation in packs of 10 and stored at 4ºC. 
SeeBlue® Plus2 prestained markers (LC5925): Purchased from Invitrogen 
Corporation. 5µl was used in one well per gel. 
5X SDS-SB was added to samples (1 part 5X SDS-SB and 4 parts sample) and heated 
at 95ºC for 5mins and centrifuged at 13,000rpm for 1min. 25µl of sample and markers were 
loaded into each well and the gel was run for approximately 50mins at a constant 200V 100-
125mA/gel (start); 60-80mA/gel (end). 
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2.8 Western Blotting 
ECL western blotting detection reagents (RPN2106): Purchased from GE Healthcare. 
PVDF Immobilon-P  0.45um (IPHV00010): Purchased from Millipore. 
The proteins on the gel were transferred to a PVDF membrane (pre-washed with 
methanol and water) for 1hr at a constant 30V. The PVDF membrane was then blocked in 5% 
milk powder in TBST for 1hr at room temperature with agitation. The primary antibody was 
diluted to the desired concentration in 5% milk powder/TBST and the PVDF membrane was 
incubated in the primary antibody for 16hrs at 4ºC. The membrane was then washed with 
TBST for 1hr (changing TBST every 10-15mins) and incubated with the secondary antibody 
(diluted to the desired concentration in 5% milk powder in TBST) for 1hr at room 
temperature. The wash step with TBST was repeated and the membrane was developed using 
ECL detection reagents and exposure to X-ray film.  
2.8.1. Stripping Blots 
Restore™ Western Blot Stripping Buffer (21059): Purchased from Pierce ready to use 
and stored at room temperature. 
The blot was first washed in TBST as previously described and then incubated in 
25mls Restore™ Western Blot Stripping Buffer for 10-15mins at room temperature. The 
TBST wash step was repeated and blot was ready to block and re-probe with primary 
antibody. 
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2.8.2. Antibodies 
 
(a) 
Antibody Supplier Working Immunogen
Dilution
Mouse monoclonal [AC-15] 
to beta Actin (ab6276)
AbCam 1:40,000 DDDIAALVIDNGSGL (aa 1-14 of 
X.Laevis)
AGR2 monoclonal antibody 
(M03), clone 1C3 
(H00010551-M03)
Abnova 
(Tebu-Bio)
1µg/ml 
(1:1000)
Raised against a full length 
recombinant AGR2
Rabbit polyclonal to 
Annexin A1 (ab33061)
AbCam 1.25µg/m
l (1:1600)
synthetic peptide derived from aa 12-
61 of human Annexin A1
Mouse monoclonal [Col-1] 
CEA (ab17254)
AbCam 1:200 human CEA
EMMPRIN (N-19) (sc-
9752)
Santa Cruz 1:1000 N-terminus human EMMPRIN
Rabbit monoclonal [E144] 
to EpCAM (TACSTD1) - 
(ab32392)
AbCam 1:2,500 C-terminus of human EpCAM
Rabbit polyclonal to Hsc70 
(ab1427)
AbCam 1µg/ml 
(1:500)
not specified
Rabbit Anti-HSP90α 
(Hsp86) Polyclonal 
antibody (SPS-771)
Stressgen 
Bioreagents 
1:2000 synthetic peptide 
PEETQTQDQPM(C) from 2-12 of 
mouse Hsp86
Mouse Anti-Hsp90ß 
Monoclonal antibody (SPA-
842)
Stressgen 
Bioreagents 
1µg/ml 
(1:950)
Immunogen is purified recombinant 
human Hsp90ß
Anti-OLFM4 (Olfactomedin 
4) polyclonal antibody 
(60B898)
Antagene 1µg/ml N-terminal human OLFM4
Anti- Human Selenium 
Binding Protein (M061 3)
MBL 1µg/ml 
(1:1000)
hybridoma - fusion of mouse 
myeloma cell SP2/0 with Balb/c 
mouse splenocyte immunised with 
GST-full length human SBP protein.  
 
. 
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(b) 
Antibody Supplier Working
Dilution
Goat anti-mouse IgG-HRP (sc-2005) Santa Cruz 1:5000
Goat anti-rabbit IgG-HRP (sc-2004) Santa Cruz 1:5000
Goat anti-mouse IgM-HRP (sc-2064) Santa Cruz 1:5000
Donkey anti-goat IgG-HRP (sc-2020) Santa Cruz 1:5000  
Table 2. 2 : Antibodies. 
(a) Details of all primary antibodies used throughout this study. (b) Details of all secondary 
antibodies used throughout this study. 
 
2.8.3. Densitometry 
Western blots were analysed for differences in protein expression using the GS-800 
calibrated densitometer and the Quantity One software. 
2.9 Staining of Protein Gels  
2.9.1. Coomassie Staining 
Coomassie Brilliant Blue (CBB) G250 Stain: 0.08% CBB G250, 1.6% 
orthophosphoric acid, 8% ammonium sulphate, 20% methanol. The CBB G250 was 
purchased from Sigma and stored at room temperature. Staining solution was made up in the 
following order: 8ml orthophosphoric acid in 384ml distilled water and 40g ammonium 
sulphate was added. 0.5g CBB G250 was dissolved in 10ml distilled water and 8mls was 
added to previous solution. Then 100ml methanol was added whilst stirring (final volume 
500ml). 
Destain Solution: 1% acetic acid in distilled water. 
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The coomassie stain was prepared as described above. Protein gels were stained at 
room temperature with coomassie for 16hrs and destained for 6-8hrs (changing the destain 
solution every 30-60mins) or until the background looked clear (Shevchenko et al., 1996). 
Gels were stored at 4ºC. 
2.9.2. Silver Staining 
All solutions were made fresh each time and stored at room temperature. 
Fixing Solution: methanol : acetic acid : distilled water (45 : 5 : 45). 
Sensitising Solution: 0.02% sodium thiosulphate (0.1g Na2S2O3 in 500ml distilled 
water). 
Silver Stain: 0.1% silver nitrate (0.5g AgNO3 in 500ml distilled water -store in the 
dark). 
Developing Solution: 0.04% formaldehyde, 2% sodium carbonate (10g Na2CO3, 540µl 
formalin 37% in 500ml distilled water). 
Stop Solution: 1% acetic acid in distilled water. 
All steps were carried out at room temperature on a shaker. The gel was fixed in the 
fixing solution for 30mins and washed in distilled water for 20-60mins to remove acid 
(change water 2-3 times). The gel was then incubated in the sensitising solution and washed 
twice with distilled water for 1min each. The gel was then incubated with the silver stain for 
20-40mins and washed twice with distilled water for 1min each. The gel was incubated in the 
developing solution until the gel had developed enough (0.5-4mins) and the stop solution was 
added (Shevchenko et al., 1996). The gels were stored at 4ºC. 
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2.10 In-Gel Digestion  
Acetonitrile (SO-2856-B025): Purchased from LGC Promochem and stored at room 
temperature. 
Water for HPLC (23 595 328): Purchased from VWR BDH PROLABO and stored at 
room temperature. 
Formic Acid (F/1850/PB08): Purchased from Fisher Scientific and stored at room 
temperature. 
Sequencing Grade Modified Trypsin (V5111): Purchased from Promega and stored at -
20ºC. 
DTT (Diothiothreitol ultrapure- 15397): Purchased from USB Corporation and stored 
at -20ºC. 
Iodoacetamide (I6125): Purchased from Sigma and stored at 4ºC. 
All tubes were rinsed with 0.1% formic acid/50% acetonitrile before use (unless sterile 
tubes from an unopened bag were used). The gel was placed on a clean glass plate and bands 
were excised from the gel (smallest size possible) and placed in the clean tubes. 
The following step was for silver stained gels only. The bands were washed with 
300µl of water for 15mins to remove the acetic acid. The supernatant was removed and 200µl 
of 15mM potassium ferricyanide/50mM sodium thiosulphate was added and incubated at 
room temperature on a shaker until the silver was removed (>1hr). The supernatant was 
removed and the bands were washed with 300µl of water for 15mins. 
 The in-gel digestion protocol is the same for both silver and coomassie stained gels 
following destain. The bands were washed twice with 200µl of 50% acetonitrile/50mM 
ammonium bicarbonate for 45mins each at 37°C. The supernatant was removed and the bands 
were dried using a vacuum evaporator for 15mins. 50µl of 50mM DTT (made up in 10% 
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acetonitrile/50mM ammonium bicarbonate) and incubated at 56°C for 1hr to reduce the 
disulphide bonds involved in protein folding. The supernatant was removed and 50µl of 
100mM iodoacetamide (made up in 10% acetonitrile/50mM ammonium bicarbonate) was 
added to amidomethylate the cysteine residues to prevent re-folding of the protein. The bands 
were then incubated at room temperature in the dark for 30mins. The supernatant was 
removed and the bands were washed three times with 10% acetonitrile/50mM ammonium 
bicarbonate for 15mins each at room temperature with agitation.  The bands were dried using 
a vacuum evaporator for 2-3 hrs. The bands were then rehydrated in 20µl of 12.5µg/ml 
sequencing grade modified trypsin in 10% acetonitrile/50mM ammonium bicarbonate for 1hr 
at room temperature. 30µl of 10% acetonitrile/50mM ammonium bicarbonate was added and 
the bands were incubated at 37°C for 16hrs. The supernatant was collected and 30µl of 3% 
formic acid in water was added and incubated at 37°C for 1hr. The supernatant was collected 
and added to previous supernatant. This step was repeated for 30min and supernatant was 
collected (a final volume of 70-90µl).  The sample was stored at -20ºC until ready for mass 
spectrometry. 
2.11 Mass Spectrometry 
Figure 2.1 shows a schematic of the HPLC and LCQ Deca XP plus setup. 
BioBasic C18 Reverse Phase Column 150x0.18 mm – particle size 5µm (72105-
150265): Purchased from Thermo Electron Corporation. 
µ-Precolumn™ cartridge (C18, 5µm, 100Å, 30µm ID x 5mm) P/N 16045: Purchased 
from LC Packings (Dionex) 
Acetonitrile (SO-2856-B025): Purchased from LGC Promochem and stored at room 
temperature. 
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Figure 2. 1 : LC MS/MS set up used in this study.  
(a) Photo of the LC Packings (Dionex) Ultimate HPLC system. (b) Photo of the LCQ Deca 
XP ion-trap mass spectrometer from Thermo Finnigan.  (c) Schematic diagram of the setup of 
the HPLC coupled to the LC MS/MS. Samples (up to 100µl) are drawn from the sample vials 
by syringe into the sample loop. The sample is then passed through a C18 µ-precolumn 
cartridge at a flow rate of 30µl/min before then being loaded onto the reverse phase (RP) 
column. The C18 µ-precolumn cartridge cleans the sample and protects RP column from 
blockages. The peptides are then eluted from the RP column with an increasing acetonitrile 
gradient at a flow rate of 1µl/min and sprayed into the ion tube where they are analysed by the 
mass spectrometer. 
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Water for HPLC (23 595 328): Purchased from VWR BDH PROLABO and stored at 
room temperature. 
Formic Acid (F/1850/PB08): Purchased from Fisher Scientific and stored at room 
temperature. 
Solution A: 5% acetonitrile/0.1% formic cid in HPLC grade water. 
Solution B: 95% acetonitrile/0.1% formic acid in HPLC grade water. 
2.11.1. Calibration 
Caffeine (C-6035): Purchased from SIGMA-ALDRICH. 1mg/ml solution of caffeine 
in 100% methanol was prepared and stored at 4ºC. 
MRFA: Supplied in the accessory kit from manufacturers (Thermo Electron 
Corporation) and has an average molecular weight of 523.6u. 1ml stock solution of 5nmol/µl 
in 50:50 methanol/water was prepared by dissolving 3mg of the MRFA in 1ml 50:50 
methanol:water and mixing thoroughly. Stored at 4ºC. 
ULTRAMARK 1621 (L16698): Purchased from Alfa Aesar (distributor was Lancaster). 
A 10ml stock of 0.1% ultramark was prepared by mixing 10µl with 10ml of acetonitrile using 
a syringe.  
ESI CALIBRATION SOLUTION: 5ml of the calibration solution was prepared by 
adding 100µl of the caffeine stock solution, 2.5ml of the stock solution of ultramark 1621 and 
50µl of glacial acetic acid to 2.34ml of 50:50 methanol:water. Solution was mixed thoroughly 
and stored at 4ºC. 
The calibration solution was sprayed directly into the mass spectrometer at 2µl/min 
and the spectra were observed for the presence of the caffeine, MRFA and ultramark peaks 
and then the mass spectrometer was calibrated. Figure 2.2a shows an example of the typical 
spectra obtained during calibration. 
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(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
Figure 2. 2 : Calibration and Tuning Spectra. 
(a) Spectra of the peaks (in bold) found during calibration: Caffeine: 195.11; MRFA: 524.48; 
Ultramark 1621: 122.45, 1322.60, 1422.25, 1521.67, 1622.38, 1722.23, 1822.01, 1922.60. (b) 
Spectra of the peaks found during tuning (in bold). The doubly and triply charged species of 
the peptides are more commonly seen: [Val5] Angiotensin I: 642.20 (+2), 428.54 (+3); [Asn1, 
Val5] Angiotensin II: 516.51 (+2); Bradykinin: 531.02 (+2); Angiotensin: 648.2 (+2), 433.11 
(+3). 
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 2.11.2. Tuning using Peptide Standards 
[Val5] Angiotensin I (A-9402):  Purchased from SIGMA-ALDRICH. Mass of 1282.5 
(+1), 642.2 (+2), 428.5 (+3). 
[Asn1, Val5] Angiotensin II (A-6402): Purchased from SIGMA-ALDRICH. Mass of 
1031.2 (+1), 516.5 (+2), 344.7 (+3). 
Bradykinin (B-3259): Purchased from SIGMA-ALDRICH. Mass of 1060.2 (+1), 
531.1 (+2), 354.3 (+3). 
Angiotensin (A-9650): Purhased from SIGMA-ALDRICH. Mass of 1296.5 (+1), 648.2 
(+2), 433.11 (+3). 
1mg of each of the above peptide standards were reconstituted in 1ml of solution A 
(5% acetonitrile, 0.1% formic acid). The stock solution of tuning standards was made by 
adding 10µl of each peptide to 960µl of solution A. This was diluted 1:10 to make the 
working stock for tuning. This solution was sprayed directly into the mass spectrometer at 
2µl/min and the spectra were observed for the presence of the above peaks. The most 
abundant peak was chosen for tuning i.e. 428.54 which corresponds to triply charged species 
of Angiotensin I (see Figure 2.2b). 
2.11.3. Testing sensitivity using a BSA standard 
A 1mg/ml (15.15nmoles/ml) stock of BSA (in 25mM ammonium bicarbonate) was 
prepared. 50µl of 100mM DTT was added to 1ml of the BSA stock and then incubated at 
56ºC for 1hr. 50µl of 200mM iodoacetamide was added and then incubated at room 
temperature for 30mins in the dark. Another 50µl of 100mM DTT was added to inactivate the 
excess iodoacetamide (interferes with trypsin digestion of proteins) followed by 10µg of 
sequencing grade modified trypsin (in 25mM ammonium bicarbonate) was added. The BSA 
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was incubated at 37ºC for 12-16hrs. The digested BSA was diluted to in solvent A to 
312.5fmoles/ml. 
80µl of the diluted digested BSA (25fmoles) was then analysed by LC MS/MS using 
the acetonitrile gradient outlined in Figure 2.3. The raw file was searched against a bovine 
database, created from an nr database downloaded from the NCBI website 
(ftp://ftp.ncbi.nih.gov/blast/db/FASTA/). If the LC MS/MS was working optimally, the results 
would show >25% coverage of BSA when the Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, 
+/-3: 2.50) filter was used. 
2.12 SILAC 
2.12.1. Preparing Media 
2.12.1.1. For the C13 Arg SILAC experiments 
L-Arginine:HCL (U-13C6) CLM-2265-01: Purchased from Cambridge Isotope 
Laboratories, Inc. Supplied as 100mg of lyophilised powder. Stored at  room temperature. 
L-Lysine Biotechnology Performance certified (L9037-25G): Purchased from SIGMA-
ALDRICH. Stored at room temperature. 
L-Arginine, reagent grade (A-5006): Purchased from SIGMA-ALDRICH. Stored at 
room temperature. 
DMEM with 4.5g/L D-glucose and 25mM HEPES. Without L-glutamine, L-arginine 
and L-lysine (KI-05060 cat no 06-1055-52-1A): Custom made by Geneflow supplied in 10 x 
500ml bottles. Stored at 4ºC. 
Fetal Bovine Serum dialysed (F-0392): Purchased from SIGMA-ALDRICH and 
supplied in 500ml bottles. Stored at 4ºC. 
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Figure 2. 3 : Acetonitrile gradients used in this Study. 
The sample is loaded onto the RP column (i) and at 7mins, the acetonitrile gradient increases 
from 5% to 45% solvent B over 40 or 93mins (ii). The gradient is then sharply increased to 
95% to clean the column for 10mins (iii) at which time it returns to 5% solvent B for 10mins 
to equilibrate column before the next sample is loaded (iv). (a) Diagram to show the 
increasing acetonitrile gradient used when analysing a BSA standard. (b) Diagram to show the 
increasing acetonitrile gradient used when analysing SILAC samples.  
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The media was prepared as follows: 
For the ‘heavy’ SILAC media, 42mg of L-arginine:HCL, 73mg of L-lysine and 290g 
of L-glutamine were all added to separate tubes of 5ml of DMEM and mixed thoroughly. All 
3 tubes were added to a 500ml bottle of DMEM along with 5ml of penicillin/streptomycin, 
380µl insulin and 680µl of hydrocortisone. This was then divided into 12 x 40ml aliquots and 
stored at 4ºC. The final concentrations of amino acids were: 84mg/L L-arginine, 146mg/L L-
lysine and 580mg/L glutamine. Immediately before use, 10ml of dialysed FBS was added and 
the media was filter sterilised using a 0.45µm syringe filter. The media for the ‘light’ SILAC 
was prepared as described above, replacing the L-arginine:HCl with L-arginine. 
2.12.1.2. For the C13 Lys SILAC experiments 
SILAC™ Protein Identification (ID) and Quantitation kit (SM1002) – Purchased from 
Invitrogen. Contents include: DMEM (2 x 1000ml); fetal bovine serum, dialysed (2 x 100ml); 
L-glutamine (100x) liquid (20ml); L-lysine HCl (100mg); L-arginine (2 x 100mg) and [U-
13C6]-L-lysine (*Lys) (100mg). All components were stored at 4ºC except for glutamine and 
FBS which was stored at -20ºC. Additional dialysed FBS (100ml) was purchased from 
Invitrogen (26400-036). 
The media for the C13 Lys SILAC experiments were prepared as per manufacturers 
(Invitrogen) instructions using the reagents supplied with the kit. 100mg of L-lysine HCl, [U-
13C6]-L-lysine (*Lys), 100mg L-arginine (x2) were added to separate 1ml tubes of 
unsupplemented DMEM and mixed thoroughly. 200ml of DMEM was removed from each of 
the 2 x 1000ml bottles and stored at 4ºC. For the ‘light’ SILAC media, add the 1ml aliquot L-
lysine HCl and one of the 1ml aliquots of L-arginine to 1 bottle of DMEM. For the ‘heavy’ 
SILAC’ media, add the 1ml aliquot of [U-13C6]-L-lysine and the other 1ml aliquot of L-
arginine. To each bottle add 10ml of 100x L-glutamine and 10ml of penicillin/streptomycin. 
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Each bottle was divided into 40 ml aliquots and stored at 4ºC. Immediately before use, 10ml 
of dialysed FBS (for a final concentration of 20%) was added and the media was filter 
sterilised using a 0.45µm syringe filter. 
2.12.2. Confirming labelling efficiency 
Each cell line was grown in either ‘heavy’ or ‘light’ SILAC media for 6 doublings and 
the serum free CM (using serum free media containing the appropriate ‘heavy’ and ‘light’ 
amino acids) was collected to confirm the labelling efficiency. The CM was acetone 
precipitated as previously described and 20ug was loaded onto a 4-12% Bis-Tris gel. Five 
bands were excised from each lane, in-gel digestion was performed and the samples were 
analysed by LC MS/MS. The raw data was searched against a human IPI database and the 
percentage of ‘heavy’ and ‘light’ Arg or Lys was calculated. 
2.12.3. LC-MS/MS Analysis 
The RG/C2 cell line was grown in media containing [12C6]-L-arginine and [12C6]-L-
lysine (i.e. light Arg and Lys) and the PRG/C2 cell line was grown in media containing either 
[13C6]-L-arginine and [12C6]-L-lysine or [12C6]-L-arginine and [13C6]-L-lysine (heavy Arg or 
heavy Lys) as described in Section 2.12.1. MVs were prepared from the CM as described in 
section 2.2. The MV fractions from the RG/C2 and either the heavy Arg PRG/C2 or heavy 
Lys PRG/C2 were mixed in a 1:1 ratio (normalised by cell number). 
The proteins in the MV sample were then separated by 1D electrophoresis on a 4-12% 
Bis-Tris gel. The whole lane was then cut into 40 equal slices and in-gel digestion was 
performed as previously described. The samples were then analysed by LC MS/MS using the 
acetonitrile gradient outlined in Figure 2.3b. The raw files were searched against a human IPI 
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database and the statistical analysis and relative abundance ratios were calculated using the 
TransProteomic Pipeline (TPP) (Section 2.13). 
2.13 Data Analysis 
2.13.1. Bioworks Browser v3.1 
Bioworks Browser v3.1 was supplied with LCQ Deca XP plus from Thermo Finnigan 
and uses SEQUEST browser. The software uses the raw files from the LC MS/MS analysis 
and generates dta files for each spectra which are in turn searched against a database of 
known proteins. The peaks detected in the full scans and their accompanying MS2 scans are 
used by the software to determine a peptide sequence match followed by a protein match for 
the peptides found. 
Dta generation parameters: Tolerance and limits for Dta generation –  
precursor mass - 1.40  
group scan - 20 (The number of intermediate MS/MS scans between two MS/MS 
scans that have the same precursor m/z value). 
minimum group count - 1 (The minimum number of MS/MS scans with the same 
precursor m/z value). 
minimum ion count – 15 (The minimum number of ions that must be present in the 
MS/MS spectrum of a peptide before the spectrum is included in the results of a search.  
 
Dta search parameters: Tolerance and limits for Dta search –  
Peptide - 1.50  
fragment ions - 0  
number results score - 250  
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ion series calculated in Dta search A, B and Y ions 
 
Modifications: 
 Carboxyamidomethylation on Cys residues 57.02 
 For SILAC experiments only: 6.00 on Lys or Arg residues 
Databases:  
IPI databases were downloaded from http://www.ebi.ac.uk/IPI/IPIhelp.html. 
NCBI human databases were generated from the non-redundant (nr) database 
downloaded from ftp://ftp.ncbi.nih.gov/blast/db/FASTA/ . 
The search results were exported to excel for further analysis and reporting. When 
using the IPI database, the protein names associated with accession numbers were not always 
shown in the exported excel spreadsheet. Single protein names could be found on the IPI 
website directly. This was also carried out in batches (up to 200 proteins at a time) using the 
DBfetch utility http://www.ebi.ac.uk/cgi-bin/dbfetch . A list of IPI accession numbers was 
generated in notepad and sorted in alphabetical order. A list of the associated protein names 
was retrieved in fasta format by uploading the notepad list of accession numbers on the 
DBfetch website. 
2.13.2. Trans Proteomic Pipeline (TPP) 
The TPP software is freely available online from the Institute for Systems Biology 
website (http://tools.proteomecenter.org/windows.php) (A. Keller et al., 2005, A. Keller et al., 
2002a, X. J. Li et al., 2003, Nesvizhskii et al., 2003). Figure 2.4 outlines the basic steps in 
using TPP for the analysis of large proteomic datasets. The software uses Cygwin, a Linux-
like environment for Windows. The MS/MS spectra were searched against a database of 
known proteins using Bioworks Browser (Section 2.13.1). The first step in the TPP analysis 
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involved converting the output files from SEQUEST to html and mzXML files as follows: 
(type in bold are the commands typed into the Cygwin terminal) 
The raw file was placed in the same folder as the dta and out files and these folders 
were placed in the wwwroot folder. When you right click on your folder, the command 
prompt box will open. 
out2summary *.out>my file.html .This converted the out files to 1 html file. 
(myfile refers to name of results folder) 
t2x.exe rawfilename.raw c . This converted the raw file to mzXML. 
(rawfilename refers to the name of the raw file) 
Sequest2XML myfile.html –Psequest.params . This converted the html file to xml 
file. 
The 3 files generated in steps 2-4 were moved to one folder for all 40 samples in one 
SILAC experiment for combined analysis using PEPTIDE PROPHET™ and PROTEIN 
PROPHET™. 
PEPTIDE PROPHET™ 
For C13 Arg SILAC: xinteract –X-nR,6.0 –A-lR *.xml  
For C13 Lys SILAC: xinteract –X-nK,6.0 –A-lK *.xml 
PROTEIN PROPHET™ 
For C13 Arg and C13 Lys SILAC: runprophet –OXA interact.xml 
A web address is given in the Cygwin terminal to access the results. 
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Figure 2. 4 : The TransProteomic Pipeline (TPP). 
The above diagram outlines the basic steps in analysing large proteomic datasets using the 
TPP software. Stage 1 involves converting output files (both dta and out files) to an XML 
format. Stage 2 involves validating the peptide sequence assigned to each acquired spectra 
using Peptide Prophet (includes quantification using Xpress or ASAPRatio) and calculates a 
probability score that the correct assignment has been made. Stage 3 involves validating the 
protein assignment to the peptide sequences. This stage also involves calculating a probability 
that the correct protein assignment has been made and also calculates an Xpress or 
ASAPRatio for that protein based upon those calculated for each individual peptide assigned 
to that protein in Peptide Prophet. Figure taken from (A. Keller et al., 2005). 
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2.13.3. FatiGO+ 
Before looking at gene ontology and functional annotation of proteins, the IPI 
accession numbers were converted to entrez gene ID symbols. This was carried out using an 
online resource known as REFDIC http://refdic.rcai.riken.jp/welcome.cgi (Hijikata et al., 
2007). A list of IPI accession numbers was generated in notepad. On the REFDIC website, 
choose tools then X-REF converter in toolbar. Options chosen: 
 Species – homosapiens 
 Type of input – IPI accession 
 Type of output – Entrez gene ID 
Then, the list generated in notepad was uploaded then submit. This list of gene 
symbols was then used to look at functional annotation and gene ontology. 
The GO terms for these proteins were then generated using an online resource known 
as FatiGO+ http://fatigo.bioinfo.cnio.es/bioinfo/ (Al-Shahrour et al., 2007, Al-Shahrour et al., 
2006). A list of gene symbols was generated in notepad and uploaded on the FatiGO website. 
Then all the functions required were highlighted (i.e. GO terms biological processes, cellular 
component and molecular function; KEGG pathways and BIOCARTA pathways) and submit. 
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Chapter 3 : Investigating the secretome from RG/C2 and PRG/C2 cells to identify 
potential biomarkers for the early detection of colorectal cancer using proteomic 
techniques. 
3.1 Introduction 
Proteomic techniques have been used to identify potential candidate cancer 
biomarkers from tumour tissues, serum, plasma and urine in a range of cancer types (W. C. 
Cho, 2007, Kozak et al., 2003, Ward et al., 2008a, Ward et al., 2006c). An increasing number 
of proteomic studies are now utilising cell-based models to identify secreted proteins as a 
source of potential biomarkers under the hypothesis that proteins released by cancer cell lines 
could escape into the bloodstream (Gronborg et al., 2006, Kulasingam and Diamandis, 2007, 
Looi et al., 2008, Mbeunkui et al., 2006, Mbeunkui et al., 2007, C. C. Wu et al., 2008, Zhong 
et al., 2008). The aim of this study was to identify differentially secreted proteins from the 
colorectal cancer cell lines RG/C2 and PRG/C2 in an attempt to identify potential markers of 
early tumour progression using proteomic techniques (see section 2.1.6 for description of cell 
lines). 
3.2 Analysis of Conditioned Media using 2D Gel Electrophoresis 
The starting point for this study was to use two-dimensional gel electrophoresis (2-
DE) to investigate differentially secreted proteins from colorectal cancer cell lines. 2-DE is a  
proteomic technique commonly used to identify differences between two samples (e.g. cancer 
vs normal) and has been used in a variety of studies using cell lines (Al-Ghoul et al., 2008, 
Cecconi et al., 2007, Looi et al., 2008, Rondepierre et al., 2009), conditioned media (CM) 
(Kulasingam and Diamandis, 2007, Mbeunkui et al., 2006, Mbeunkui et al., 2007, Roessler et 
al., 2006, Sardana et al., 2008, Sato et al., 2001, C. C. Wu et al., 2008), tumour tissue 
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(Friedman et al., 2004, Iwadate, 2008), serum ((no-authors-listed), 1996, Ahmed et al., 2004, 
He et al., 2008, Looi et al., 2008) and plasma (S. Y. Cho et al., 2008, Darde et al., 2007). CM 
was collected from both the RG/C2 and PRG/C2 cell lines and the proteins were acetone 
precipitated and re-suspended in PBS (see Section 2.2). The protein concentration was 
determined by BCA protein assay and 125µg of protein from both cell lines was then acetone 
precipitated again and re-suspended in 100µl of 2D Re-hydration buffer. The proteins in both 
samples were then separated by 2-DE (see Section 2.6). Figure 3.1 shows the 2-D gels of the 
CM from the RG/C2 and the PRG/C2 cell lines. Both gels showed very few spots indicating 
that not enough protein was loaded onto the gels due to either not enough starting material or 
loss of protein during two rounds of acetone precipitation. 
CM from both cell lines were collected again (as previously described), the proteins 
were acetone precipitated and re-suspended in 2D re-hydration buffer. The protein 
concentration was determined using the 2D Quant Kit (Pierce) (see Section 2.6) and 160µg of 
protein from both cell lines were separated by 2-DE. Figure 3.2 shows the 2-D gels of the CM 
from the RG/C2 and the PRG/C2 cell lines. Both gels still did not show the presence of many 
protein spots and the gels also exhibited horizontal and vertical streaking. This could be due 
to one the following: 
• Incomplete or excessive isoelectric focusing. Incomplete focusing does not allow 
proteins the opportunity to form discrete spots. Also, isoelectric focusing of IPG 
strips of varying pH ranges at the same time can lead to the same problem. If a 
sample is more conductive, it will draw most of the current and decrease the focusing 
rate for the other strips.  
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Figure 3. 1 : Initial 2D-PAGE Analysis of CM collected from the RG/C2 and PRG/C2 
cell lines. 
CM from 8.4x105 cells for both cell lines were acetone precipitated and re-suspended in PBS 
and the protein concentration was determined using BCA protein assay. The proteins were 
then acetone precipitated again for re-suspension in re-hydration buffer and the proteins were 
separated by 2D gel electrophoresis. (a) CM derived from the RG/C2 cell line (125µg). (b) 
CM derived from the PRG/C2 cell line (125µg). 
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Figure 3. 2 : 2D-PAGE Analysis of CM collected from the RG/C2 and PRG/C2 cell lines. 
CM from both cell lines was acetone precipitated and re-suspended in re-hydration buffer. 
Protein concentration was determined using the 2D Quant kit (Pierce) and the proteins were 
separated by 2D electrophoresis. (a) CM derived from the RG/C2 cell line (160µg). (b) CM 
derived from the PRG/C2 cell line (160µg). 
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• Protein Overloading. This causes aggregation of proteins resulting in precipitation at 
their isoelectric point. This is prevented by ensuring the protein load is within the 
guidelines set by the manufacturer. The recommended load for the IPG strips used in 
this study is 100-200µg and only 160µg of protein was used suggesting that protein 
overloading was not a problem in this case. 
• Problems with Protein Preparation. Contaminants such as salt, detergents, nucleic 
acids and lipids can alter a protein isoelectric point therefore altering its focusing on 
an IPG strip. As these samples were only acetone precipitated prior to IEF, it’s 
possible they may contain a few of these contaminants. 
• Protein Oxidation and Disulphide Formation. Disulphide bond formation prior to 
2DE can occur randomly intra- and inter molecularly to create various protein 
aggregates altering their isoelectric points and accumulation of protein multimers. 
Protein refolding and oxidative cross linking can be prevented by adding 
iodoacetamide to the equilibration buffer to IEF to block the cysteine sulfhydryl 
groups. As the equilibration buffer used in this buffer already contains 
iodoacetamide, this is unlikely to be the cause of streaking in these gels. 
• Poor Protein Solubilisation. This can be prevented by adding urea, NP-40, CHAPS, 
DTT or ASB-14 to the samples. The re-hydration buffer used in this study contains 
urea, DTT and CHAPS therefore poor protein solubilisation is unlikely to be the 
cause of streaking in these gels. 
• Poor placement of IPG strips on the 2nd dimension gel. 
After considering the possible reasons for streaking in the 2D gels shown in Figure 
3.2, the most likely cause appeared to be problems with protein preparation due to the 
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presence of contaminants. The experiment was then repeated including a sample cleanup step 
using the 2D Cleanup Kit (Pierce). 
CM was collected from the RG/C2 and PRG/C2 cell lines as previously described. 
The proteins were acetone precipitated and re-suspended in 2D Re-hydration buffer. The 
protein concentration was determined using the 2D Quant Kit (Pierce) (as described in 
Section 2.6) and 200µg of protein from both cell lines was prepared for 2DE using the 2D 
Cleanup Kit (Pierce) (as described in Section 2.6). The proteins in both samples were then 
separated by 2DE and Figure 3.3 shows the 2D gels for both the RG/C2 and the PRG/C2 cell 
lines carried out in biological triplicate. 
Figure 3.3 shows that the 2D gels were more successful with an increased number of 
spots observed demonstrating very similar protein spot patterns between the replicate 
experiments. Examination of the 2D gels from the biological replicates from the same cell line 
shows very similar spot patterns with differences in the staining intensities although the 
sample preparation in both experiments were identical. Figure 3.3 also shows very little 
difference in spot patterns between the RG/C2 and PRG/C2 gels in all three experiments. 
Each of the 2D gels also shows an area of the gel of heavy CBB G250 staining (circled) 
representing an area of high abundance proteins that do not resolve very well using 2-DE. 
These results suggested that the sample requires some pre-fractionation steps prior to 2-DE. 
As described Section 1.4.4.1, 2-DE does have its limitations as demonstrated by the 
gels in Figure 3.3 with only moderate reproducibility and suboptimal separation of proteins. 
Taking into account these limitations and difficulties and after examination of the 2D gels in 
Figure 3.3, it was evident that due to the complexity of the sample, pre-fractionation of the 
CM was required to identify differences in the secreted proteins from these cell lines.
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Figure 3. 3 : 2D-PAGE Analysis of CM collected from the RG/C2 and PRG/C2 cell lines 
following sample cleanup using the 2D Cleanup Kit. 
CM from both cell lines was collected and acetone precipitated followed by re-suspension in 
re-hydration buffer. The protein concentration was determined using the 2D Quant kit (Pierce) 
and then cleaned using the 2D Cleanup kit (Pierce). 200µg of protein from both cell lines 
were separated by 2D electrophoresis. (a), (b) and (c) represent biological triplicates. (Dashed 
circle indicates area of gel with an abundance of proteins that do not resolve very well). 
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3.3 Analysis of Microvesicles Isolated from Conditioned Media 
As described in Section 1.6, the importance of proteins being released in vesicles has 
been described in a variety of species and physiological conditions and is thought to be crucial 
in development  (Ellis et al., 1989, Muraoka et al., 1993), platelet activation (Polette et al., 
1997) and in the immune system (Klein et al., 2002, Sun and Hemler, 2001, Yurchenko et al., 
2005). Vesicle shedding has been demonstrated in normal cells under certain physiological 
conditions (Klein et al., 2002, Polette et al., 1997, Yurchenko et al., 2002) but occurs at much 
higher rates in tumour cells (Tang and Hemler, 2004, Yurchenko et al., 2001). It’s thought to 
play an important role in tumour progression and malignant transformation by shedding 
tumour surface antigens from plasma membranes; protecting the tumour from immune 
responses (Fiucci et al., 2002, P. Liu et al., 2002b, Razani and Lisanti, 2001, Tang and 
Hemler, 2004); important in angiogenesis (Basset et al., 1990) and plays an important role in 
tumour-stroma interactions (Guo et al., 2000). MVs consist of two types of vesicles: small 
exosome-like vesicles (formed in MVBs and secreted after fusion with the plasma membrane) 
and larger membrane derived vesicles often termed shedding vesicles. As the importance of 
MV release by tumour cells has already been shown, they could potentially be a useful source 
of proteins that could serve as biomarkers of early tumour progression.  
Extracellular Matrix MetalloProteinase Inducer (EMMPRIN) or CD147/Basigin was 
first identified as a factor expressed on the surface of tumour cells responsible for inducing 
MMP synthesis in neighbouring fibroblasts (Ellis et al., 1989, Guo et al., 1997, Kataoka et al., 
1993, Nabeshima et al., 1991). It was first isolated and purified from plasma membranes as a 
58kDa glycoprotein and was originally designated tumour collagenase stimulating factor 
(TCSF) (Biswas et al., 1995). The cellular localisation of EMMPRIN at the cell surface was 
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confirmed by immunofluorescent staining but could also be observed in intracellular vesicles 
(Caudroy et al., 1999). 
In various cell lines EMMPRIN stimulates the production of MMP-1, MMP-2, MMP-
3 and MT-MMPs (membrane types MMPs) but has no effect on their inhibitors TIMP-1 or 
TIMP-2 (Ellis et al., 1989, Guo et al., 1997, Kanekura et al., 2002, Kataoka et al., 1993, 
Polette et al., 1997, Taylor et al., 2002). EMMPRIN induced expression of MMPs is thought 
to be cell specific with not all MMPs stimulated at the same time (Kanekura et al., 2002, 
Toole, 2003). EMMPRIN has also shown increased expression in various human carcinoma 
cells compared to normal cells (Guo et al., 1997, R. Li et al., 2001, Lim et al., 1998, Taylor et 
al., 2002) and expression levels can be correlated with MMP expression levels in stromal 
fibroblasts from various tumours (Caudroy et al., 1999, Thorns et al., 2002).  
It was originally thought that tumour derived EMMPRIN acted on fibroblasts only by 
cell-to-cell contacts but evidence shows that native soluble or recombinant EMMPRIN in 
tumour cell derived CM induces MMP production/secretion from fibroblasts (Ronnov-Jessen 
et al., 1996, Sidhu et al., 2004). Taylor et al showed that full length EMMPRIN was the factor 
in CM from the breast cancer cell line MDA MB 231 responsible for inducing MMP2 
secretion from fibroblasts which was mediated through the activation of the phospholipase 
A2/5-lipoxygenase pathway (Taylor et al., 2002). Sidhu et al later demonstrated that 
EMMPRIN was released from lung carcinoma cell lines in MVs and could be used as a way 
for epithelial cells to communicate with distant cells as well as neighbouring cells (Sidhu et 
al., 2004). These MVs were short-lived, releasing there contents within four hours when 
incubated at 37ºC. 
As EMMPRIN is known to be secreted in MVs and play an important role in 
tumourigenesis, it was an ideal protein to use as a positive control to optimise the techniques 
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used to investigate differentially secreted proteins in MVs from RG/C2 and PRG/C2 cell 
lines. 
CM was collected from both cells lines (serum starved for 24hrs), the MV and REM 
CM fractions were collected and Western blotting analysis was performed. The Western blot 
shown in Figure 3.4a confirms the presence of EMMPRIN in the total CM and the MV 
fraction collected from both cell lines but with very little EMMPRIN observed in the REM 
CM fraction. These results demonstrate that the majority (if not all) of the EMMPRIN 
observed in CM is secreted in MVs and is in agreement with the observations made by Sidhu 
et al in lung carcinoma cell lines (Sidhu et al., 2004). The Western blot for EMMPRIN 
identified a band at 58kDa indicating that full length EMMPRIN is released in the MV 
fraction and not as a cleaved product from the plasma membrane, also in agreement with 
previous reports (Sidhu et al., 2004). 
The cell lysates from both cell lines were also harvested and nuclear, heavy membrane 
and cytosolic/light membrane fractions were prepared as described in Section 2.2. Western 
blot analysis showed EMMPRIN was present in the heavy membrane fraction and very little 
in the nuclear or cytosolic/light membrane fraction (Figure 3.4b) confirming that EMMPRIN 
is a membrane-bound protein in these cells as published in many other cell lines (Guo et al., 
2000). There was also an increased expression of EMMPRIN released in the heavy membrane 
of the PRG/C2 cells compared to the RG/C2 cells suggesting it may play a role in early 
tumour progression. 
The MV preparation protocol described by Sidhu et al isolates a mixed population of 
both the small exosomes (50-100nm) and the larger shedding vesicles (100nm-1µm). An 
additional fractionation step to isolate the two subtypes using sucrose density gradient
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Figure 3. 4 : Investigating the presence of EMMPRIN in RG/C2 and PRG/C2 cells and 
its release into CM. 
The presence of full length EMMPRIN was confirmed by Western blotting in total CM, the 
MV fraction and the REM CM fraction prepared from RG/C2 and PRG/C2 cells (3x106 cells). 
The samples were normalised using cell number. (b) The cell lysate was harvested from both 
cell lines and fractionated to identify where EMMPRIN is located in the cell. 20µg of each 
fraction was blotted for EMMPRIN and actin (loading control).  
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ultracentrifugation could be used to enrich vesicle sub species. In an attempt to investigate 
whether EMMPRIN is released by the RG/C2 cell line in exosomes or shedding vesicles, 
MVs were collected and enrichment for both types using the sucrose density gradient 
ultracentrifugation method (described in Section 2.3) was performed. The proteins in 5µl of 
each fraction were separated on 4-12% tris-glcine gels and the presence of EMMPRIN and 
MHC class 1 (an exosome marker) was investigated by Western blot analysis (Figure 3.5a). 
The remaining 30µl were also run on a 4-12% tris-glcine gel and the proteins were stained 
with CBB G250 (Figure 3.5b). 
Western blot analysis showed the presence of EMMPRIN in the sucrose fractions 
between 2.60-0.75M and absent in fractions 0.50M and 0.25M with EMMPRIN enriched in 
the four fractions between 1.75-1.00M. MHC class 1 was also present in the sucrose fractions 
between 2.60-0.75M and enriched in the three fractions between 1.50-1.00M. These results 
could indicate that EMMPRIN is present in the same species of vesicle as MHC class 1 is 
released in (i.e. exosomes). However, EMMPRIN was present in seven of the nine fractions 
suggesting this method couldn’t determine the subspecies of vesicle EMMPRIN was present 
in. This could be because it is present in both subtypes or could be very abundant leading to 
it’s detection in most of the fractions. The CBB G250 stained gel shown in Figure 3.5b shows 
that similar protein staining patterns bands in multiple fractions indicating that the sucrose 
density gradient technique didn’t successfully separate the vesicle subtypes. Also, the Western 
blots show bands for EMMPRIN and MHC class I in the majority of the fractions with the 
most intense coomassie staining i.e. 1.75M – 1.25M. This suggests that the more intense 
bands for both proteins are a result of more total protein being present in that fraction. As the 
sucrose density gradient method didn’t appear to separate the vesicle subtypes very well, this 
technique was not investigated any further in this study. 
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(a) 
 
(b) 
 
Figure 3. 5 : Enrichment of MVs prepared from CM derived from RG/C2 cells using  
Sucrose Density Gradient Ultracentrifugation. 
MV’s were prepared from CM derived from RG/C2 cells (2x108 cells) and the vesicles were 
then separated using a sucrose density gradient protocol to attempt to enrich the 2 sub-types of 
MVs. (a) Presence of EMMPRIN and MHC Class I in each fraction (5µl) was confirmed by 
Western blot analysis. (b) The remaining 35µl of each fraction was run on a 4-12% tris –
glycine gel and stained with CBB G250. 
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Next, the proteins in the MV fractions from the RG/C2 cell line were separated by 1D 
gel electrophoresis and proteomic techniques were used to detect EMMPRIN. CM was 
collected from RG/C2 cells (6 x 106) and an MV fraction was prepared. The proteins in the 
total CM, MV and REM CM fractions were separated on a 4-12% tris-glycine gel twice. One 
gel was stained with CBB G250 and the other was used to confirm the presence of 
EMMPRIN by Western blot analysis. The whole MV lane of the CBB G250 stained gel was 
cut into 10 equal size bands and the proteins in each band were digested with trypsin (Figure 
3.6). Each sample was then analysed by LC MS/MS using an acetonitrile gradient shown in 
Figure 2.3a and the acquired spectra was searched against a human database (generated from 
an nr database downloaded from www.ncbi.nlm.nih.gov). The results were filtered using the 
Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50) parameter. There were 47 proteins 
identified (with at least 2 first hit peptides) however, no EMMPRIN peptides could be 
detected in any of the samples even after decreasing the filter parameters to Xcorr = 1.00 (see 
Supplementary Table 3a). 
There are two possible reasons why EMMPRIN could be detected by Western blotting 
and not by LC MS/MS: 1) Western blotting is more sensitive than LC MS/MS and there was 
an insufficient amount of EMMPRIN present in the sample; or 2) The sample was far too 
complex to detect the lesser abundance proteins. The MS spectrum was collected in a data-
dependant manner and only the five highest intensity ions are picked for further fragmentation 
(MS/MS). Therefore if the sample is too complex, the lesser abundant peaks are never picked 
for further fragmentation and identified. 
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(a) 
 
 
(c) 
 
      
 
Figure 3. 6 : Preparation of an MV fraction from CM derived from RG/C2 cells (6x106 
cells) to attempt to identify EMMPRIN using proteomic techniques. 
Proteomic techniques were used to confirm the presence of EMMPRIN in total CM, the MV 
and the remaining CM fractions derived from RG/C2 cells. (a) Western blot analysis for the 
presence of EMMPRIN in all fractions (3x106 cells). (b) The proteins in each fraction (6x106 
cells) were separated on a 4-12% tris-glycine gel and stained with CBB G250. (The 
unlabelled lanes were samples from a cell line that’s not relevant to this study). (c) The MV 
fraction was cut into 10 equal size bands and in-gel digestion was performed for each band. 
 
 
EMMPRIN57 kDa
Total
CM
MV REM
CM
148
kD
a
98
64
51
36
22
16
6
Total
CM
MV REMCM
Chapter 3  Results 
145 
In this case, an insufficient amount of EMMPRIN seems the most likely reason why it 
could not be detected using proteomic techniques. There were very few intensely stained and 
discrete bands in the MV lane shown in Figure 3.6b indicating that more protein 
identifications could be made by starting with more protein. Also, there were proteins 
identified in the areas of the gel with very little staining (i.e. bands 7-10) indicating that the 
CBB G250 is not as sensitive as the LC-MS. 
The previous experiment was repeated using twice the starting material in an attempt 
to identify EMMPRIN using LC/MS/MS methods. MVs collected from 1.2 x 107 RG/C2 cells 
(twice the starting material previously used) and the proteins were again separated on a 4-12% 
tris-glycine gel and stained with CBB G250 (Figure 3.7a). The presence of EMMPRIN was 
confirmed by Western blot analysis (data not shown) and the region of the MV lane between 
40-70kDa was cut into 4 bands for in-gel digestion (Figure 3.7b). Each band was analysed by 
LC MS/MS and the acquired spectra were searched against the same human database used 
previously. The CBB G250 stained gel shown in Figure 3.7a shows an increased number of 
discrete protein bands with much greater staining intensity observed throughout the whole 
MV lane compared to the previous experiment (Figure 3.6). There were 194 proteins 
identified (see Supplementary Table 3b) in the 4 bands (with at least 2 first hit peptides) using 
the single threshold filter parameter of Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 
2.50). Again, there were no EMMPRIN peptides observed in this region of the gel despite its 
presence being confirmed by Western blot analysis even when the filter parameters were 
reduced to Xcorr = 1.00 (data not shown). Figure 3.7a also shows that the proteins in the MV 
lane resolved well with discrete bands observed throughout the lane. Whereas, in the total CM 
and the REM CM lanes, there was diffuse staining throughout the whole lane with a large 
intensely stained band at ~64kDa not observed in the MV lane. These results demonstrate that 
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 (a) 
 
 
 
 
 
 
 (b) 
 
 
 
 
 
 
 
Figure 3. 7 : Investigating the presence of EMMPRIN in MVs from RG/C2 cells (1.2x107 
cells) using proteomic techniques. 
Proteomic techniques were used to confirm the presence of EMMPRIN in total CM, the MV 
and the remaining CM fractions derived from RG/C2 cells. (a) The proteins from the total 
CM, the MV and the remaining CM fractions from RG/C2 cells (1.2x107 cells) were 
separated on a 4-12% tris-glycine gel and the proteins were stained with CBB G250. (b) The 
region between 40-70kDa of the MV lane was cut into 4 bands and in-gel digestion was 
performed. 
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this large region of the most abundant proteins observed in the total CM fraction was isolated 
and retained in the REM CM fraction during MV preparation. These results demonstrate that 
the MV preparation protocol is an ideal method for fractionating the CM prior to 1D gel 
electrophoresis as the removal of these proteins should improve the identification of the lower 
abundance proteins. 
This experiment was repeated (as described above) one more time in an attempt to 
successfully identify EMMPRIN peptides using a MV fraction prepared from 2.4x107 RG/C2 
cells. The region of the MV lane between 40-70kDa was cut into 6 bands and digested with 
trypsin for peptide analysis by LC MS/MS (Figure 3.8). The results generated 163 proteins 
(with at least 2 first hit peptides) using the single threshold filter parameter of Xcorr vs charge 
state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50) (see Supplementary Table 3c). EMMPRIN peptides 
still could not be identified even after reducing the filter parameters to Xcorr = 1.00 (data not 
shown). The gel shown in Figure 3.8a shows very intense CBB G250 staining throughout the 
whole gel indicating it has been overloaded with protein. The sample would need further 
fractionation either prior to separation by SDS-PAGE or peptide fractionation following in-
gel digestion using a strong cation exchange column. Although more protein was used in this 
experiment compared to the previous experiment (Figure 3.7) which in theory should lead to 
more protein identifications as an increased amount of the lower abundance proteins are 
present, only 163 proteins were identified compared to the 194 proteins previously identified 
in the same region of the gel. These results demonstrate that more total protein does not 
necessarily lead to more protein identifications. This could be due to either experimental error 
when the bands were excised or most likely due to the gel being overloaded with protein. The 
most abundant proteins are no longer seen as discrete bands but become much more diffuse 
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 (a) 
 
 
 
 
 
 
 
 (b) 
 
 
 
 
 
 
 
Figure 3. 8 : Investigating the presence of EMMPRIN in MVs from RG/C2 cells (2.4x107 
cells) using proteomic techniques. 
The proteins from the total CM, the MV and the remaining CM fractions derived from RG/C2 
cells (2.4x107 cells) were separated on a 4-12% tris-glycine gel and the proteins were stained 
with CBB G250. (b) The region between 40-70kDa of the MV lane was cut into 6 equal size 
bands and in-gel digestion was performed. 
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and can be identified in multiple bands and the abundant proteins prevent the identification of 
the lower abundant ones.  
One example is the protein KIAA0051 (gi40789059), Table 3.1 shows the peptides 
identified from this protein in the experiments outlined in Figures 3.7 and 3.8. Table 3.1a 
show that there were 19 peptides identified in 1 out of the 4 protein bands analysed in Figure 
3.7 and there were 15, 10 and 10 proteins identified respectively in 3 of the 6 bands analysed 
in Figure 3.8. These results demonstrate that increasing the amount of protein does increase 
the number of peptides however, multiple peptides in only one band is sufficient to have 
confidence that the protein is present. The presence of same peptides in multiple bands only 
prevents the identification of other peptides that are present i.e. suppression of the lower 
abundant peptides by the high abundance ones preventing them from being isolated for further 
fragmentation and therefore being identified. This illustrates the importance of optimising the 
protein pre-fractionation methods before LC MS/MS analysis to allow sufficient separation of 
proteins. 
3.4 Conclusion 
The aim of this chapter was to use 2-DE to investigate differentially secreted proteins 
from the colorectal cancer cell lines RG/C2 and PRG/C2. CM was collected from both cell 
lines and the proteins were separated on a 2D gel. The gels shown in Figure 3.3 demonstrated 
the complexity of CM collected from these cell lines and also highlighted some of the 
difficulties with 2-D gel technology. The gels exhibited moderate reproducibility between 
biological replicates and an area of the gel showed poor separation of proteins therefore 
highlighting the need for pre-fractionation of the sample to improve separation of proteins. 
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Table 3. 1 : The identification of KIAA0051 (gi40789059) in the experiments outlined in 
Figures 3.7 and 3.8. 
KIAA0051 is an example of a protein identified in just 1 band out of the 4 analysed in Figure 
3.7 and in 3 bands out of the 6 identified in Figure 3.8. Table (a) shows the 19 peptides 
identified in 1 sample from Figure 3.7. Table (b) shows the 15, 10 and 10 peptides identified 
in 3 separate protein bands from Figure 3.8. 
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As previously described, MV release from cells occurs at much higher rates in tumour 
cells compared to normal cells and are thought to play an important role in tumour 
progression and malignant transformation. It has been shown in many studies that MVs can be 
isolated from CM derived from cancer cell lines. Therefore, MVs were isolated from CM 
from both the RG/C2 and PRG/C2 cell lines in an attempt to pre-fractionate the CM further 
using EMMPRIN as a positive control for MV preparation. In both the RG/C2 and PRG/C2 
cells, Western blot analysis confirmed the presence of full length EMMPRIN in the total CM 
and the MV fraction but not in the REM CM fraction indicating that all the EMMPRIN 
released by these cells is released via vesicle shedding (Figure 3.4a). 
Western blot analysis of the subcellular fractions of the cell lysates collected from 
both cell lines also confirmed that in these cell lines EMMPRIN is a membrane bound protein 
with an increase in the membrane fraction of the PRG/C2 cell line. Separation of the two main 
sub-types of MV using sucrose density gradient ultracentrifugation failed to distinguish 
conclusively whether EMMPRIN was released in the smaller exosome like vesicles or those 
shed from the plasma membrane although logic would dictate that EMMPRIN is released in 
those shed from the plasma membrane as evidence shows it is a membrane bound protein. 
The next step was to use proteomic techniques to further study the importance of 
EMMPRIN release in MVs during early stage tumour progression. After three attempts, 
EMMPRIN peptides could not be identified in MVs from the RG/C2 cell line despite 
confirmation of it’s presence by Western blotting and double checking EMMPRIN’s presence 
in the database used. In Figure 3.7, the area of the MV lane between 40-70kDa was excised in 
four bands and analysed by LC MS/MS. There were 194 proteins (with at least 2 first hit 
peptides) identified in this region of the gel but failed to identify EMMPRIN. These results 
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suggest that there may be other very interesting proteins released in MVs during early stage 
colorectal cancer that could be equally as important as EMMPRIN. 
The remainder of the gel shown in Figure 3.7 was cut into 12 equal size bands, the 
proteins were digested with trypsin and the tryptic peptides were analysed by LC MS/MS. 
The combined results were filtered using XCorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 
2.50) and identified a total of 638 proteins (with at least two first hit peptides) (results not 
shown). These results indicate that quantitative proteomic techniques could be used to 
investigate the differential secretion of proteins in MV from the RG/C2 and PRG/C2 cell lines 
to identify possible markers of early tumour progression in colorectal cancer. 
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Chapter 4 : Optimisation of Conditions Required for Quantitative Proteomic Profiling 
of MVs Released by RG/C2 and PRG/C2 Cell Lines. 
 
4.1 Introduction 
As discussed in the Section 1.1, there are currently two non-invasive biomarkers for 
CRC in use, FOBT and CEA. Both have limited uses and show low sensitivity and specificity 
for detecting early stage colorectal cancer (H. J. Kim et al., 2008). The FOBT test can be 
affected by the patient’s diet to yield false-positive results and studies have shown the test to 
be unreliable. Serum CEA can only detect 30-40% of early stage colorectal cancers (Dukes’ 
stage A and B) and its main use has been as a prognostic marker following surgery in patients 
with elevated pre-operative CEA. There are many proteomic studies investigating potential 
new biomarkers in serum for early tumour progression in colorectal cancer for use in 
screening programs but as of yet there are no successful candidates that have been transferred 
to the clinic. 
The majority of these studies involve investigating possible markers in clinical 
samples such as serum, plasma and urine. With the large number of proteins identified in 
MVs from RG/C2 described in Chapter 3, it may be possible to identify small changes in 
these proteins in a cell model of early tumour progression that could be detected in the 
bloodstream. Studies have shown that MVs can be detected in clinical samples and using a 
quantitative shotgun proteomics approach to identify the proteins within MVs released by 
cells could reveal new potential biomarkers. 
The aim of the work described in this chapter was to test the sensitivity of the LCQ 
Deca XPPLUS instrument, and to optimise the search and filter parameters required for 
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analysing large scale shotgun proteomic datasets. This optimisation is essential to ensure that 
the number of false peptide and protein identifications is kept to a minimum whilst 
minimising the loss of true protein identifications (see Section 1.3 for a review of data 
analysis methods). 
4.2 Demonstrating the Sensitivity of the LCQ Deca XPPLUS 
Firstly, the sensitivity of the LCQ Deca XPPLUS was investigated by analysing 
increasing amounts of BSA peptides to determine the detection limits of the instrument. BSA 
was digested with trypsin in solution (Section 2.11.3) and diluted to a concentration of 
1000fmoles/80µl. This stock solution was then used to perform a further nine 2-fold serial 
dilutions (Table 4.1a) and 80µl of each dilution was analysed by LC MS/MS using a 45min 
acetonitrile gradient (Figure 2.3a). The raw files were searched against a bovine database 
generated from an NR database downloaded from the NCBI website and Table 4.1a shows the 
number of BSA peptides identified and the percentage coverage of the total protein sequence 
represented by these peptides for each dilution using the Xcorr vs charge state (+/-1: 1.50, +/-
2: 2.00, +/-3: 2.50) filter parameters. The highest percentage coverage of BSA was observed 
in the 1000, 500, and 250fmole samples (22.90%) with 104, 86 and 80 total peptides 
identified respectively with 14 unique peptides identified in each. There is no change in 
percentage coverage because the same peptides are identified in all three samples with some 
identified multiple times due to their high abundance at the higher concentrations. Multiple 
identifications of a single peptide sequence in a sample increase the confidence that the 
sequence is present especially if both the (+2) and (+3) charged species are identified. 
Therefore, the percentage coverage of a protein identified can be used as a good indicator of 
confidence that a protein is present but the number of total and unique peptides should also be 
considered. 
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Table 4. 1 : Determination of the sensitivity of the LCQ Deca XPPLUS using BSA digested 
with trypsin in solution. 
(a) Table to show the amount of BSA in fmoles and ng present in 80µl of each 2-fold serial 
dilution prepared from a 1000fmole/80µl stock solution and the number of peptides and 
percentage coverage observed in each sample (using the Xcorr vs charge state (+/-1: 1.50, +/-
2: 2.00, +/-3: 2.50) filter parameters. (b) Table to show the retention time (RT), the peak 
intensity (NL) and the m/z ratio of the 5 most commonly identified peptides for each dilution. 
 
Number of fmoles in 80µl ng Dilution 
factor
Total 
Peptides
Unique 
peptides
Percent 
Coverage
1000.00 66.00 Stock 104 14 22.90
500.00 33.00 1 : 2 86 14 22.90
250.00 16.50 1 : 4 80 14 22.90
125.00 8.25 1 : 8 46 13 17.13
62.50 4.13 1 : 16 35 12 19.28
31.25 2.06 1 : 32 31 10 17.63
15.63 1.03 1 : 64 19 7 13.84
7.80 0.52 1 : 128 11 6 10.05
3.90 0.26 1 : 256 3 2 3.95
1.90 0.13 1 : 512 0 0 0.00
(a)
m/z
No of 
fmoles
RT 
(mins)
NL RT 
(mins)
NL RT 
(mins)
NL RT 
(mins)
NL RT 
(mins)
NL
1000 28.66 1.54E+08 33.23 2.67E+08 27.53 3.00E+08 36.57 1.63E+08 37.5 5.66E+08
500 28.92 1.21E+08 33.33 1.41E+08 27.52 1.47E+08 36.91 5.89E+07 37.59 1.66E+08
250 28.96 5.11E+07 33.36 5.69E+07 27.41 6.46E+07 37.07 3.53E+07 37.9 1.20E+08
125 28.66 2.43E+07 33.12 3.04E+07 27.17 3.51E+07 36.95 1.34E+07 37.47 7.46E+07
62.5 28.59 1.80E+07 33.17 1.35E+07 27.17 1.40E+07 36.74 5.44E+06 37.42 4.24E+07
31.25 28.9 4.11E+06 33.35 7.26E+06 27.32 6.67E+06 37.5 7.90E+06 37.8 8.99E+06
15.63 30.7 3.30E+06 34.9 4.16E+06 29.12 3.58E+06 - - 39.39 1.00E+07
7.8 30.5 2.08E+06 35 1.92E+06 29 2.28E+06 - - 40 3.66E+06
3.9 - - - - 29.82 2.26E+06 - - - -
1.9 - - - - - - - - - -
740.6
KVPQVSTPTLV
EVSR  (+2)
LVNELTEFAK  
(+2)
HLVDEPQNLI
K  (+2)
RHPYFYAPEL
LYYANK (+2)
LGEYGFQNALI
VR (+2)
547.6 582.5 653.6 682.6
(b)
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The number of peptides identified and the percentage coverage then decreases with 
each serial dilution with no peptides identified in the lowest dilution (1.90fmole).  The results 
in Table 4.1a indicate that the detection limit for BSA peptides was ~4 fmoles with only a 
single peptide observed. Table 4.1b shows the observed retention time, the peak intensity 
(NL), the m/z ratio and the sequence of the five peptides most commonly observed in the 
BSA peptide standards routinely used as indicators of optimal sensitivity in our lab. Each 
peptide has very similar retention times regardless of the amount of BSA with the NL 
decreasing as the amount of BSA decreases as expected.  
4.3 Investigating the Sensitivity of CBB G250 and Silver Staining Protocols 
Next, the sensitivity of both the CBB G250 and the MS compatible silver staining 
protocols for proteins separated by 1D gel electrophoresis was determined by investigating 
the detection limits of both stains. A stock solution of 100fmoles/µl BSA was prepared and 
used to prepare eight further 2-fold serial dilutions (Figure 4.1a). 10µl of each sample (1000-
3.91fmoles) was loaded onto a 4-12% bis-tris gel and stained using either the CBB G250 or 
the silver staining protocols described in Section 2.9.2. The table in Figure 4.1c shows the 
concentration, the number of fmoles and amount of BSA (in ng) present in 10µl of each 
dilution. Figure 4.1a and b shows the detection limits of both CBB G250 and the silver stain 
was 250fmoles (16.50ng) and ~31fmoles (~2ng) respectively. Winkler et al have since 
published a study comparing the detection limits of two CBB G250 staining protocols and 
fourteen different silver staining protocols (including the protocol used in this study) 
(Shevchenko et al., 1996, Winkler et al., 2007). The detection limit of their CBB G250 
staining protocol for BSA was 125fmoles which was more sensitive than the 250fmole 
detection limit determined in this study. There is a slight difference in the composition of the 
two stains used which could explain these differences in sensitivity. Winkler et al also 
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 (a)      (b) 
 
 
 
 
 
(c) 
CBB G250 Silver
Conc 
(fmoles/µl)
fmoles in 
10µl
ng Total 
peptides
Unique 
peptides
Percentage 
coverage
Total 
peptides
Unique 
peptides
Percentage 
coverage
100 1000 66 7 6 9.23 8 6 9.88
50 500 33 5 5 7.08 3 3 5.44
25 250 16.5 1 1 1.81 1 1 1.65
12.5 125 8.25 0 - - 0 - -
6.25 62.5 4.13 0 - - 0 - -
3.13 31.25 2.06 0 - - 0 - -
1.56 15.63 1.03 0 - - 0 - -
0.78 7.82 0.52 0 - - 0 - -
0.39 3.91 0.26 0 - - 0 - -  
Figure 4. 1 : CBB G250 versus Silver staining? 
A stock concentration of BSA (100fmoles/µl) was prepared and used to make a further eight 
2-fold serial dilutions. 10µl of each concentration of BSA was then run on a 4-12% Bis- Tris 
gel to test the sensitivity of both the CBB G250 (a) and silver staining protocols (b).  Each 
BSA band was excised and digested with trypsin for LC MS/MS analysis. Table (c) shows the 
number of fmoles and the amount (ng) in 10µl of each concentration along with the number of 
peptides and the percentage coverage of BSA. 
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determined the detection limit of BSA using the Shevchenko silver staining protocol to be 
31fmoles in agreement the results shown here. 
For both the CBB G250 and silver stained gels, the region of the gel where BSA runs 
to (~66kDa) (whether a band was present or not) for each concentration was excised and in-
gel digestion was performed. Each sample was analysed by LC MS/MS on a 45min 
acetonitrile gradient to investigate the number of peptides and the sequence coverage of BSA 
at each concentration. The raw files were searched against a bovine database and the results 
were filtered using Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50) and Table 4.1c 
shows the number of peptides identified and sequence coverage of BSA at each concentration 
for both stains.   
Both stains showed very similar limits of detection, no BSA peptides were identified 
in  samples containing <125fmoles with 1, ~4, and ~7 peptides identified in the 250, 500 and 
1000fmoles samples respectively. These results suggest there are no differences in yields 
when using the in-gel digestion protocol for CBB G250 or silver stained bands. The results 
also indicate that an intensely stained band on a silver stained gel does not guarantee the 
protein being identified when analysed by LC MS/MS using the LCQ Deca XPPLUS. However, 
this is not the case with CBB G250 stained bands. A band on a CBB G250 stained gel stands 
a good chance of a peptide from that protein being identified with a single peptide identified 
in the 250fmoles sample. These results suggest that for this study, the CBB G250 stain would 
be more efficient for a SILAC survey as both samples will be mixed 1:1 prior to 1D gel 
electrophoresis and the differences will be observed at the LC-MS level rather than by 
comparison of bands on a gel. 
The results in Figure 4.1c also shows a poor recovery of BSA peptides from the in-gel 
digestion with the detection limit at 250fmoles compared to the digestion in solution results 
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shown in Table 4.1a where the detection limit was ~4fmoles. This is due to the loss of protein 
and peptides during the in-gel digestion protocol suggesting that digestion in solution would 
be preferential to the in-gel digestion protocol due to the significant increase in sample 
recovery. If the sample is very simple, clean and only contains a single protein (like the 
samples analysed in Figure 4.1) then digestion in solution would be the method of choice but 
most samples are complex mixtures of proteins that have been prepared from a biological 
sample and require a separation step prior to LC MS/MS. These samples also require a clean 
up step to remove contaminants such as salts and detergents and the proteins also need to be 
present in buffers compatible with conditions required for trypsin digestion and analysis by 
MS. Experience within the lab has shown this can be time consuming and each type of 
experiment requires some optimisation to clean up the sample. Separation of proteins by ID 
gel electrophoresis can overcome both these problems by cleaning the sample and using a 
very simple well established protein separation protocol requires no other optimisation other 
than investigating the amount of starting material required.  
4.4 Optimising the Parameters used for Filtering Database Search Results 
Analysis of small datasets such as those from experiments to investigate interacting 
proteins with a target (e.g. immunoprecipitations) is relatively simple. The parameters used to 
filter the database search results can be lowered to identify proteins present in a test sample 
compared to an appropriate control. Peptide sequence assignments to MS/MS spectra can be 
manually inspected to ensure they are correct but the analysis of large datasets is much more 
complex. Manual inspection of each peptide assignment is time consuming, requires a certain 
amount of experience and can be subjective. Optimised filter parameters are required to 
minimise the loss of true peptide and protein identifications and ensuring the number of false 
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identifications are kept to a minimum. There is no ‘gold standard’ for which filter parameters 
should be used. 
A database search result from a sample described in Figure 3.7 was used to investigate 
the optimal filter parameters to be used in this study. Figure 4.2 shows examples of ‘good 
hits’ and ‘poor hits’ when spectra are manually inspected. The process of distinguishing 
between ‘good’ and ‘poor’ hits is subjective but the MS/MS spectra shown here demonstrate 
clear differences between them, the peaks shown in green, red and blue (representing the a, b 
and y ions respectively) are those identified in the acquired MS/MS spectrum that matches 
those in the database. As seen in Figure 4.2a, a ‘good hit’ identifies a large percentage of the 
fragment ion peaks from theoretical MS/MS spectra in the database. In particular, the y ions 
are important as they contain the C-terminal residue which should be an Arg or Lys when 
digested with trypsin. In the case of ‘poor hits’, only a small number of peaks in the acquired 
MS/MS data matches to those in the database for that sequence. 
For all experiments described so far, the parameters used to filter the results of a 
database search, i.e. Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50), are those that 
were routinely used in many proteomic studies and recommended by the manufacturer 
(Thermo Electron). Recommendations for filter parameter values that ‘constitute a good hit’ 
have been suggested by Novatia (http://www.enovatia.com). Table 4.2 shows the comparison 
of four different filter parameters (see Figure legend for description of parameters). The 
comparison of FILTERS I and II identified 31 and 36 proteins respectively. FILTER II 
identified all 31 proteins identified in FILTER I with an additional 5 proteins not identified 
using the latter parameters. Manual inspection of the spectra showed that the peptides of 4 of 
these proteins (in red) were ‘good hits’ and the peptides identified in the remaining protein 
were ‘poor hits’. These results indicate that FILTER I was too strict but FILTER II was too 
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(a) gi|483474|emb|CAA55699.1| 90K [Homo sapiens 
Reference     Score  Peptides 
Scan(s) Sequence MH+ Charge XC Delta Cn Sp RSp Ions
gi|483474     20.14  2 (2 0 0 0 0)
1053 -.AVDTWSWGER.- 1207.3 2 1.71 0.4 853.5 1 13/18
2204 -.ELSEALGQIFDSQR.- 1593.7 2 2.73 0.35 1068.9 1 17/26  
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(b) gi|49456749|emb|CAG46695.1| VEGFC [Homo sapiens] 
Reference     Score  Peptides 
Scan(s) Sequence MH+ Charge XC Delta Cn Sp RSp Ions
gi|49456749     20.47  2 (2 0 0 0 0)
370 .GKKFHHQTCSC*YR. 1652.9 3 1.64 0.17 337.9 5 15/48
1053 .TC*PTNYMWNNHICR. 1811 3 1.17 0.14 266.6 5 16/52  
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Figure 4. 2 : Examples of MS/MS spectra that match the theoretical spectra in the 
database and are considered to be ‘good hits’ and ‘poor hits’. 
Figure to show examples of spectra acquired from a gel slice in the MV preparation described 
in Figure 3.7 that were used to optimize the filter parameters used for data analysis. Fig 4.2(a) 
shows examples ms/ms data that matches the database very well and are considered to be 
‘good hits’. Fig 4.2(b) shows examples of ms/ms data that doesn’t match the database very 
well and are considered to be ‘poor hits’. The a, b and y ions highlighted in green, red and blue 
respectively are those ions observed in the acquired ms/ms spectra which matched with those 
in the theoretical fragmentation pattern for that peptide sequence in the database used. The  y–
ion series is considered to be the most important ion series used to determine the amino acid 
sequence as it identifies the C-terminal Arg or Lys present (if digested with trypsin). The 
tables show the score values used by Bioworks Browser for both the protein and the peptides. 
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FILTER I FILTER II FILTER III FILTER IV
Reference Score Peptides Score Peptides Score Peptides Score Peptides
gi|9622850 30.1 3 30.1 3 30.1 3 30.1 3
gi|904214 20.1 2 20.1 2 20.1 2 20.1 2
gi|7328175 20.2 2 20.2 2 20.2 2 20.2 2
gi|7243131 20.1 2 30.1 3 30.1 3 30.1 3
gi|66361423 20.2 2 20.2 2 20.2 2 20.2 2
gi|6470150 200.4 20 258.4 25 246.4 23 258.4 25
gi|6424942 20.4 2 22.4 2 22.4 2 22.4 3
gi|62914009 70.2 7 116.2 11 106.2 10 106.2 10
gi|62898357 20.1 2 20.1 2 20.1 2 20.1 2
gi|62897167 90.2 9 90.2 9 90.2 9 90.2 9
gi|5572747 50.1 5 50.1 5 50.1 5 50.1 5
gi|556514 20.3 2 30.3 3 30.3 3 40.3 4
gi|52545896 20.2 2 20.2 2 20.2 2
gi|49456749 20.5 2 20.5 2
gi|48762682 30.2 3 30.2 3 20.2 2 30.2 3
gi|48425720 70.4 7 90.4 9 80.4 8 90.4 9
gi|483474 20.3 2 20.1 2 20.1 2 20.1 2
gi|48257068 20.3 2 20.3 2 20.3 2
gi|47115169 20.1 2 20.1 2
gi|40789059 100.2 10 126.2 12 126.2 12 110.2 11
gi|3891633 30.2 3 30.2 3 30.2 3 30.2 3
gi|37674412 70.2 7 70.2 7 80.2 8 80.2 8
gi|3273383 20.4 2 20.4 2 20.4 2
gi|32172416 324.2 31 372.2 37 368.2 36 332.2 33
gi|30923274 110.2 11 130.2 13 130.2 13 130.2 13
gi|29126831 120.2 12 130.2 13 130.2 13 130.2 13
gi|2351110 20.2 2 20.2 2 20.2 2 20.2 2
gi|16878197 30.2 3 38.2 3 30.2 3 28.2 2
gi|14250593 50.2 5 70.2 7 60.2 6 70.2 7
gi|136378 20.2 2 20.2 2 20.2 2 20.2 2
gi|12653989 20.3 2 20.3 2 20.3 2
gi|12225000 30.2 3 40.2 4 40.2 4 40.2 4
gi|11414998 20.1 2 20.1 2 20.1 2 20.1 2
gi|10716563 30.2 3 30.2 3 30.2 3 30.2 3
gi|105155 30.2 3 30.2 3 30.2 3 30.2 3
gi|10437873 20.1 2 20.1 2 20.1 2 20.1 2  
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Table 4. 2 : Various filter parameters were changed to optimise those suitable for the 
analysis of large datasets using Bioworks Browser v3.1. 
Table to show which filter parameters were modified to optimise those to be used for data 
analysis of large datasets. Data collected from one of the samples from the vesicle collection 
outlined in Figure 3.7 was used for the optimisation. Only proteins with 2 first hit peptides 
were included in the analysis. The proteins in blue writing had peptides that looked like ‘poor 
hits’ and the proteins in red writing had peptides that looked like ‘good hits’. FILTER I –
Single Threshold Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50) 31 proteins 
identified; FILTER II – Default Multiple Threshold (Match = 4, Delta Cn = 0.085, Xcorr = 
1.00, Sp = 500, RSp = 5, Percent ions = 30%) 36 proteins identified; FILTER III -  Novatia 
Multiple Threshold (Match = 4, Delta Cn = 0.100, Xcorr = 1.50, Sp = 200, RSp = 5, Percent 
ions = 70%) 34 proteins identified; FILTER IV – Modified Multiple Threshold (Match = 4, 
Delta Cn = 0.100, Xcorr = 1.00, Sp = 350, RSp = 5, Percent ions = 50%) 35 proteins. The 
proteins found using all 4 filter parameters are highlighted in bold. The proteins highlighted in 
green are proteins identified with additional first hit peptides identified in proteins using 
FILTER IV compared to FILTER I. 
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relaxed. Next, FILTERS II and III were compared and 36 and 34 proteins identified 
respectively. FILTER II identified all 34 proteins identified using FILTER III with an 
additional 2 proteins, manual inspection confirmed that the peptides identified in both of these 
proteins were ‘good hits’ indicating that FILTER III is too strict. FILTER II was then 
modified to create a set of filter parameters that would be a compromise between FILTERS II 
and III. 
The results were then analysed using FILTER IV and compared to FILTERS I, II and 
III with 35, 31, 36 and 34 proteins identified respectively. The 35 proteins identified using 
FILTER IV all the proteins with ‘good hit’ peptides from the other three parameters and 
didn’t identify the 1 protein with peptides that were ‘poor hits’ when inspected manually. The 
proteins highlighted in green in Table 4.2 also identified additional peptides using FILTER IV 
in proteins identified using FILTER I. These results indicate that the modified parameters set 
in FILTER IV were optimal for analysing the large datasets that would be generated by a 
proteomic profile of MVs, i.e. generate very low number of false positive identifications 
whilst keeping the loss of true identifications to a minimum. 
4.5 Source of Database 
In a review by Nesvizhskii and Aebersold, the benefits and drawbacks of using 
databases from several sources were discussed (Nesvizhskii and Aebersold, 2005). As 
discussed in Section 1.3, the correct peptide sequence assignment to MS/MS spectra is limited 
to those found within the database therefore the experiment should determine the database 
required. The comparisons in their review suggested that a human IPI or a human database 
generated from the NCBI nr database would be most suitable for the large dataset that would 
be generated in the quantitative shotgun proteomic approach planned for this study. The search 
results from the previous chapter identified numerous proteins entries with vague names (e.g. 
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unknown, hypothetical protein) which require further manual investigation to decipher the 
actual protein present.  
The NCBI database also contains a large number of non-redundant protein entries, i.e. 
many entries from the same protein entered by different research groups and proteins with 
small amino acid sequence changes making it very difficult to determine the exact protein 
present. Deciphering the identity of each unknown protein or whether the wild type or a 
variant is present in the sample would be time consuming when analysing large datasets. 
In an attempt to overcome these problems, a raw data file generated in Figure 3.7 that 
illustrated the problems discussed above was used to compare search results using an NCBI 
and an IPI database. Table 4.3 shows that there were 43 proteins (with at least 2 first ‘hit’ 
peptides) identified from the search using the human IPIv3.14 database and compared to the 
31 proteins identified in the NCBI database. There were 171 first hit peptides identified in the 
31 proteins identified in the NCBI search and 306 first hit peptides in the 43 proteins 
identified in the IPI search. The search results also identified 45 and 76 proteins in the NCBI 
and IPI search results respectively with only a single peptide assignment. The results show 
that more protein assignments were made in the IPI search results compared to the NCBI 
results with all peptides in ‘multiple peptide hit’ proteins from the NCBI results represented in 
the IPI results. Table 4.3 also shows that some peptides identified in ‘single peptide hit’ 
proteins in the NCBI search results corresponded to multiple peptide hit proteins in the IPI 
search results, partly accounting for the increase in protein identifications found using the IPI 
database. The IPI results show that peptides were not assigned to proteins with unspecified 
names such as hypothetical or unknown proteins as observed in the NCBI results (proteins in 
bold) and these peptides were assigned to protein entries that doesn’t require further 
investigation or BLAST searches to determine the protein they may have originated from. 
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Table 4. 3 : Which Database? IPI vs NCBI. 
Table to show the results of database searching using a human IPI database (IPIv3.14) and a 
human database generated from an NCBI nr database and filtered using Xcorr vs charge state 
(+/-1: 1.50, +/-2: 2.00, +/-3: 2.50). The table lists all the proteins identified in the NCBI 
search results with at least 2 ‘first hit’ peptides alongside the equivalent protein identification 
in the IPI search results. Those highlighted in red are proteins with similar names to other 
proteins identified in the same sample. All peptide sequences from these proteins were 
checked to determine whether they could have originated from the same protein. The names 
in bold are entries in the NCBI database search that would require further investigation to 
determine the protein identification (Sample taken from Figure 3.7).  
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One problem highlighted in the NCBI search results was the identification of multiple 
isoforms of the same protein in the same sample e.g. 2 Transferrin proteins gi|48425720 and 
gi|136378 highlighted in red in Table 4.3. The peptides identified in both of theses proteins 
were manually inspected, Figure 4.3 shows the peptides assigned to these proteins and their 
correlation scores (Figure 4.3a) and the location of the identified peptides in the full protein 
sequences (Figure 4.3b).  
The peptide sequences highlighted in green and orange correspond to the peptides 
identified in gi|48425720 and gi|136378 respectively. The peptide sequence 
LTHDVELNLDYER, underlined and highlighted in orange in Figure 4.3b, was identified in 
gi|136378. A near identical sequence could also be found in gi|48425720 i.e. 
LTHDVELNLDYEE (underlined and highlighted in grey) with only a difference in the C-
terminal residue. As all 7 peptide sequences could be found in gi|136378, this could suggest 
that only this protein is present in the sample but further investigation would be required to 
determine whether this is true. Database searching using the IPI database does not appear to 
completely solve this problem as there are still peptides identified that could belong in more 
than one protein entry but all the proteins identified had names that didn’t require further 
analysis to determine the identity of that protein. Therefore, the IPI database would be more 
suitable for the analysis of large datasets as it requires less manual interpretation. 
4.6 False-Positive Rate Determination 
Large datasets generated during shotgun proteomic approaches require additional 
statistical analyses to give some indication that the correct peptide and protein sequence has 
been assigned to MS/MS spectra. One such analysis is the calculation of the false-positive rate 
or False Discovery Rate (FDR) determination as described by Elias et al (Elias et al., 2005).  
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(a) 
Reference     Score  Peptides (Hits)
Scan(s) Sequence MH+ Charge XC Delta Cn Sp RSp Ions
gi|48425720   70.38  7 (7 0 0 0 0)
1040 - 1048 -.SGVGTALLLK.- 959.17 2 2.54 0.25 668.5 1 15/18
1113 -.AFTYINLDK.- 1085.24 2 2.09 0.32 496.7 2 11/16
1324 - 1328 -.SSGLPNIPVQTISR.- 1469.67 2 2.59 0.10 367.8 1 14/26
1354 - 1360 -.SSGLPNIPVQTISR.- 1469.67 2 2.01 0.18 516.4 1 15/26
1474 - 1484 -.VEYHFLSPYVSPK.- 1566.78 2 3.46 0.43 641.5 1 15/24
2426 - 2432 -.VSASPLLYTLIEK.- 1434.70 2 3.70 0.53 1035.6 1 19/24
2564 -.ILNIFGVIK.- 1017.29 2 3.20 0.24 728.1 1 15/16
gi|136378    20.15  2 (2 0 0 0 0)
818 -.LTHDVELNLDYER.- 1617.74 2 3.08 0.36 1880.4 1 19/24
1895 - 1901 -.YNSQLLSFVR.- 1227.40 2 2.13 0.32 1094.1 1 15/18  
 
(b) 
>gi|48425720|pdb|1SUV|B Chain B, Structure Of Human Transferrin 
Receptor-Transferrin Complex 639 aa 
LYWDDLKRKLSEKLDSTDFTSTIKLLNENSYVPREAGSQKDENLALYVENEFREFKLSKVWRDQHFVKIQ 
VKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGK 
ITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPN 
IPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDH 
YVVVGAQRDAWGPGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYL 
SSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAA 
FPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDY 
EEYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRV 
EYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSG 
DVWDIDNEF 
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>gi|136378|sp|P02786|TFR1_HUMAN Transferrin receptor protein 1 (TfR1) 
(TR) (TfR) (Trfr) (CD71 antigen) (T9) (p90) 760aa 
MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPKRCSGSICYGT 
IAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDF 
TSTIKLLNENSYVPREAGSQKDENLALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLV 
YLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVL 
IYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNME 
GDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAWGPGAAKSG 
VGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLG 
TSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCED 
TDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRA 
DIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHV 
FWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF 
 
Figure 4. 3 : Manual Inspection of the peptides from the proteins 
gi|48425720|pdb|1SUV|B Chain B, Structure Of Human Transferrin Receptor-
Transferrin Complex and gi|136378|sp|P02786|TFR1_HUMAN Transferrin receptor 
protein 1 (TfR1) identified in the NCBI database search results. 
(a) Table to show the peptides assigned to each protein with their corresponding correlation 
scores. (b) Shows the location of the identified peptide sequences in the full length protein 
sequence. The peptide sequences highlighted in green and orange correspond to the peptides 
identified in gi|48425720 and gi|136378 respectively. The two underlined peptide sequences 
(one in grey and the other in orange) are identical apart from the C-terminal residue (in bold). 
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This is achieved by searching the raw files against a database that contains randomised 
sequences of all the proteins present in that database as well as the non-randomised 
sequences. This is known as target-decoy database searching and is described in Section 
1.3.3). In this study, this method was tested on a single raw file acquired in Figure 3.7. The 
protein sequences in the human IPIv3.14 database were randomised using a perl script 
downloaded from the matrix science website (www.matrixscience.com/help/decoy) and the 
raw file was searched against this database (containing the correct and random protein 
sequences). The results were filtered using the four different filter parameters shown in Table 
4.2 and the results are shown in Table 4.4. The  results  show the number  of MS/MS  spectra  
assigned to random protein sequences and the percentage of the total protein and peptide 
assignments made to random entries for proteins with at least 2 ‘first hit’ peptides and 
proteins with at least 1 ‘first hit’ peptide. A 0% false positive rate was calculated for all 4 
filter parameters at the peptide and protein level when only proteins with at least 2 ‘first hit’ 
peptides were considered. When proteins with at least 1 ‘first hit’ peptide were also 
considered, the false positive rate increased to 43, 48, 54 and 46% for filters I, II, III and IV 
respectively at the protein level and 12, 23, 19 and 20% respectively at the peptide level. The 
results demonstrate that quite a large margin of error is introduced when proteins with only 1 
‘first hit’ peptide is included in the analysis but failed to show any differences in false positive 
rates between the filter parameters used.  
Next, all 16 raw files generated from Figure 3.7 were searched against the same 
randomised IPI database and the false positive rates were calculated as a percentage and the 
FDR (Elias et al., 2005) for each of the 4 filter parameters (see Table 4.5). Firstly, Table 4.5 
shows that calculating the false positive rate as a percentage or the FDR yields the same result 
if the percentage is represented as a decimal number. Table 4.5 also shows that calculating the 
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             Proteins with at least 2 first hit peptides             Proteins with at least 1 first hit peptides
Filter no of proteins no of peptides   % of false positives no of proteins no of peptides   % of false positives
Parameters IPI / random IPI / random PROTEIN PEPTIDE IPI / random IPI / random PROTEIN PEPTIDE
Filter I 43 / 0 320 / 0 0% 0% 105 / 46 382 / 46 43.81 12.04
Filter II 49 / 0 345 / 0 0% 0% 282 / 137 578 / 137 48.58 23.70
Filter III 49 / 0 341 / 0 0% 0% 194 / 106 535 / 106 54.64 19.8
Filter IV 49 / 0 342 / 0 0% 0% 228 / 106 521 / 106 46.49 20.35  
 
 
Table 4. 4 : False positive determination of a single sample following database searching 
using a decoy database. 
A raw file collected in Figure 3.7 was searched against the randomised IPIv3.14 database to 
determine the false positive rate using the four previously discussed filter parameters. The 
Table shows the number of ‘true’ proteins and the ‘false’ or random proteins identified. The 
false positive rate is expressed as the percentage of the total protein identifications that were 
random entries i.e. (number of random hits / number of true hits) x 100. FILTER I –Single 
Threshold Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 2.50); FILTER II – Default 
Multiple Threshold (Match = 4, Delta Cn = 0.085, Xcorr = 1.00, Sp = 500, RSp = 5, Percent 
ions = 30%); FILTER III -  Novatia Multiple Threshold (Match = 4, Delta Cn = 0.100, Xcorr 
= 1.50, Sp = 200, RSp = 5, Percent ions = 70%); FILTER IV – Modified Multiple Threshold 
(Match = 4, Delta Cn = 0.100, Xcorr = 1.00, Sp = 350, RSp = 5, Percent ions = 50%). 
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false positive rate using the decoy database method is useful for large datasets but not single 
gel bands as random proteins were identified in a relatively small number of samples in all 4 
filter parameters. One way of identifying which filter parameters are useful for a particular 
dataset is to adjust them to yield a certain false positive rate. 
The results in Table 4.5 show an FDR of 0.0081, 0.0132, 0.0058 and 0.0086 at the 
protein level and 0.0036, 0.0046, 0.0019 and 0.0032 at the peptide level for filters I, II, III and 
IV respectively. The lowest FDR was achieved using filter III but as shown in Table 4.2, 
many ‘good hits’ were missed using this parameter. As previously discussed, the results in 
Table 4.2 indicated that Filter IV was the optimal set of filter parameters for analysing 
proteomic datasets. Using these filter parameters on multiple samples from a single 
experiment generated an FDR of 0.0086 (false positive rate <1%) at the protein level which 
was comparable to those previously used on a routine basis in the lab (filter I FDR = 0.0081). 
Using these modified multiple threshold filter parameters, more protein and peptide hits were 
generated compared to Filter I without dramatically increasing the false positive rate. These 
results therefore confirm that the modified filter parameters are optimal for analysing a large 
proteomic dataset. 
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(a) 
FILTER I - Proteins with at least 2 first hit peptides
NUMBER OF PROTEINS NUMBER OF PEPTIDES   % of false positives FDR
Sample no IPI random IPI random PROT PEP PROT PEP
1 9 0 100 0 0.00 0.00 0.0000 0.0000
2 33 0 323 0 0.00 0.00 0.0000 0.0000
3 49 1 364 2 2.04 0.55 0.0200 0.0055
4 36 0 411 0 0.00 0.00 0.0000 0.0000
5 49 0 354 0 0.00 0.00 0.0000 0.0000
6 45 4 276 8 8.89 2.90 0.0816 0.0282
7 44 1 294 2 2.27 0.68 0.0222 0.0068
8 53 0 337 0 0.00 0.00 0.0000 0.0000
9 51 0 268 0 0.00 0.00 0.0000 0.0000
10 53 0 337 0 0.00 0.00 0.0000 0.0000
11 84 0 404 0 0.00 0.00 0.0000 0.0000
12 81 0 306 0 0.00 0.00 0.0000 0.0000
13 76 0 325 0 0.00 0.00 0.0000 0.0000
14 95 1 221 5 1.05 2.26 0.0104 0.0221
15 53 0 215 0 0.00 0.00 0.0000 0.0000
16 42 0 159 0 0.00 0.00 0.0000 0.0000
total 853 7 4694 17 0.82 0.36 0.0081 0.0036  
 
(b) 
FILTER II - Proteins with at least 2 first hit peptides
NUMBER OF PROTEINS NUMBER OF PEPTIDES   % of false positives FDR
Sample no IPI random IPI random PROT PEP PROT PEP
1 14 0 121 0 0.00 0.00 0.0000 0.0000
2 38 0 383 0 0.00 0.00 0.0000 0.0000
3 56 1 432 2 1.79 0.46 0.0175 0.0046
4 43 0 486 0 0.00 0.00 0.0000 0.0000
5 59 0 426 0 0.00 0.00 0.0000 0.0000
6 47 2 380 4 4.26 1.05 0.0408 0.0104
7 45 2 376 4 4.44 1.06 0.0426 0.0105
8 56 0 470 0 0.00 0.00 0.0000 0.0000
9 51 0 292 0 0.00 0.00 0.0000 0.0000
10 57 1 362 2 1.75 0.55 0.0172 0.0055
11 93 0 464 0 0.00 0.00 0.0000 0.0000
12 90 0 360 0 0.00 0.00 0.0000 0.0000
13 85 1 369 2 1.18 0.54 0.0116 0.0054
14 53 2 258 6 3.77 2.33 0.0364 0.0227
15 60 1 251 2 1.67 0.80 0.0164 0.0079
16 49 2 185 4 4.08 2.16 0.0392 0.0212
total 896 12 5615 26 1.34 0.46 0.0132 0.0046  
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(c) 
FILTER III - Proteins with at least 2 first hit peptides
NUMBER OF PROTEINS NUMBER OF PEPTIDES   % of false positives FDR
Sample no IPI random IPI random PROT PEP PROT PEP
1 12 0 112 0 0.00 0.00 0.0000 0.0000
2 36 0 375 0 0.00 0.00 0.0000 0.0000
3 54 0 419 0 0.00 0.00 0.0000 0.0000
4 40 0 465 0 0.00 0.00 0.0000 0.0000
5 53 0 399 0 0.00 0.00 0.0000 0.0000
6 46 1 288 2 2.17 0.69 0.0213 0.0069
7 42 0 314 0 0.00 0.00 0.0000 0.0000
8 54 0 359 0 0.00 0.00 0.0000 0.0000
9 49 1 268 2 2.04 0.75 0.0200 0.0074
10 55 1 353 2 1.82 0.57 0.0179 0.0056
11 89 0 437 0 0.00 0.00 0.0000 0.0000
12 87 0 345 0 0.00 0.00 0.0000 0.0000
13 85 1 362 2 1.18 0.55 0.0116 0.0055
14 49 0 239 0 0.00 0.00 0.0000 0.0000
15 59 0 240 0 0.00 0.00 0.0000 0.0000
16 49 1 180 2 2.04 1.11 0.0200 0.0110
total 859 5 5155 10 0.58 0.19 0.0058 0.0019  
 
(d) 
FILTER IV- Proteins with at least 2 first hit peptides
NUMBER OF PROTEINS NUMBER OF PEPTIDES   % of false positives FDR
Sample no IPI random IPI random PROT PEP PROT PEP
1 14 0 116 0 0.00 0.00 0.0000 0.0000
2 38 0 381 0 0.00 0.00 0.0000 0.0000
3 58 2 433 2 3.45 0.46 0.0333 0.0046
4 41 0 474 0 0.00 0.00 0.0000 0.0000
5 56 0 398 0 0.00 0.00 0.0000 0.0000
6 48 1 298 2 2.08 0.67 0.0204 0.0067
7 42 0 318 0 0.00 0.00 0.0000 0.0000
8 56 0 371 0 0.00 0.00 0.0000 0.0000
9 51 1 281 2 1.96 0.71 0.0192 0.0071
10 56 1 351 2 1.79 0.57 0.0175 0.0057
11 88 0 447 0 0.00 0.00 0.0000 0.0000
12 129 0 364 0 0.00 0.00 0.0000 0.0000
13 84 1 363 2 1.19 0.55 0.0118 0.0055
14 52 1 252 4 1.92 1.59 0.0189 0.0156
15 59 0 242 0 0.00 0.00 0.0000 0.0000
16 49 1 184 3 2.04 1.63 0.0200 0.0160
total 921 8 5273 17 0.87 0.32 0.0086 0.0032  
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Table 4. 5 : False positive rate determination of all samples in a single experiment 
following database searching using a decoy database. 
All the raw files collected in Figure 3.7 were searched against an IPI_RANDOM database to 
determine the false positive rate using the four previously discussed filter parameters. The 
Table shows the number of ‘true’ proteins and the ‘false’ or random proteins identified. The 
false positive rate is expressed as both the percentage of ‘false’ hits (as described in Table 4.4) 
and as FDR. FILTER I –Single Threshold Xcorr vs charge state (+/-1: 1.50, +/-2: 2.00, +/-3: 
2.50); FILTER II – Default Multiple Threshold (Match = 4, Delta Cn = 0.085, Xcorr = 1.00, 
Sp = 500, RSp = 5, Percent ions = 30%); FILTER III -  Novatia Multiple Threshold (Match = 
4, Delta Cn = 0.100, Xcorr = 1.50, Sp = 200, RSp = 5, Percent ions = 70%); FILTER IV – 
Modified Multiple Threshold (Match = 4, Delta Cn = 0.100, Xcorr = 1.00, Sp = 350, RSp = 5, 
Percent ions = 50%). FDR = False Discovery Rate (FP/(FP+TP)). FP = False positive. TP = 
True Positive. 
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4.6 Conclusions 
The aim of this chapter was to analyse the sensitivity of the LCQ Deca XPPLUS and to 
optimise the search conditions and filter parameters to be used for the analysis of large 
proteomic datasets. Firstly, the instrument sensitivity was tested by digesting BSA with 
trypsin in solution and investigating the number of BSA peptides identified and percentage 
coverage with increasing concentrations. Table 4.1 indicated the sensitivity of the LCQ Deca 
XPPLUS for BSA as ~4fmoles (0.26ng). This sensitivity was decreased when the BSA was 
digested with trypsin in gel slices following protein separation by electrophoresis with 
peptides identified by MS in bands >250fmoles (16.5ng), these results were the same for 
both CBB G250 and silver stained gels. 
The sensitivity of both the CBB G250 and silver staining protocols was also 
investigated. Although the silver staining protocol was more sensitive, detection of a band on 
a gel did not guarantee protein identification when LC MS/MS analysis was performed and 
CBB G250 staining was chosen for the SILAC survey to be carried out as a high level of 
sensitivity at the protein staining level is not required. Also, there is a loss of sample 
recovery when performing in-gel digestion compared to digestion in solution however when 
analyzing complex mixtures of proteins, separation using gel electrophoresis is still 
favourable due to the added benefits of contaminant removal prior LC MS/MS analysis. 
Next, the choice of database used for searching the raw files against was investigated. 
Table 4.3 indicated that the IPI database would be more suitable for analysing large datasets 
generated from shotgun proteomic experiments compared to a human NCBI database as less 
manual interpretation was required. Finally, the optimal filter parameters for analysing the 
search results were investigated. The results in Table 4.2 indicated that the modified multiple 
threshold filter parameters (Match = 4, Delta Cn = 0.100, Xcorr = 1.00, Sp = 350, RSp = 5, 
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Percent ions = 50%) was optimal to keep the number of false positive identifications to a 
minimum whilst ensuring that few true identifications were missed. Xcorr is a score 
resulting from a cross correlation analysis of the top 500 identified amino acid sequences 
and is a measure of the similarity of the obtained spectra with the theoretical spectra. Delta 
cn is a measure of the difference in Xcorr values for the top candidate and the given 
candidate. The Sp value is a preliminary score given to a predicted amino acid sequence 
which takes into account the number of predicted fragment ions that match the observed ions 
and their abundance. The RSp is the ranking of the Sp score among the candidate amino acid 
sequences. The percent ions parameter is the percentage of the fragment ions of the 
candidate sequence that matches the total number of the theoretical fragment ions. The 
Match parameter stipulates that each candidate must match at least four of the threshold 
parameters. This was confirmed in the results of the decoy database search results shown in 
Table 4.5. These filter parameters identified more proteins and peptides when compared to 
the Xcorr vs charge state filter parameters previously used on a routine basis in our lab (+/-1: 
1.50, +/-2: 2.00, +/-3: 2.50) without increasing the false positive rate (<1%). The conditions 
optimised in this chapter were then ready to analyse the large proteomic dataset that would 
be generated by the SILAC analysis of MVs from the RG/C2 and PRG/C2 cell lines. 
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Chapter 5 : Quantitative analysis of proteins secreted in MV's from CM derived from 
colorectal cancer cell lines using Stable Isotope Labeling of Amino acids in Culture 
(SILAC) 
5.1 Introduction 
SILAC is a quantitative proteomic method used to investigate the relative abundance 
of proteins in two or more samples by the metabolic incorporation of stable isotopically 
labeled amino acids (see Section 1.2.3.1). 
The aim of this chapter was to use SILAC to investigate the relative abundance of 
proteins in MVs released by the RG/C2 and PRG/C2 cell lines to identify differentially 
secreted proteins that could have the potential to be used as markers of early tumour 
progression. Any of the essential amino acids can be used but Arg and Lys are more 
commonly used. Trypsin digestion cleaves proteins on the C-terminal side of basic residues 
therefore every tryptic peptide generated should contain a C-terminal Arg or Lys (except for 
the C-terminal peptide). For this study, the RG/C2 cell line was grown in media containing 
[13C6 ] labeled Arg (‘heavy’) and [12C6] labeled Lys (‘light’) or [13C6 ] labeled Lys (‘heavy’) 
and [12C6 ] labeled Arg (‘light’). The PRG/C2 cell line was grown in [12C6 ] labeled Lys 
(‘light’) and [12C6 ] labeled Arg (‘light’) in both cases as described in Section 2.12. The 
labeling efficiency was investigated after six rounds of cell division (approx 5 weeks) by 
harvesting a cell lysate from both cell lines and separating the proteins by 1D gel 
electrophoresis in separate lanes (Figure 5.1). A single gel slice was excised from both lanes, 
in-gel digestion was performed and the tryptic peptides were analysed by LC MS/MS using a 
120min acetonitrile gradient (Figure 2.3). 
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Figure 5. 1 : SILAC Labeling Efficiency. 
RG/C2 cells were grown in media containing ‘heavy’ Arg and PRG/C2 cells were grown in 
media containing ‘light’ Arg for six rounds of cell divisions (5 weeks). The labeling 
efficiency was investigated by preparing a cell lysate and 25µg of the protein sample was 
separated on a 4-12% Bis-Tris gel and stained with CBBG250. A single gel slice was excised 
from both lanes for each experiment, in-gel digestion was performed and the tryptic peptides 
were analysed by LC MS/MS to calculate the percentage of proteins with each label. 
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The CBB G250 stained gel shown in Figure 5.1 was overloaded with protein but was 
sufficient for confirming the labeling efficiency of the cell lines grown in SILAC media. The 
results were searched against the human IPIv3.14 database and the results were filtered using 
the multiple thresholds parameters optimised in Chapter 4. There were a total of 48 proteins 
identified in the gel slice from the ‘heavy’ Arg labeled cells with 45 of these containing Arg 
residues. There were a total of 366 peptides identified in the 48 proteins, 166 of these 
contained Arg residues and 160 of those peptides contained ‘heavy’ labeled Arg residues 
which were not represented by the identical ‘light’ labeled peptide. Therefore the labeling 
efficiency was calculated as approx 97% (100 / 166 x 161 = 96.99). All the peptides identified 
in the gel slice from the PRG/C2 cell lysate contained ‘light’ labeled Arg residues (data not 
shown). 
CM was then collected from the RG/C2 cell line grown in ‘heavy’ Arg media and the 
PRG/C2 cell line ‘light’ Arg media (2.5x107 cells each) and MV fractions were prepared as 
previously described. This was repeated for a total of four SILAC experiments with biological 
duplicate MV fractions prepared from CM collected from the RG/C2 cell line grown in either 
‘heavy’ Arg or Lys and the PRG/C2 cell line grown in ‘light’ Arg and Lys. These four 
experiments are referred to as C13 ARG-A, C13 ARG-B, C13 LYS-A and C13 LYS-B 
throughout this study. The MV fractions for both the RG/C2 and PRG/C2 cell lines in each 
experiment were mixed in a 1:1 ratio (normalised by cell number) and the proteins were 
separated by 1D gel electrophoresis over 4cm of a 4-12% tris-bis gel (Figure 5.2a). The whole 
lane was then excised into 40 equal sized bands and in-gel digestion was performed on each. 
Each sample was numbered 1 → 40 (Figure 5.2b) and analysed by LC MS/MS using a 2hr 
acetonitrile gradient (as shown in Figure 2.3b). 
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(a)       (b)  
 
 
 
 
Figure 5. 2 : First collection of MV’s from SILAC labeled RG/C2 and PRG/C2 cells. 
MV’s prepared from CM derived from RG/C2 with ’heavy’ labeled Arg residues and PRG/C2 
with ‘light’ labeled Arg residues were mixed in a 1:1 ratio (2.5x107 cells each). (a) The 
proteins were then separated over 4 lanes of a 4-12% Tris-Glycine gel (b) and the whole lane 
was cut into 40 equal sized bands. 
 
 
 
 
 
1
40
Chapter 5                                                     Results 
191 
The raw files collected from experiment C13 ARG-A were then searched against the 
human IPI v3.14 database. The search results were filtered using the modified multiple 
threshold parameters optimised in Chapter 4 and only proteins with two unique peptides were 
included in the analysis. Supplementary Table 5a shows there were 485 proteins identified in 
total with the false positive rate calculated as 0.89% and a FDR of 0.0089. Only 34.7% of the 
total proteins identified were represented in both the ‘light’ and ‘heavy’ samples i.e. 168 out 
of 485. 128 of these proteins demonstrated an increase (≥ 1.5-fold) in secretion via MVs in 
the PRG/C2 cell line and none of the proteins showed a decrease (≤ 1.5-fold) in the PRG/C2 
cell line. The false positive rate calculated for this dataset was identical to that calculated in 
the test dataset used in Table 4.5 when using the modified multiple thresholds filter 
parameters optimised in Chapter 4. 
5.2 Using the Xpress Function to calculate an Abundance Ratio 
Supplementary Table 5a shows the relative abundance ratio as calculated using Xpress 
(light to heavy ratio) by Bioworks Browser. The software identifies the co-eluting ‘light’ and 
‘heavy’ peaks and uses the area under the peak to calculate the relative abundance. In order to 
determine how accurate the Xpress function calculated the abundance ratio, a small number of 
the peaks used to calculate these ratios were manually inspected. Further investigation showed 
that many ratios were calculated using peaks that were incorrectly picked and Figure 5.3 
shows an example of one of these peaks (peptide sequence IQGLTVEQAEAVVR identified 
from Dynein heavy chain IPI00456969 in sample 2). Xpress has chosen two peaks to 
calculate the area under the peak for both the light and the heavy peptides although manual 
inspection showed that only the first peak in both cases should be used. Xcalibur can be used 
to manually calculate the ratio by highlighting the ‘light’ and ‘heavy’ peaks and labeling the 
peaks using the area under the peak label function and Figure 5.3b shows the manual 
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(a) 
 
         
        
 
                     
 
 
 
(b) 
 
 
 
 
 
(c) 
 
 
 
 
 
 
Reference     Score  Peptides (Hits)
Scan(s) Sequence MH+ Charge XC Delta Cn Sp RSp Ions XPRESS
IPI00456969     786.24 82 (75 3 0 2 2)
1429 - 1435 R.IQGLTVEQAEAVVR.L 1513.72 2 4.12 0.54 1526.6 1 21/26
1444 - 1462 R.IQGLTVEQAEAVVR#.L 1519.72 2 3.72 0.34 1594.2 1 20/26 1 : 0.53
these peaks should not 
be included in ratio calculation
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(d) 
 
 
 
 
Figure 5. 3 : Example of an incorrectly calculated Xpress value. 
Diagram to show an example of how the Xpress function in Bioworks can miscalculate the 
abundance ratio, highlighting the need to manually check all ratios. (a) Peak picking by 
Xpress used to calculate an abundance ratio. (b) Manual calculation of the ratio for the 
peptide sequence IQGLTVEQAEAVVR. (c) Spectrum to show the ‘light’ (m/z 757.15) and 
‘heavy’ (m/z 760.01) peaks co-eluting at ~42mins. (d) MS/MS spectra for both the ‘light’ and 
‘heavy’. The MS/MS peaks circled in red represent the identical peaks in both the ‘light’ and 
‘heavy’ spectra with a difference of 6Da indicating the fragments containing the heavy Arg 
residue. 
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calculation of the light/heavy ratio for the peak shown in Figure 5.3a. 
The table in Figure 5.3a shows that Xpress has calculated the ratio as 1:0.53 but the 
ratio was calculated to be 1:0.37 when manually inspected therefore demonstrating a greater 
relative abundance ratio. These results suggest an increased amount of the ‘light’ peptide 
therefore demonstrating a 2.7-fold increase in that protein secreted by the PRG/C2 cell line 
compared to the 1.88 fold increase calculated by Xpress. Figure 5.3c shows the ‘light’ (m/z 
757.15) and ‘heavy’ (m/z 760.01) peaks co-eluting at ~42mins and Figure 5.3d shows the 
MS/MS data for both peaks confirming that both ions have the same peptide sequence. Heavy 
Arg and Lys residues have a mass increase of 6 but the mass spectrometer measures the m/z 
ratio and not the mass. Therefore the observed mass difference is dependant upon the charge 
state of the peptide. The example shown in Figure 5.3 is the (+2) charged species of the 
peptide therefore giving a mass difference of 3 between the ‘light’ and ‘heavy’ peaks. The 
peak fragments highlighted by red circles in Figure 5.3d indicate those containing the labeled 
Arg residue (i.e the Y ion series) with a mass difference of 6 in the MS/MS spectra. 
The analysis shown above demonstrated differences between the manual ratio 
calculation and the ratio calculated by Xpress for the peptide shown in Figure 5.3, other 
peptides with Xpress ratios were also manually inspected. Table 5.1 compares these ratios for 
a small number of proteins. The protein named IPI00024067.2 (sim to Clathrin heavy chain) 
has 10 peptide sequences where both the ‘light’ and ‘heavy’ peptides were identified. The 
Xpress ratios for these peptides range from 1:0.25 to 1:0.74 (average ratio of 1:0.45) whereas 
those manually calculated demonstrate a relatively narrow range of values of 1:0.17 to 1:0.39 
(average ratio of 1:0.28). Not only does the manual calculation of the relative abundance 
demonstrate a greater difference in the light/heavy ratio but the ratios calculated for peptides 
from the same protein appear to show a greater consistency. 
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Xpress manual
Protein name Peptide sequence ratio ratio
sim to Clathrin heavy chain -.ALEHFTDLYDIKR.-
IPI:IPI00024067.2 -.ALEHFTDLYDIKR#.- 1 / 0.45 1 / 0.17
-.NNLAGAEELFAR.-
-.NNLAGAEELFAR#.- 1 / 0.63 1 / 0.34
-.TSIDAYDNFDNISLAQR.-
-.TSIDAYDNFDNISLAQR#.- 1 / 0.40 1 / 0.24
-.LAELEEFINGPNNAHIQQVGDR.-
-.LAELEEFINGPNNAHIQQVGDR#.- 1 / 0.47 1 / 0.21
-.ISGETIFVTAPHEATAGIIGVNR.-
-.ISGETIFVTAPHEATAGIIGVNR#.- 1 / 0.28 1 / 0.22
-.WLLLTGISAQQNR.-
-.WLLLTGISAQQNR#.- 1 / 0.25 1 / 0.21
-.LLLPWLEAR.-
-.LLLPWLEAR#.- 1 / 0.42 1 / 0.34
-.KFDVNTSAVQVLIEHIGNLDR.-
-.KFDVNTSAVQVLIEHIGNLDR#.- 1 / 0.48 1 / 0.29
-.LTDQLPLIIVC*DR.-
-.LTDQLPLIIVC*DR#.- 1 / 0.74 1 / 0.39
-.VGYTPDWIFLLR.-
-.VGYTPDWIFLLR#.- 1 / 0.39 1 / 0.35
Ras GTPase-activating-like protein -.IFYPETTDIYDR.-
IQGAP1 -.IFYPETTDIYDR#.- 1 / 0.60 1 / 0.67
IPI:IPI00009342.1 -.IIGNLLYYR.-
-.IIGNLLYYR#.- 0.29 / 1 1 / 0.38
-.LEGVLAEVAQHYQDTLIR.-
-.LEGVLAEVAQHYQDTLIR#.- 1 / 0.35 1 / 0.30
splice isoform 4 of Filamin B -.EATTDFTVDSRPLTQVGGDHIK.-
IPI:IPI00382698.1 -.EATTDFTVDSR#PLTQVGGDHIK.- 1 / 0.97 1 / 0.89
-.VLFASQEIPASPFR.-
-.VLFASQEIPASPFR#.- 1 / 0.72 1 / 0.57
splice isoform long of Spectrin beta chain, -.LLEVLSGER#.- 1 / 0.94 1 / 0.85
brain 1 -.LLEVLSGER.-
IPI:IPI00005614.5 -.ITDLYTDLR#.- 0.42 / 1 1 / 0.94
-.ITDLYTDLR.-
splice isoform 1 of Solute carrier family -.EGAQYLMQAAGLGR.-
12 member 2 IPI:IPI00022649.3 -.EGAQYLMQAAGLGR#.- 1 / 0.43 1 / 0.53
splice isoform long of Na/K transporting -.GVGIISEGNETVEDIAAR.-
ATPase alpha chain 1 IPI:IPI00006482 -.GVGIISEGNETVEDIAAR#.- 1 0.48 1 / 0.38  
 
Table 5. 1 : Comparison of Xpress ratio and manually calculated ratio. 
Table to show all proteins identified in sample 5 from experiment C13 Arg-A with both light 
and heavy peaks identified. Also shows the comparison of abundance ratios calculated by 
Xpress compared to those calculated manually.  
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These results suggest that manual calculation of all the ratios for peptides with 
matching SILAC pairs would be more accurate than the Xpress function used by Bioworks 
Browser. However, this would be a very time-consuming task to perform not just for one 
experiment but for replicate experiments also. For a large dataset such as this, software that 
could calculate the ratio in an accurate and automated fashion is required to enable the 
analysis to be less labour intensive with reliable results. 
5.3 Data Analysis using the Trans Proteomic Pipeline (TPP) 
The Trans Proteomic Pipeline (TPP) is a free to download data analysis software 
package (http://tools.proteomecenter.org/windows.php) developed by the Institute for 
Systems Biology  (Seattle) for the analysis of large proteomic datasets which has been utilised 
in a number of proteomic studies (Desiere et al., 2005, Han et al., 2001, A. Keller et al., 
2002a, X. J. Li et al., 2003, Nesvizhskii and Aebersold, 2004, Nesvizhskii et al., 2003, von 
Haller et al., 2003). TPP involves a series of perl scripts which first converts all MS/MS files 
(generated from the spectra) to one XML file, it then calculates a probability score for peptide 
and protein assignments using Peptide Prophet™ and Protein Prophet™ respectively (A. 
Keller et al., 2002b, Nesvizhskii et al., 2003). As well as calculating an Xpress ratio, it also 
uses a program called Automated Statistical Analysis of Protein Abundance Ratios 
(ASAPRatio) to quantify both peptides and proteins and has been reported to be more 
accurate than Xpress (X. J. Li et al., 2003). TPP also automatically predicts the false positive 
rate of the dataset to enable the user to set a minimum protein probability threshold based 
upon the reported error rates (A. Keller et al., 2002a). Figure 2.4 shows an overview of the 
processes involved in TPP data analysis. As it was previously shown, the manual validation of 
the abundance ratios calculated using the Xpress function in the Bioworks Browser software 
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is time consuming for large datasets therefore TPP was used to analyse the data of the SILAC 
experiments described in this study. 
The proteins in the MV fractions for the remaining three SILAC experiments were 
also separated by 1D electrophoresis, the whole lane was excised as 40 equal sized bands, 
digested with trypsin and analysed by LC MS/MS as described above. The raw files for each 
experiment were searched against a human IPI database (v3.22). Then using TPP, the raw 
files were converted to a mzXML file and all the .out and .dta files created by the database 
search for each individual experiment were converted to a single XML file. The data was then 
in the correct format for analysis by Peptide Prophet™ followed then by Protein Prophet™ 
analysis and ASAPRatio was used to calculate the abundance ratios at the peptide and protein 
level respectively. This analysis was performed for each of the four SILAC experiments and 
the results were compared manually in an excel spreadsheet format (Supplementary Table 
5b).  
Supplementary Tables 5d, 5e, 5f and 5g show the TPP results for experiments C13 
ARG-A, C13 ARG-B, C13 LYS-A and C13 LYS-B respectively. Table 5.2 outlines the 
results of the comparison of the TPP results using a threshold of protein probability >0.90 and 
>0.70. The error rates calculated by TPP are very similar for all four SILAC experiments 
when using protein probability >0.90 with 0.013, 0.012, 0.011 and 0.007 for C13 ARG A, 
C13 ARG B, C13 LYS A and C13 LYS B respectively. These values increase when the 
threshold was decreased to protein probability >0.70 with 0.042, 0.042, 0.023 and 0.017 for 
C13 ARG A, C13 ARG B, C13 LYS A and C13 LYS B respectively (see Supplementary 
Figure 5a for the sensitivity and error rates observed for each of the four datasets). All 
proteins identified by the TPP analysis using the protein probability >0.70 threshold 
(including proteins with only a single peptide identified) for all 4 experiments were used for 
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the comparison. Table 5.2 shows there were a total of 1396 proteins identified with 136, 252, 
561 and 1396 proteins identified in at least 4, 3, 2 and 1 experiment. It also shows the number 
of proteins with multiple and single peptides, proteins with a >1.5-fold change as calculated 
by the ASAPRatio and the number of proteins with increased and decreased secretion in MVs 
by the PRG/C2 cell line for each of the four experiments. A direct comparison of the 
manually calculated ratios with the ASAPRatio was not carried out as the software utilises 
extra functions to calculate the relative abundance ratio that would be very difficult to 
perform manually such as background subtraction and standard deviation calculation to 
determine the reliability of the ratio calculated. 
Supplementary Table 5b shows the results of this comparison including the name and 
IPI accession number of all the proteins identified, ASAPRatios and the protein probabilities 
for each individual experiment and also the average protein probability and ASAPRatio over 
the four SILAC experiments. The proteins identified in multiple experiments have a higher 
protein probability than those identified in a single experiment adding greater confidence that 
the proteins identified in multiple experiments are present in MVs released by these cell lines. 
The proteins identified in 4, 3, 2 and 1 experiment demonstrate protein probabilities >0.92, 
0.88, 0.76 and 0.70 respectively. Table 5.2 also shows the percentage of total proteins 
identified in all 4 experiments with calculated ASAPRatios. There were 49% and 65% of 
proteins identified in the Arg experiments A and B. The percentages were higher in Lys 
experiments A and B with 83% and 84% of the total proteins with calculated ASAPRatios. 
These results show that Lys should be the amino acid of choice for SILAC experiments using 
only a single labeled amino acid residue with at least 80% of all proteins containing peptides 
suitable for relative abundance calculation. Supplementary Table 5h shows the average 
protein probability, the average ASAPRatio and the individual ASAPRatios calculated in each  
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>0.90 PROTEIN PROBABILITY >0.70 PROTEIN PROBABILITY
C13ARG C13LYS C13ARG C13LYS
A B A B A B A B
Error rate (FDR) 0.013 0.012 0.011 0.007 0.042 0.042 0.023 0.017
Total proteins identified 829 542 348 364 977 643 369 379
Proteins with single peptides 210 139 114 153 311 137 133 149
Proteins with multiple peptides: 619 403 234 211 666 505 236 230
 -with ASAPRatios # 415 231 195 184 435 249 199 191
 ->1.5 fold change # 290 143 160 160 305 157 159 160
 -Increased release in PRG/C2 # 250 122 157 153 259 132 157 153
 -Decreased release in  PRG/C2 # 40 21 3 7 46 25 4 7
% of proteins with multiple peptides
with ASAPRatios 67.04 57.32 83.33 87.20 65.30 49.30 84.32 83.04
Total number of proteins* 1198 1396
Proteins found in all 4 experiments* 108 136
Proteins found in 3 experiments* 89 116
Proteins found in 2 experiments* 314 315
Proteins found in 1 experiment* 1198 829  
 
 
 
Table 5. 2 : Comparison of the results from the TPP analysis of the 4 SILAC 
experiments using protein probability values of >0.90 and >0.70. 
Table to show the false positive rates, number of proteins identified the number of proteins 
with ASAPRatios and the percentage of the total number of proteins identified with peptides 
used to calculate abundance ratios. * - includes proteins with single peptides. # - proteins with 
multiple peptides only.  
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experiment for the 1396 proteins identified in all four experiments using protein probability 
>0.70 threshold. 
5.4 Data Analysis using Babelomics 
Data analysis of genomic-profiling experiments (i.e. micoarray gene expression 
experiments) often involves interpretation of up-regulated and down-regulated genes to 
identify pathways or a particular biological function which has shown significant differences 
between two biological conditions. Babelomics (http://www.babelomics.org/) is an online set 
of tools used to perform this type of data interpretation required for microarray gene 
expression profiles (Al-Shahrour et al., 2006). FatiGO+ (http://www.fatigo.org/) is one of 
these tools used to compare the GO (Gene Ontology) terms associated with two lists of genes 
(Al-Shahrour et al., 2007). The Gene Ontology (GO) project (http://www.geneontology.org/) 
is a collaborative effort to address the need for consistent descriptions of gene products in 
different databases (Ashburner et al., 2000). They have developed a database that describes 
gene products in terms of their associated biological processes, cellular components and 
molecular functions in a species-independent manner. The ontologies are structured so they 
can be viewed at different levels of complexity and gene products might be associated with 
one or more processes, cellular components or molecular function. Cellular component refers 
to an anatomical structure (e.g. rough endoplasmic reticulum or nucleus) or a gene product 
group (e.g. ribosome, proteasome or a protein dimer). Biological process is described by the 
GO project as a series of events accomplished by one or more ordered assemblies of 
molecular functions and is not equivalent to a pathway. Molecular function refers to activities, 
such as catalytic or binding activities, that occur at the molecular level and generally 
corresponds to activities that can be performed by individual gene products, but some 
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activities are performed by assembled complexes of gene products. Another function of 
FatiGO+ is to associate gene products with KEGG pathways (http://www.genome.jp/kegg/). 
KEGG (Kyoto Encyclopaedia of Genes and Genomes) is a database that associates gene 
products with biological pathways (Kanehisa et al., 2004). 
The references described above were all used to interpret the proteomic data described 
in this chapter. The SILAC data generated in this study was analysed in the same way that 
microarray data is analysed using the following: Babelomics was used to investigate the 
biological function, the KEGG pathways and cellular components associated with the proteins 
identified in this study. Firstly, the protein accession numbers were converted to gene symbols 
using REFDIC (http://refdic.rcai.riken.jp/welcome.cgi) (Hijikata et al., 2007) and those found 
in at least 2 out of 4 experiments were then analysed using FATIGO+ as described in Section 
2.13.3 (see Figure 5.4 for results). The table shown in Figure 5.4a shows the biological 
processes with ≥5 proteins identified in this survey associated with that particular process. 
The top three processes were apoptosis, regulation of cell death and glucose metabolic 
processes with 38, 32 and 21 proteins respectively. The table shown in Figure 5.4a shows the 
gene symbols associated with each of the biological processes. The bar chart in Figure 5.4b 
shows the KEGG pathways involving ≥7 of the identified proteins with ribosomal pathways 
and regulation of the actin cytoskeleton associated 30 and 28 proteins respectively. The table 
in Figure 5.4b shows the gene symbols associated with each of the KEGG pathways. Finally, 
the pie chart in Figure 5.4c shows the number of proteins found in each of the cellular 
components. These results show that the proteins found in these MVs originate from various 
compartments within the cell including the nucleus, cytosol, mitochondria and the 
cytoskeleton. 
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(a) Biological Processes (GO Level 8) 
Biological process Genes list NºGenes
apoptosis PPP2R1A PDIA3 HSPA1A TIAF1 CYCS VDAC1 YWHAG ACTN4 HSPD1 CIB1 
DAD1 HSPE1 ACTN1 MIF ARHGDIA CFL1 EEF1E1 TUBB2C CLIC1 EIF5A VCP 
PDCD6IP PRDX2 YWHAH ANXA1 HSP90B1 RTN4 ALB CSE1L NME1 TPT1 PHB 
HSPA5 TUBB GSTP1 PDCD6 CALR ANXA5
38
regulation of programmed cell 
death
PPP2R1A PDIA3 HSPA1A TIAF1 CYCS YWHAG ACTN4 HSPD1 HSPE1 ACTN1 
MIF ARHGDIA CFL1 EEF1E1 TUBB2C CLIC1 VCP PRDX2 YWHAH ANXA1 
HSP90B1 RTN4 ALB NME1 TPT1 PHB HSPA5 TUBB GSTP1 PDCD6 CALR 
ANXA5
32
glucose metabolic process PGK1 PFKP PGM1 PGAM1 PFKL PCK2 LDHB FBP1 PKM2 MDH1 ALDOA 
TALDO1 UGDH ENO1 MDH2 TPI1 UGP2 GAPDH GPI ENO3 LDHA
21
hexose catabolic process PGK1 PFKP PGM1 PGAM1 PFKL LDHB PKM2 MDH1 ALDOA TALDO1 ENO1 
MDH2 TPI1 GAPDH GPI ENO3 LDHA
17
regulation of transcription, DNA-
dependent
STAT3 RPL6 SOD2 CARHSP1 PFN1 TTLL3 XRCC6 CTNND1 MYO6 VPS25 
RUVBL2 RAN ENO1 NME1 RAB1A CALR SUB1
17
proteolysis involved in cellular 
protein catabolic process
PSMB5 PSMB4 PSMB8 PSMB1 PSMB3 PSMA2 PSMA7 PSMA1 PSMB2 PEPD VCP 
UCHL3 PSMA5 PSMA4 PSMC6 PSMA6 PSMA3
17
protein targeting PDIA3 YWHAZ YWHAG HSPD1 YWHAQ SSR3 SDCBP AP1M2 RAN YWHAB 
CSE1L RHOA KPNB1 CALR COPB1
15
actin polymerization and/or 
depolymerization
SPTBN1 DSTN ARF6 CAPZA2 ARPC3 TTLL3 ARPC5L VIL1 ARPC2 CAPZB 
ARPC5 CAPZA1 SPTAN1 DIAPH1
14
regulation of actin filament 
length
SPTBN1 DSTN ARF6 CAPZA2 ARPC3 ARPC5L VIL1 ARPC2 CAPZB ARPC5 
CAPZA1 SPTAN1
12
purine ribonucleotide 
biosynthetic process
ATP5A1 PAICS ATP5C1 ATP5O ATP5J2 ATP5B ATP5F1 NME1 ATP5L 9
proton transport ATP5A1 ATP5C1 ATP5O ATP5J2 ATP4A ATP5B ATP5F1 ATP5L ATP1A1 9
neuron differentiation PLXNB2 YWHAG MYO6 HPRT1 YWHAH RTN4 CNP MTPN NAPA 9
purine nucleoside triphosphate 
biosynthetic process
ATP5A1 ATP5C1 ATP5O ATP5J2 ATP5B ATP5F1 NME1 ATP5L 8
ribonucleoside triphosphate 
biosynthetic process
ATP5A1 ATP5C1 ATP5O ATP5J2 ATP5B ATP5F1 NME1 ATP5L 8
purine ribonucleoside 
triphosphate metabolic process
ATP5A1 ATP5C1 ATP5O ATP5J2 ATP5B ATP5F1 NME1 ATP5L 8
tRNA aminoacylation TARS EPRS FARSLA CARS RARS NARS DARS 7
Rho protein signal transduction ARF6 ARHGDIA CFL1 TAX1BP3 PTPLAD1 ARHGDIB RHOA 7
ER to Golgi vesicle-mediated 
transport
RAB2 ARF6 ARF1 RAB1A ARF4 NAPA 6
mitosis YWHAG TTN KIF23 YWHAH RAN PAFAH1B1 6
microtubule-based movement TUBB2C KIF23 PAFAH1B1 DST DYNC1H1 TUBB 6
tricarboxylic acid cycle SUCLG2 IDH1 MDH1 ACO1 MDH2 FH 6
epidermis development FABP5 KRT9 SFN KRT10 DSP KRT2 6
hexose biosynthetic process PGM1 PCK2 FBP1 TPI1 GPI 5
transcription from RNA 
polymerase II promoter
STAT3 SOD2 PFN1 MYO6 SUB1 5
chromatin assembly or 
disassembly
H1F0 H2AFJ H2AFY HIST1H2BM NAP1L4 5
arginine metabolic process ASL ASS1 CAD DDAH1 CLIC1 5
actin filament-based movement MYH9 MYH14 MYO6 MYL6 MYO1A 5
cell projection biogenesis SDCBP CDC42 ITGA6 CAPZB VCL 5
potassium ion transport ATP1B1 ATP4A SLC12A2 ATP1A1 ATP1B3 5
intra-Golgi vesicle-mediated 
transport
COPE ARCN1 COPG COPB1 NAPA 5
nuclear import PDIA3 RAN CSE1L RHOA KPNB1 5
sodium ion transport NDUFA9 ATP1B1 SLC12A2 ATP1A1 ATP1B3 5  
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(b) KEGG pathways 
KEGG pathways Genes list NºGenes
Ribosome RPL19 RPS8 RPL38 RPL6 RPS5 RPS6 RPS3 RPS7 RPS15A RPS27L RPS19 
RPL30 RPL18A RPS25 RPL18 RPS4X RPL11 RPL7 RPS17 RPL12 RPS20 
RPL24 RPS9 RPL27 RPS10 RPSAP15 RPS13 RPLP2 RPS16 RPS24
30
Regulation of actin cytoskeleton ITGB1 MYH9 ARPC1B ACTN4 MYH14 TTN IQGAP1 VIL2 ACTN1 PFN1 
CFL1 ARPC3 ROCK2 TTLL3 ITGA2 ARPC5L ACTC1 IQGAP3 GNG12 
CDC42 ITGA6 ARPC2 ACTB RHOA ITGB4 ARPC5 VCL DIAPH1
28
Focal adhesion ITGB1 ACTN4 TTN ACTN1 FLNB ROCK2 MYL6 ITGA2 ACTC1 CDC42 
ITGA6 ACTB RHOA ITGB4 TLN1 VCL DIAPH1
17
Glycolysis / Gluconeogenesis PGK1 PFKP PGM1 PGAM1 PFKL LDHB FBP1 ALDH2 PKM2 ALDOA 
ENO1 TPI1 GAPDH GPI ALDH1B1 ENO3 LDHA
17
Proteasome PSMB5 PSMB4 PSMB1 PSMB3 PSMD3 PSMA2 PSMC3 PSMA7 PSMA1 
PSMB2 PSMA5 PSMA4 PSMC6 PSMA6 PSMC4 PSMA3
16
Oxidative phosphorylation CYC1 ATP5A1 NDUFA9 UQCRC2 COX5A COX7A2 PPA1 ATP5C1 ATP5O 
ATP5J2 COX2 ATP4A ATP5B ATP5F1 UQCRB ATP5L
16
Tight junction PPP2R1A MYH9 ACTN4 MYH14 PPP2CB ACTN1 CLDN3 MYL6 ACTC1 
CDC42 ACTB CLDN9 RHOA SPTAN1 TJP2
15
Pathogenic Escherichia coli 
infection - EPEC
ITGB1 YWHAZ YWHAQ VIL2 TUBB2C ROCK2 ARPC5L ACTC1 CDC42 
ACTB RHOA TUBB ARPC5 KRT18
14
Leukocyte transendothelial 
migration
ITGB1 ACTN4 VIL2 ACTN1 ROCK2 CLDN3 CTNND1 MYL6 ACTC1 
CDC42 ACTB CLDN9 RHOA VCL
14
Pathogenic Escherichia coli 
infection - EHEC
ITGB1 YWHAZ YWHAQ VIL2 TUBB2C ROCK2 ARPC5L ACTC1 CDC42 
ACTB RHOA TUBB ARPC5 KRT18
14
Pyruvate metabolism ME1 PCK2 LDHB ALDH2 PKM2 MDH1 MDH2 ALDH1B1 LDHA GRHPR 
ACAT1
11
Cell Communication KRT9 KRT8 ACTC1 ITGA6 ACTB ITGB4 LMNA KRT10 KRT19 KRT2 
KRT18
11
Antigen processing and 
presentation
PDIA3 HSPA1A HSP90AB1 HSP90AA1 HSPA8 B2M PSME1 CANX HSPA5 
CALR
10
Carbon fixation PGK1 ME1 FBP1 PKM2 MDH1 ALDOA MDH2 TPI1 TKT 9
Arginine and proline metabolism ASL CKMT1A ASS1 EPRS ALDH2 ALDH1B1 MAOA RARS LAP3 9
Adherens junction ACTN4 IQGAP1 ACTN1 CTNND1 ACTC1 CDC42 ACTB RHOA VCL 9
Purine metabolism PAICS GDA AK2 PKM2 HPRT1 ATIC NME1 APRT ENTPD6 9
Pentose phosphate pathway PFKP PGM1 PFKL FBP1 ALDOA TALDO1 TKT GPI 8
Insulin signaling pathway PFKP RPS6 PFKL PCK2 FBP1 CALM1 PKM2 FASN 8
Fatty acid metabolism HADHA ALDH2 HADHB HADH ACSL5 ALDH1B1 ACAA2 ACAT1 8
Fructose and mannose 
metabolism
PFKP HSD17B12 PFKL FBP1 ALDOA PHPT1 TPI1 SORD 8
Valine, leucine and isoleucine 
degradation
HADHA ALDH2 HADHB HADH ALDH1B1 ACAA2 TRIM23 ACAT1 8
Calcium signaling pathway VDAC1 SLC25A5 TTN CALM1 GNA14 TAX1BP3 VDAC3 SLC25A4 8
Citrate cycle (TCA cycle) PCK2 SUCLG2 IDH1 MDH1 ACO1 MDH2 FH 7
PPAR signaling pathway ME1 PCK2 FABP5 APOA1 ACSL5 FABP1 DBI 7
Tryptophan metabolism HADHA ALDH2 CAT HADH ALDH1B1 MAOA ACAT1 7
Cell cycle YWHAZ YWHAG YWHAQ YWHAH SFN YWHAB YWHAE 7
Aminoacyl-tRNA biosynthesis TARS EPRS FARSLA CARS RARS NARS DARS 7
Propanoate metabolism HADHA SUCLG2 LDHB ALDH2 ALDH1B1 LDHA ACAT1 7  
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(c) Cellular Components (GO level 8) 
Cellular Components Genes list NºGenes
nucleus PPP2R1A HSPA1A MYH9 STAT3 PSMB4 YWHAZ TIAF1 TAGLN2 PTBP1 RPS6 CYCS 
CMPK RPS7 ACTN4 PSMB3 CIB1 HSPA8 ANP32B TTN ABHD14B PTGES3 RPS19 MVP 
SFRS3 PSMC3 TSN PFN1 SDCBP CFL1 SH3BGRL HINT1 LGALS3 EEF1E1 PSMA1 FER1L3 
CLIC1 EIF5A TTLL3 XRCC6 CTNND1 KIF23 PSMB2 HNRPH1 MYO6 TAX1BP3 VCP RBMX 
H1F0 VPS25 C11orf54 ACTB HNRPAB RUVBL2 RAN H2AFJ RTN4 HNRPK H2AFY CSE1L 
ENO1 PREP CSTB NME1 PAFAH1B1 KPNB1 PHB TRIM23 ANXA11 HSPA5 PARK7 
RPSAP15 PSMC6 HIST1H2BM LMNA PDCD6 SH3BGRL2 FKBP4 G3BP1 TJP2 NAP1L4 SUB1 
UBE2N HNRPA2B1 PSMC4 PSMA3 S100P CSRP1 RACGAP1 SYNCRIP HNRPF 90
cytosol PPP2R1A PSMB5 RPS8 PFKP MYH9 RPL6 RPS5 PSMB4 ME1 CCT7 LGALS4 RPS6 CYCS 
RPS3 PSMB8 RPS7 PSMB1 PGAM1 PSMB3 PFKL HSP90AA1 CCT3 RPS15A RPS19 PSMD3 
RPL18A CCT2 RPS25 PSMA2 IDH1 VIL2 PSMC3 RPL18 PSME1 JUP PSMA7 RPL7 PKM2 
PSMA1 VBP1 MDH1 CCT8 CCT5 PSMB2 RPS17 VCP PDCD6IP RPL12 RPS20 PHPT1 ACTB 
RUVBL2 HSP90B1 ENO1 PSMA5 PSMA4 CYB5R3 HBA1 CCT4 RPS9 RPS10 ENO3 LDHA 
AKR7A3 HSPA5 TLN1 RPSAP15 PSMC6 CALR RPS13 COPB1 RPLP2 RPS16 PSMA6 RPS24 
PSMC4 ARL2 PSMA3 78
cytoskeleton PPP2R1A MYO1C MYH9 SPTBN1 TIAF1 ARPC1B DSTN ACTR2 ACTN4 MYH14 CCT3 TTN 
PTK9 IQGAP1 VIL2 ACTN1 KRT9 SLC9A3R1 TBCA ARHGDIA PFN1 SDCBP CAPZA2 JUP 
CFL1 HINT1 KRT8 ARPC3 PLS1 TUBB2C FLNB ROCK2 TTLL3 CTNND1 KIF23 WDR1 
MYO6 MYL6 ARPC5L ACTC1 TPM3 CAP1 VIL1 ANXA1 ARPC2 ACTB CAPZB ARHGDIB 
RHOA ACTR3 TPT1 PAFAH1B1 DST DYNC1H1 TLN1 TUBB ARPC5 LMNA CAPZA1 
MYO1D VCL SPTAN1 KRT20 KRT10 LASP1 KRT19 DSP KRT2 MYO1A RACGAP1 KRT18 
DIAPH1 72
mitochondrion PPP2R1A HINT2 C1QBP HSPA1A CYC1 ATP5A1 CLTC YWHAZ HADHA CYCS VDAC1 
HSP90AB1 NDUFA9 SOD2 HSPD1 CKMT1A PCK2 SUCLG2 SLC25A5 ALDH2 HSPE1 
CYB5B LYPLA1 HADHB UQCRC2 AK2 ETFA COX5A COX7A2 BRP44 PKM2 ATP5C1 
TUFM ATP5O PRDX5 SLC25A17 ATP5J2 COX2 CAT MDH2 HADH ATP5B CYB5R3 ATP5F1 
UQCRB ACSL5 ALDH1B1 VDAC3 MAOA ATP5L FH IMMT ECH1 ACAA2 PHB SLC25A4 
ACAT1 LAP3 DSP PRDX4 MGST1 61
organelle membrane CYC1 ATP5A1 CLTC RPN2 HADHA TAGLN2 CYCS COPE VDAC1 NDUFA9 SOD2 DAD1 
SLC25A5 SSR3 CYB5B SSR4 UQCRC2 AK2 COX5A COX7A2 ARCN1 AP1M2 MYO6 ATP5C1 
ATP5O SLC25A17 JPH4 ATP5J2 COX2 HSP90B1 RAN RTN4 CAT CSE1L HADH ATP5B 
CYB5R3 ATP5F1 UQCRB ACSL5 VDAC3 IMMT COPG KPNB1 ACAA2 PHB SLC25A4 
HSPA5 LMNA COPB1 DDOST ACAT1 AP1S1 MGST1 54
endoplasmic reticulum HYOU1 PDIA3 ITGB1 HSPA1A PGRMC1 DNAJC14 RPN2 RAB2 ERO1L HSD17B12 CIB1 
DAD1 MGST3 SSR3 SDCBP PDIA4 SSR4 ERP29 CANX NCSTN VCP P4HB PPIB TMEM4 
HSP90B1 PDIA6 DPEP1 RTN4 TXNDC12 CYB5R3 PTGFRN PRKCSH RAB1A CDIPT HSPA5 
TMCO1 CALR DDOST NAPA MGST1 SYNCRIP PTP4A1 GANAB 43
organelle envelope CYC1 ATP5A1 HADHA TAGLN2 CYCS VDAC1 NDUFA9 SOD2 SLC25A5 CYB5B HADHB 
UQCRC2 AK2 COX5A COX7A2 FER1L3 CLIC1 MYO6 ATP5C1 ATP5O SLC25A17 ATP5J2 
COX2 RAN RTN4 CSE1L HADH ATP5B CYB5R3 ATP5F1 UQCRB ACSL5 VDAC3 
PAFAH1B1 IMMT KPNB1 ACAA2 PHB ANXA11 SLC25A4 LMNA ACAT1 MGST1 43
integral to plasma
membrane
ITGB1 MYH9 PGRMC1 ATP8B1 TFRC SLC25A5 ATP1B1 CEACAM5 SDCBP ABCC3 
GALNT8 CLDN3 NCSTN ITGA2 SLC25A17 TAX1BP3 SLC1A5 ITGA6 TMEM4 GPR109B 
LNPEP ATP4A VDAC3 SLC12A2 ITGB4 PHB SLC25A4 CD97 RPSAP15 GPA33 SLC1A4 CD81 
ATP1A1 TSPAN8 TJP2 CD9 LAMP1 ATP1B3 38
ribosome RPL19 RPS8 RPL38 RPL6 RPS5 RPS6 RPS3 RPS7 RPS15A RPS27L RPS19 RPL30 RPL18A 
RPS25 RPL18 RPS4X RPL11 RPL7 RPS17 RPL12 RPS20 GCN1L1 RPL24 RPS9 RPL27 RPS10 
RPSAP15 RPS13 RPLP2 RPS16 RPS24 31
Golgi apparatus ARL1 RNPEP COPE CORO7 RAB2 GDI2 ARCN1 RAB11A RAB10 MYO6 NCSTN JPH4 
RAB1A COPG COPB1 AP1S1 NAPA 17  
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nucleus, 90
cytosol, 78
cytoskeleton, 72
mitochondrion, 61
organelle 
membrane, 54
endoplasmic 
reticulum, 43
organelle envelope, 
43
integral to plasma 
membrane, 38
ribosome, 31
others, 154
Golgi apparatus, 17
 
Figure 5. 4 : Analysis of all proteins found in at least 2 experiments using software 
commonly used in microarray analysis, Babelomics. 
The accession numbers for the proteins identified in this survey that were found in at least 2 
experiments were converted to gene names using online software called REFDIC. The gene 
names were then used to investigate which biological processes, cellular components and 
pathways these proteins are involved in Babelomics. (a) A bar chart to show the biological 
processes with ≥5 proteins identified in this survey (GO level 8). The table identifies the gene 
symbols of the proteins involved in each biological process. (b) A bar chart to show the 
KEGG pathways with ≥7 proteins identified in this survey. The table identifies the gene 
symbols of the proteins involved in each pathway. (c) Table and pie chart to show the number 
of proteins that are localized to various cellular compartments (GO level 8). The table 
identifies the gene symbols of the proteins found in each cellular component. 
Chapter 5                                                     Results 
206 
5.5 Potentially Interesting Proteins for Further Investigation 
Next, the combined TPP results from the four SILAC experiments were compared to 
identify proteins with consistent ASAPRatios in multiple experiments that could be used to 
validate both the presence of the proteins in MVs and the relative abundance ratios. Table 5.3 
shows 86 proteins identified in at least 2 out 4 experiments with an average ASAPRatio ≥2.00 
and an average protein probability ≥0.90 also including the ASAPRatio calculated in each 
individual experiment. This list was used to identify proteins that were differentially released 
in MV by the RG/C2 and PRG/C2 cell lines that would be suitable to validate the SILAC 
results. The biological processes, KEGG pathways and cellular components associated with 
these proteins were investigated using FATIGO+. 
The bar chart and table shown in Figure 5.5a shows the top two biological processes 
were also apoptosis and regulation of cell death with the same 12 proteins identified in both. 
The bar chart and table shown in Figure 5.5b show the top two KEGG pathways identified 
were ribosomal pathways and antigen processing and presentation with 8 and 7 associated 
proteins respectively. The table and pie chart shown in Figure 5.5c demonstrate these proteins 
are associated with a variety of cellular components with the top three compartments being 
mitochondria, the cytosol and the endoplasmic reticulum with 16, 15 and 15 associated 
proteins respectively. 
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Table 5. 3 : Potentially interesting proteins suitable for validating the results of the 
SILAC proteomic profile of MV’s secreted by RG/C2 and PRG/C2 cell lines. 
Table to show a list of 86 proteins that were found in at least 2 SILAC experiments with an 
average ASAPRatio >2.00. All the proteins in the list have an average protein probability 
score >0.90. Grey cell = protein not identified in experiment. ASAPRatio of -1 = protein 
identified in experiment but ratio couldn’t be calculated. 
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(a) Biological Processes (GO level 8) 
Biological Function Genes list NºGenes
apoptosis PDIA3 HSPA1A PRDX2 HSPA5 CYCS ALB 
CALR HSPD1 ANXA5 HSPE1 ACTN1 VCP 12
regulation of programmed cell death PDIA3 HSPA1A PRDX2 HSPA5 CYCS ALB 
CALR HSPD1 ANXA5 HSPE1 ACTN1 VCP 12
proton transport ATP5L ATP5A1 ATP1A1 ATP5B ATP5O 5
glucose metabolic process ALDOA UGDH MDH1 MDH2 GPI 5
protein targeting PDIA3 KPNB1 CALR HSPD1 4
purine nucleoside triphosphate biosynthetic process ATP5L ATP5A1 ATP5B ATP5O 4
hexose catabolic process ALDOA MDH1 MDH2 GPI 4
ribonucleoside triphosphate biosynthetic process ATP5L ATP5A1 ATP5B ATP5O 4
purine ribonucleotide biosynthetic process ATP5L ATP5A1 ATP5B ATP5O 4
purine ribonucleoside triphosphate metabolic process ATP5L ATP5A1 ATP5B ATP5O 4
regulation of transcription, DNA-dependent PFN1 STAT3 CALR 3
proteolysis involved in cellular protein catabolic process UCHL3 PSMB2 VCP
3
epidermis development KRT9 KRT10 KRT2 3
transcription from RNA polymerase II promoter PFN1 STAT3 2
ER to Golgi vesicle-mediated transport ARF6 NAPA 2
cortical actin cytoskeleton organization and biogenesis CALR ARF6 2
tricarboxylic acid cycle MDH1 MDH2 2
malate metabolic process MDH1 MDH2 2
potassium ion transport ATP1A1 ATP1B3 2
nuclear import PDIA3 KPNB1 2
sodium ion transport ATP1A1 ATP1B3 2  
 
(b) KEGG pathways 
KEGG Pathway Genes list NºGenes
Ribosome RPS10 RPL38 RPL7 RPS13 RPS15A RPL30 RPS24 RPL18A 8
Antigen processing and presentation PDIA3 HSPA1A HSPA5 HSP90AB1 CALR HSP90AA1 CANX 7
Oxidative phosphorylation ATP5L ATP5A1 COX2 ATP5B ATP5O 5
Regulation of actin cytoskeleton ITGA6 PFN1 GNG12 ACTN1 4
Cell Communication KRT9 ITGA6 KRT10 KRT2 4
Carbon fixation ALDOA MDH1 MDH2 3
MAPK signaling pathway HSPA1A HSPA5 GNG12 3
Prion disease HSPA5 HSPD1 2
Reductive carboxylate cycle (CO2 fixation) MDH1 MDH2 2
Cholera - Infection PDIA4 ARF6 2
Glyoxylate and dicarboxylate metabolism MDH1 MDH2 2
Pyruvate metabolism MDH1 MDH2 2
Citrate cycle (TCA cycle) MDH1 MDH2 2
Pyrimidine metabolism CMPK ENTPD6 2
Glycolysis / Gluconeogenesis ALDOA GPI 2
Starch and sucrose metabolism UGDH GPI 2
Focal adhesion ITGA6 ACTN1 2
Pentose phosphate pathway ALDOA GPI 2  
 
 
Chapter 5                                                     Results 
212 
(c) Cellular Components (GO level 8) 
Cellular Component Genes list NºGenes
mitochondrion ATP5L C1QBP HSPA1A ATP5A1 ECH1 SLC25A4 COX2 CYCS 
HSP90AB1 HSPD1 CKMT1A MDH2 ATP5B ATP5O MGST1 HSPE1 16
cytosol RPS10 HSPA5 RPL7 CYCS CALR RPS13 MDH1 HSP90AA1 CCT5 
RPS15A PSMB2 HBA1 RPS24 RPL18A VCP 15
endoplasmic reticulum HYOU1 PDIA3 HSPA1A PPIB PDIA4 HSPA5 DPEP1 CALR DDOST 
ERP29 CANX NAPA MGST1 PRKCSH VCP 15
nucleus PFN1 HSPA1A KPNB1 STAT3 HSPA5 CYCS CMPK SH3BGRL2 
PSMB2 PREP VCP 11
organelle membrane ATP5A1 KPNB1 SLC25A4 HSPA5 COX2 CYCS DDOST ATP5B 
ATP5O MGST1 10
ribosome RPS10 RPL38 RPL7 RPS13 RPS15A RPL30 RPS24 RPL18A 8
organelle envelope ATP5A1 KPNB1 SLC25A4 COX2 CYCS ATP5B ATP5O MGST1 8
cytoskeleton KRT9 PFN1 KRT10 WDR1 KRT2 ACTN1 6
integral to plasma 
membrane
ITGA6 CEACAM5 SLC25A4 GPR109B ATP1A1 ATP1B3
6  
 
organelle envelope, 8
cytoskeleton, 6
others, 27
integral to plasma 
membrane, 6
mitochondrion, 16
cytosol, 15
endoplasmic 
reticulum, 15
nucleus, 11
organelle membrane, 
10
ribosome, 8
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Figure 5. 5 : Analysis potentially interesting proteins with an average ASAPRatio ≥2.00 
using software commonly used in microarray analysis, Babelomics. 
The accession numbers for the potentially interesting proteins identified that could be 
candidates for validating the SILAC data were converted to gene names using online software 
called REFDIC. The gene names were then used to investigate which biological processes, 
cellular components and pathways these proteins are involved in Babelomics. (a) A table to 
show the biological processes with ≥2 proteins identified in this survey. The Table identifies 
the gene symbols of the proteins involved in each biological process. (b) A table to show the 
KEGG pathways with ≥2 proteins identified in this survey. The Table identifies the gene 
symbols of the proteins involved in each pathway. (c) Pie chart to show the number of 
proteins that are localized to various cellular compartments. The Table identifies the gene 
symbols of the proteins found in each cellular component. 
 
 
 
 
 
 
 
Chapter 5                                                     Results 
214 
5.6 Comparison with Previously Reported Secreted Protein Studies 
Many proteomic profiling surveys of secreted proteins from various cancer cell lines 
have already been published but not many have compared the proteins secreted during early 
stage tumour progression. A literature search was performed in Pubmed for proteomic surveys 
to build a list of identified secreted proteins from various cancer cell lines to compare with all 
the proteins identified in this survey. Eight proteomic surveys of secreted proteins from 
pancreatic, breast, prostate, melanoma and osteosarcoma cell lines and one survey of proteins 
secreted in MVs from the HT29 cell line (human colorectal cancer cell line) were all used for 
this comparison. The venn diagram shown in Figure 5.6 shows the comparison of proteins in 
the first eight proteomic surveys (A) with those identified in MVs from  the HT29 cell line 
(B) and the proteins identified in at least 2 out of 4 experiments in this study (C) (see Figure 
5.6 for references). Supplementary Table 5c shows the 243 proteins out 564 proteins 
identified in this survey also previously been identified in the proteomic surveys outlined in A 
and B. Supplementary Table 5h shows the 101 proteins identified in both this survey and 
those identified in MVs from HT29 (Choi et al., 2007) and Supplementary Table 5i lists the 
proteins that were unique to this study. 
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Figure 5. 6 : Comparison of proteins identified in RG/C2 and PRG/C2 SILAC proteomic 
profile with other similar studies to identify secreted proteins in CM derived from 
various cell lines.  
The data generated in this SILAC study of MV’s was compared to previously reported 
proteomic profiles of CM: A) Proteins identified in other secreted proteins proteomic surverys 
(Gronborg et al., 2006, Kulasingam and Diamandis, 2007, Mbeunkui et al., 2006, Mbeunkui 
et al., 2007, Mears et al., 2004, Ratajczak et al., 2006b, Sardana et al., 2008, C. C. Wu et al., 
2008); B) Proteins identified in proteomic study of MV’s derived from HT29 cell line (Choi 
et al., 2007); C) Proteins identified in MV’s derived from RG/C2 and PRG/C2 cell lines 
generated in this study. 
A 
3209 
proteins 
B 
429 proteins 
C 
564 proteins 
2874 205 
321 
122 
72 
141 30 
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5.7 Conclusions 
The aim of this chapter was to identify proteins released in MV by colorectal cancer cells and 
to also identify differentially secreted proteins which could have the potential to act as 
markers of early tumour progression using SILAC. The RG/C2 cell line was cultured in media 
containing either ‘heavy’ Arg or Lys and the PRG/C2 cell line was cultured in ‘light’ Arg and 
Lys for approximately 6 doublings. Figure 5.1 shows that the labeling efficiency of the 
technique was approx 97%. The MV fractions collected from both cell lines in experiment 
C13 ARG-A were then mixed 1:1 and the proteins were separated by 1D gel electrophoresis 
followed by in-gel digestion and LC MS/MS analysis. The results were analysed and filtered 
using the multiple thresholds filter parameters optimised in Chapter 4 using Bioworks 
Browser. Supplementary Table 5a shows there were 485 proteins with at least 2 unique 
peptides identified with an FDR of 0.00089 which was very similar to the test dataset used in 
Chapter 4. The Xpress function in Bioworks Browser calculates the relative abundance ratio 
from the area under the co-eluting ‘light’ and ‘heavy’ peaks. Figure 5.3 and Table 5.1 
demonstrate that Xpress can sometimes yield misleading ratio values by using the wrong 
peaks to calculate the area under the peak. The ratios can be calculated manually but this is 
time consuming and requires a level of expertise and familiarity with the software 
highlighting the need for accurate and automated software to analyse the SILAC data. TPP 
was used to analyse all four SILAC experiments and the table in Figure 5.4a shows that a 
similar FDR could be achieved using a threshold of protein probability ≥0.90. The results 
from all four experiments were then compared using a threshold of protein probability ≥0.70. 
Table 5.2 shows there were 1396 proteins identified in total with 136, 252, 561 and 1396 
proteins identified in 4, 3, 2 and 1 experiment and 86 proteins were found in multiple 
experiments with a consistent calculated ASAPRatio that would be potentially interesting to 
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investigate further (Table 5.3). The proteins identified in at least 2 out of 4 experiments (561 
proteins) were compared to other proteomic surveys of secreted proteins from various cancer 
cell lines and one survey of MV from another colorectal cancer cell line, HT29. There were 
101 proteins previously reported to be secreted in MV by cancer cell lines, these are listed in 
Supplementary Table 5h. In total there were 243 proteins previously reported and 321 
proteins previously unreported (Supplementary Table 5i). 
In order to investigate whether the proteins secreted in MV were involved in a 
particular pathway or have a common biological function, the IPI accession numbers were 
converted to gene symbols using REFDIC which were then analysed using FATIGO+. This 
analysis showed the two top biological processes were apoptosis and regulation of cell death 
for both the list of all proteins identified in at least two experiments and the list of potentially 
interesting proteins (Figures 5.5 and 5.6 respectively). The development of tumours is 
normally avoided by various mechanisms that trigger apoptosis in response to cellular 
stresses. Many cancer cells favour inhibition or inactivation of various key components of 
apoptosis to avoid cell death and allow proliferation. Many anti-apoptotic alterations in 
human tumour cells have previously been shown (Meijerink et al., 1998, Rampino et al., 
1997, Reed, 1998, Wallace-Brodeur and Lowe, 1999, Yonish-Rouach et al., 1991) and the 
results shown here indicates a number of proteins identified in this survey are involved in 
apoptosis and the regulation of cell death to ensure the survival of not just the cancer cells 
themselves but also the other types of cells found within the tumour microenevironment.  
The FATIGO+ analysis also showed that the proteins identified in this survey 
originate from a variety of cellular components. It also showed that the top two KEGG 
pathways for all proteins identified in multiple experiments were regulation of actin 
cytoskeleton and ribososmal pathways. The top two KEGG pathways associated with the list 
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of potentially interesting proteins was antigen processing and presentation and also ribosomal 
pathways. All these processes and pathways have been reported to play roles in tumour 
progression.  
Cell migration and invasion are important steps in metastasis of cancer cells to distant 
sites to occur. They are triggered by a number of chemoattractants binding to cell surface 
receptors to stimulate intracellular signalling pathways that regulate the re-organisation of the 
actin cytoskeleton. Many proteins involved in this process have been linked invasive and 
metastatic cancer cells (Olson and Sahai, 2009, Yamaguchi and Condeelis, 2007).  
Cancer cells are undergoing uncontrolled growth and proliferation and requires 
increased production of ribosomes for protein translation, this could explain the elevation of 
ribosomal proteins in this study . Whether this effect is a side effect of cancer cell 
transformation or directly involved in tumourigenesis to cause transformation is poorly 
understood but mutations in individual ribosomal protein genes have been partially correlated 
with an increased risk of cancer (Dai and Lu, 2008, Warner and McIntosh, 2009). 
Cancer cells are transformed normal cells that are undergoing uncontrolled growth and 
proliferation and evidence has shown that the immune response to tumour antigens is very 
similar to those of ‘self’ antigens. With increasing knowledge of the steps involved in tumour 
progression and the features that distinguish cancer cells from normal cells there is evidence 
evidence to show how the immune system reacts to the changes occurring within the cell 
(Hijikata et al., 2007). 
The results described in this chapter indicate that elevated levels of proteins involved 
in the regulation of the actin cytoskeleton, apoptosis and regulation of cell death and 
ribosomal proteins are secreted in MVs from colorectal cancer cell lines could play a role in 
early tumour progression. 
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Chapter 6 : Validation of selected proteins identified in the SILAC profile of MV 
released by colorectal cancer cell lines during early tumour progression 
 
6.1 Introduction 
In Chapter 5, SILAC was used to investigate proteins that were differentially secreted 
in MVs from a colorectal cancer cell model of early tumour progression to identify proteins 
that could be potential markers for early stage CRC. Table 5.3 lists 86 proteins that were 
shown to be differentially secreted in MV’s released form the RG/C2 and PRG/C2 cell lines. 
Six proteins were selected from this list to validate the SILAC results using Western blotting: 
Anterior Gradient Homolog 2 (AGR2); Olfactomedin 4 (OLFM4); Selenium-Binding protein 
1 (SBP1); Heat Shock protein 90 alpha (HSP90α), Heat Shock protein 90 beta (HSP90β) and 
Carcinoembryonic antigen-related cell adhesion 5 (CEACAM5). There were also three 
proteins selected from supplementary Table 5b with an average ASAPRatio of 1.00 to use as 
control validations. These were Tumour Associated Calcium Signal Transducer 1 precursor 
(TACSTD1) (also known as Epithelial Cell Adhesion molecule, EpCAM), Isoform 1 of Heat 
Shock Cognate 71 kDa protein (HSC70) and Annexin A1. The criteria for the selection of 
proteins were as follows: proteins identified in multiple experiments with relatively consistent 
ASAPRatios; proteins with an average protein probability score greater than 0.90; proteins 
with multiple peptides identified in each of the experiments; validation proteins with an 
average ASAPRatio >1.50 (except control proteins that required an average ASAPRatio 
~1.00); and proteins with readily available antibodies were selected for validation by Western 
blotting. Tables 6.1a and 6.1b summarises the average protein probability, average 
ASAPRatio and the ASAPRatios calculated in each experiment for all nine proteins described 
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(a) 
Average C13 ARG C13 LYS
Protein Name Accession Prot ASAPRatio ASAPRatio
Number Prob ASAPRatio A B A B
Carcinoenbryonic Antigen-related Cell 
Adhesion molecule 5 precursor CEACAM5) IPI00027486 1.00 2.74 3.88 1.6
Anterior Gradient homolog 2 (AGR2) IPI00007427 0.99 3.40 2.07 3.19 3.27 5.08
Olfactomedin 4 precursor (OLFM4) IPI00022255 1.00 3.81 2.77 4.84
Selenium Binding Protein 1 (SBP1) IPI00745729 1.00 1.86 1.9 0.69 2.44 2.41
Heat Shock Protein HSP 90-alpha (HSP90α) IPI00784295 1.00 3.08 2.55 5.11 2.23 2.43
Heat Shock Protein HSP 90-beta (HSP90β) IPI00414676 1.00 2.31 2.05 1.63 2.92 2.65  
 
(b) 
Average C13 ARG C13 LYS
Protein Name Accession Prot ASAPRatio ASAPRatio
Number Prob ASAPRatio A B A B
Tumour-Associated Calcium Signal Transducer 
1 precursor (TACSTD1) IPI00296215 1.00 1.44 1.85 1.54 0.94
Isoform 1 of Heat Shock Cognate 71 kDa 
Protein (HSC70) IPI0000386 1.00 1.29 1.23 1.17 1.23 1.54
Annexin A1 IPI00218918 1.00 1.18 0.96 1.55 1.04  
 
 
Table 6. 1 : Proteins chosen to validate ASAPRatios calculated by TPP. 
Table 6.1 shows the average protein ratio, average protein probability and ASAPRatios for 
each of the 4 SILAC experiments. Table (a) shows 6 proteins with an increased secretion in 
MV’s from PRG/C2 compared to RG/C2. Table (b) shows 3 proteins identified with a 1:1 
ratio. The grey boxes indicate the protein was identified but ASAPRatio could not be 
calculated. The black boxes indicate the protein was not identified. 
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above. These proteins were all used to validate the results of the SILAC experiments by 
Western blotting. CM was collected from cells grown under identical conditions to the SILAC 
experiment using unlabeled media supplemented with dialysed FBS. MV and REM CM 
fractions were prepared as previously described and Western blotting was used to confirm the 
presence of all eight proteins in an attempt to confirm the differential secretion of the six 
proteins mentioned above. MV fractions were prepared in biological triplicate and Western 
blot analysis for each of the proteins was performed for each experiment using the antibodies 
outlined in Table 2.2a. For each Western blot, 20μg of the total protein for both the MV and 
REM CM fractions was loaded onto the protein gel. 
6.2 Tumour Associated Calcium Signal Transducer 1 precursor (TACSTD1), Isoform 1 
of Heat Shock Cognate 71 kDa protein (HSC70) and Annexin A1 
Figure 6.1 shows the Western blots for the three proteins chosen as controls in MV 
and REM CM fractions collected from the RG/C2 and PRG/2 cell lines. Supplementary Table 
6a shows the TPP results for these proteins. HSC70 was detected by MS in all four SILAC 
experiments with ASAPRatios of 1.23, 1.17, 1.23 and 1.54 (average 1.29) with an average 
protein probability score of 1.00 (see Table 6.1b). Also, as shown in Supplementary Figure 
6a, the peptides identified in HSC70 spanned the whole amino acid sequence suggesting that 
full length protein was secreted in MVs. Figure 6.1a shows that HSC70 (64kDa) could be 
detected to varying degrees in the MV and REM CM fractions in all of the triplicate 
experiments. The densitometry results shown in Figure 6.1b demonstrate a 1.04, 0.62 and 0.75 
fold increase in MV’s from the PRG/C2 cell line with an average of 0.80 compared to an 
ASAPRatio of 1.29. 
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Figure 6. 1 : Confirmation of the presence of 3 proteins with an ASAPRatio of 1.00 using 
Western Blot analysis. 
Western blot analysis was used to confirm the presence of three proteins with an ASAPRatio 
of 1.00 in MV’s and the remaining CM (after MV removal) from RG/C2 and PRG/C2 cells 
(5x106 cells) grown in identical conditions to those used in the SILAC experiments. Fig (a) 
shows the Western blot results for TACSTD1, HSC70, Annexin A1. Fig (b) shows the 
densitometry results of the Western blots (shown in a) using a GS-800 calibrated densitometer 
(BIO-RAD) with fold change in PRG/C2 represented as a bar chart (A, B and C represent 
biological replicates). (c) Graph to show the combined results of the ASAPRatios from the 
SILAC experiments compared to the densitometry results from the Western blot validation 
experiments for the control proteins. 
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TACSTD1 was detected by MS in all four SILAC experiments with ASAPRatios 
calculated in three of them of 1.85, 1.54 and 0.94 (average 1.44) and an average protein 
probability score of 1.00 (see Table 6.1b). Also, as shown in Supplementary Figure 6b, the 
peptides identified in TACSTD1 spanned the whole amino acid sequence suggesting that full 
length protein was secreted in MVs. Figure 6.1a also shows that a single band for TACSTD1 
(39kDa) was detected in the MV fractions of both cell lines in each of the biological 
triplicates with no bands detected in the REM CM fraction. This suggests that TACSTD1 is 
primarily found in MV’s from both cell lines. The densitometry results also show a 1.42 a 
fold increase in the PRG/C2 in one of the experiments and a decrease in secretion in 2 
experiments (0.94 and 0.64 fold). This gives an average fold change in band density of 1.00 
compared to an average ASAPRatio of 1.44 as shown in Figure 6.1c. 
Annexin A1 was detected by MS in all four SILAC experiments with ASAPRatios 
calculated for three experiments as 0.96, 1.55 and 1.04 (average 1.18) and the average protein 
probability score of 1.00 (see Table 6.1b). Also, as shown in Supplementary Figure 6c, the 
peptides identified in Annexin A1 spanned the whole amino acid sequence suggesting that full 
length protein was secreted in MVs. Figure 6.1a shows that the third control protein, Annexin 
A1 (39kDa) could not be detected by Western blot analysis in any of the biological triplicate 
experiments rabbit polyclonal AbCam antibody (ab33061) described in Table 2.2. 
6.3 Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) 
As described in Chapter 3, EMMPRIN have been shown to be secreted in MV’s and is 
thought to play an important role in tumorigenesis which was used as a positive control for 
MV preparation. Therefore, Western blot analysis for EMMPRIN was performed for each of 
the biological triplicate experiments prepared for this Chapter. Figure 6.2 shows that full 
length EMMPRIN (55kDa) could be detected in both the MV and REM CM fractions  
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Figure 6. 2 : Confirmation of the presence of EMMPRIN in MV’s prepared to validate 
the SILAC results. 
Western blot analysis was used to confirm the presence of EMMPRIN in MV’s and the 
remaining CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in 
identical conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) 
shows the densitometry results of the blots using a GS-800 calibrated densitometer (BIO-
RAD).  A, B and C represent biological replicates. 
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although the bands are more intense in the MV fractions in each of the triplicate experiments. 
The densitometry results shown in Figure 6.2b show there was a 1.00, 1.37 and 1.28 fold 
increase in the MV fraction in the PRG/C2 cell line with an average increase of 1.22. The 
Western blot analysis for EMMPRIN demonstrates its presence in the MVs prepared in this 
study but could not be detected by MS in the SILAC experiments. This could be because it is 
present a too low a level to be detected in these samples without further fractionation. 
6.4 Carcinoembryonic antigen-related cell adhesion 5 (CEACAM5) 
CEA is the protein product for the Carcinoembryonic antigen-related cell adhesion 5 
(CEACAM5 or CD66e) gene. CEA is a ~200kDa highly glycosylated protein that was first 
discovered in tissue extracts from CRC patients by Gold and Freedman in 1965 who then later 
discovered it’s presence in serum from CRC patients (Gold and Freedman, 1965a, Thomson 
et al., 1969). However, CEA has since been shown to be overexpressed in other cancer types 
such as pancreatic, liver, lung, breast, ovarian, bladder and prostate (Chan and Stanners, 
2007). CEA already has limited uses as a biomarker for CRC in the clinic (see Section 1.1). 
The function of CEA is not yet fully understood but it has been demonstrated that it can act as 
homophilic and heterophilic cell adhesion molecules when expressed on the tumour cell 
surface (Benchimol et al., 1989). It has also been suggested that CEA could play an important 
role in protecting the colonic mucosa from microbial invasion (Hammarstrom, 1999). 
CEACAM5 was detected by MS in all four SILAC experiments with ASAPRatios 
calcluted in two of them as 1.66 and 3.88 (average 2.74) and an average protein probability 
score of 1.00 (see Table 6.1a). Although the ASAPRatios were not similar in both 
experiments, they both showed an increase in MVs released by the PRG/C2 cell line. Also, 
CEA (the protein product of the CEACAM5) is a currently used biomarker for CRC and it 
was therefore encouraging to detect it by MS in this study. Supplementary Figure 6d shows 
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Figure 6. 3 : Confirmation of the presence of CEACAM5 in MV’s prepared to validate 
the SILAC results. 
Western blot analysis was used to confirm the presence of CEACAM5 in MV’s and the 
remaining CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in 
identical conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) 
shows the densitometry results of the blots using a GS-800 calibrated densitometer (BIO-
RAD). A, B and C represent biological replicates. 
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that the peptides identified spanned the whole amino acid sequence suggesting that full 
length CEA was secreted in MVs. Supplementary Table 6b shows the results of the TPP 
analysis for CEACAM5. The Western blot analysis shown in Figure 6.3a demonstrated the 
presence of full length CEA (~200kDa) in both the MV and REM CM fractions in each of 
the triplicate experiments. The densitometry results shown in Figure 6.3b demonstrate a 1.81, 
1.33 and a 0.94 fold increase in CEA release in the MV fraction from the PRG/C2 cell line 
with an average fold increase of 1.37. 
6.5 Anterior Gradient Homolog 2 protein (AGR2) 
Anterior Gradient Homolog 2 protein (AGR2) (also known as hAG-2), is the 20kDa 
human orthologue of the Xenopus laevis AGR protein XAG-2 in which it plays a role in 
development (Thompson and Weigel, 1998). Its function in humans is unclear however, it 
has been shown to attenuate p53 activation when over-expressed in UV-damaged cancer cells 
leading to the suggestion it plays a role in survival (Pohler et al., 2004).  AGR2 has also been 
shown to enhance adhesion and metastatic potential in rat mammary cells when over-
expressed (Liu et al., 2005). It has also recently been suggested to be essential in the 
production of intestinal mucus (Park et al., 2009). AGR2 expression has been detected in 
breast, prostate and lung cancers and also has been suggested as a potential marker for the 
presence of circulating tumour cells in the blood of patients with metastatic disease (Fletcher 
et al., 2003, Smirnov et al., 2005, Thompson and Weigel, 1998, Zhang et al., 2005b, Zhu et 
al., 2007). AGR2 was also identified as a secreted protein in CM collected from prostate and 
breast cancer cell lines in the proteomic studies referred to in Supplementary Table 5c 
(Kulasingam and Diamandis, 2007, Sardana et al., 2008). 
AGR2 was detected by MS in all four SILAC experiments with ASAPRatios of 2.07, 
3.19, 3.27 and 5.08 (average 3.40) and an average protein probability score of 0.99 (see Table 
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6.1a). Also, as shown in Supplementary Figure 6e, the peptides identified in AGR2 spanned 
the whole amino acid sequence suggesting that full length protein was secreted in MVs. The 
Western blot analysis shown in Figure 6.4a demonstrated the presence of full length AGR2 
(~20kDa) in both the MV and REM CM fractions in each of the triplicate experiments 
although it was predominantly present in the REM CM fraction. The densitometry results 
shown in Figure 6.4b demonstrate a 2.04, 5.45 and a 2.44 fold increase in AGR2 release in the 
MV fraction from the PRG/C2 cell line with an average fold increase of 3.31. The fold change 
observed in the densitometry results are lower than those calculated in the SILAC 
experiments however, an increase ≥2.00 is observed in all experiments and the average ratios 
are similar. Therefore AGR2 shows potential as a protein that is differentially secreted in 
MVs in early tumour progression. 
6.4 Olfactomedin 4 (OLFM4) 
Olfactomedin 4 (OLFM4) (also known as hCG-1 and GW112) is 57kDa glycosylated 
protein which was originally cloned from human myeloblasts and found to be selectively 
expressed in inflamed colonic epithelium (Zhang et al., 2002). Compared to normal tissue 
samples, OLFM4 mRNA has been shown to be elevated 90%, 69% and 85% in colon, breast 
and lung cancer tissues respectively (Koshida et al., 2007). The function of OLFM4 is still 
unknown. However, several studies have suggested possible roles in proliferation and 
apoptosis and also as a marker of colon adenocarcinomas with cancer stem cell properties 
which are thought to act as tumour-initiating cells (Kobayashi et al., 2007, van der Flier et al., 
2009, Zhang et al., 2004). 
OLFM4 was detected by MS in two out of the four SILAC experiments with 
ASAPRatios of 2.77 and 4.84 (average 3.81) and an average protein probability score of 1.00 
(see Table 6.1a). Also, as shown in Supplementary Figure 6f, the peptides identified in
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Figure 6. 4 : Confirmation of the presence of AGR2 in MV’s prepared to validate the 
SILAC results. 
Western blot analysis was used to confirm the presence of AGR2 in MV’s and the remaining 
CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in identical 
conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) shows the 
densitometry results of the blots using a GS-800 calibrated densitometer (BIO-RAD). A, B 
and C represent biological replicates. 
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OLFM4 spanned the whole amino acid sequence suggesting that full length protein was 
secreted in MVs. The Western blot analysis shown in Figure 6.5a demonstrated the presence 
of OLFM4 (~57kDa) in both the MV and REM CM fractions in each of the triplicate 
experiments although it was predominantly present in the REM CM fraction. The 
densitometry results shown in Figure 6.5b demonstrate a 1.67, 3.15 and a 1.96 fold increase in 
OLFM4 release in the MV fraction from the PRG/C2 cell line with an average fold increase 
of 2.26. The ASAPRatios calculated for OLFM4 in the SILAC experiments showed a high 
degree of variability with the ratio in the second experiment being double that calculated in 
the first experiment. The densitometry results from the Western blot analysis also showed a 
high degree of variability in the extent of the increase. However, the ratios in both cases are 
all increased and therefore OLFM4 warrants further investigation. 
6.6 Selenium-binding Protein 1 (SBP1) 
SBP1 is a 55kDa protein that belongs to the selenium-binding protein family and is the 
protein product of the SELENBP1 gene. Selenium has been suggested to play a role in 
preventing cancer and selenium deficiency has been linked to cancer (Russo et al., 1997). 
Decreased protein levels of SBP1 have been demonstrated in thyroid, CRC and ovarian 
cancer tumour tissue compared to normal tissue (Brown et al., 2006, Huang et al., 2006a, H. 
Kim et al., 2006). It has also been demonstrated that CRC patients exhibiting low levels of 
SELENBP1 expression had significantly lower overall survival rates and that this suppression 
of SELENBP1 activity is a late event in colorectal carcinogenesis and could contribute to 
rapid progression of CRC (Kim et al., 2006). SBP1 was also identified as a secreted protein in 
CM collected from a prostate cancer cell line in the proteomic studies referred to in 
Supplementary Table 5c (Sardana et al., 2008). 
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Figure 6. 5 : Confirmation of the presence of OLFM4 in MV’s prepared to validate the 
SILAC results. 
Western blot analysis was used to confirm the presence of OLFM4 in MV’s and the remaining 
CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in identical 
conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) shows the 
densitometry results of the blots using a GS-800 calibrated densitometer (BIO-RAD). A, B 
and C represent biological replicates. 
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Figure 6. 6 : Confirmation of the presence of SBP1 in MV’s prepared to validate the 
SILAC results. 
Western blot analysis was used to confirm the presence of SBP1 in MV’s and the remaining 
CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in identical 
conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) shows the 
densitometry results of the blots using a GS-800 calibrated densitometer (BIO-RAD). A, B 
and C represent biological replicates. 
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SBP1 was detected by MS in all four SILAC experiments with ASAPRatios of 1.90, 
0.69, 2.44 and 2.41 (average 1.86) and an average protein probability score of 1.00 (see Table 
6.1a). Also, as shown in Supplementary Figure 6g, the peptides identified in SBP1 spanned 
the whole amino acid sequence suggesting that full length protein was secreted in MVs. The 
Western blot analysis shown in Figure 6.6a demonstrated the presence of SBP1 (~55kDa) in 
both the MV and REM CM fractions in each of the triplicate experiments and was 
predominantly present in different fractions in each. The densitometry results shown in Figure 
6.6b demonstrate a 0.73, 3.56 and a 1.01 fold increase in SBP1 release in the MV fraction 
from the PRG/C2 cell line with an average fold increase of 1.77. 
The ASAPRatios calculated for SBP1 in the SILAC experiments showed a high 
degree of variability in all four experiments ranging from a decrease in one experiment and 
increase in fold change in three experiments.The densitometry results for the Western blots 
also showed variability a decrease in one experiment and an increase and no change in the 
following two experiments. Due to the high degree of variability, SBP1 may not warrant 
further investigation. 
6.6 Heat Shock Protein 90α and Heat Shock Protein 90β (HSP90α and HSP90β) 
Heat shock proteins (HSPs) were originally identified because of their increased 
expression in response to cellular stress such as elevated temperature, heavy metals and 
oxidative stress. They are organised into families according to the molecular weight, such as 
HSP100, HSP90, HSP70, HSP60 etc. Some HSPs act as molecular chaperones which 
facilitate re-folding of proteins when they become damaged or target them for degradation if 
the damage is irreparable (Powers and Workman, 2007). HSP90 is an abundant molecular 
chaperone and accounts for 1-2% of total protein content. It functions to ensure the correct 
conformation, activity, intra-cellular localisation and proteolytic turnover of various proteins 
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involved in cell growth, differentiation and survival (Powers and Workman, 2006, Whitesell 
and Lindquist, 2005).  
HSP90 is currently being investigated as a therapeutic target for the treatment of 
cancer as it is essential for the stability and function of many oncogenic client proteins 
(Powers and Workman, 2007). These client proteins include: receptor tyrosine kinases such as 
ErbB2/HER-2 and KIT; signalling molecules such as AKT and MET; transcription factors 
such as HIF-1α and ERα-receptors; and others proteins involved in cancer such as BCR-ABL, 
Bcl-2 and MMP2 (Sharp and Workman, 2006). HSP90 inhibition results in degradation of 
client proteins causing a down-regulation in their function affecting many aspects of the 
malignant phenotype therefore, HSP90 inhibitors could potentially be used in the treatment of 
cancer and are currently being investigated in various clinical trials (Powers and Workman, 
2007). 
HSP90α was also identified as a secreted protein in CM collected from various cancer 
cell lines such as breast, prostate, ovarian and bladder as well as MVs from the colorectal 
cancer cell line HT29 in the proteomic studies referred to in Supplementary Table 5c (Choi et 
al., 2007, Kulasingam and Diamandis, 2007, Sardana et al., 2008, Wu et al., 2008). HSP90β 
was also identified as a secreted protein in CM collected from a leukaemia cell line well as 
MVs from the colorectal cancer cell line HT29 in the proteomic studies referred to in 
Supplementary Table 5c (Choi et al., 2007, Wu et al., 2008). 
There are currently five isoforms of HSP90 described. The two major isoforms are 
HSP90α and HSP90β which share 85% sequence homology at the protein level and are both 
cytoplasmic. The other three isoforms are GRP94, TRAP1 and HSP90N. 
HSP90α was detected by MS in all four SILAC experiments with ASAPRatios of 
2.50, 5.11, 2.23 and 2.43 (average 3.08) and an average protein probability score of 1.00 (see 
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Table 6.1a). Also, as shown in Supplementary Figure 6h, the peptides identified in HSP90α 
spanned the whole amino acid sequence suggesting that full length protein was secreted in 
MVs. The Western blot analysis shown in Figure 6.7a demonstrated the presence of HSP90α 
(~97kDa) in both the MV and REM CM fractions in each of the triplicate experiments. The 
densitometry results shown in Figure 6.7b demonstrate a 0.98, 2.09 and a 1.58 fold increase in 
HSP90α release in the MV fraction from the PRG/C2 cell line with an average fold increase 
of 1.55. The ASAPRatios observed for HSP90α in the SILAC experiments were fairly 
consistent with three out four experiments showing an abundance ratio between 2.23 and 
2.50. However, the densitometry results for the Western Blots showed a higher degree of 
variability with a smaller increase in two experiments and no change in the third. Although 
the great potential shown by the ASAPRatios in the SILAC experiments was not reflected in 
the Western blot analysis, HSP90α could warrant further investigation. 
HSP90β was detected by MS in all four SILAC experiments with ASAPRatios of 
2.05, 1.63, 2.92 and 2.65 (average 2.31) and an average protein probability score of 1.00 (see 
Table 6.1a). Also, as shown in Supplementary Figure 6i, the peptides identified in HSP90β 
spanned the whole amino acid sequence suggesting that full length protein was secreted in 
MVs. The Western blot analysis shown in Figure 6.8a demonstrated the presence of HSP90β 
(~97kDa) in both the MV and REM CM fractions in each of the triplicate experiments. The 
densitometry results shown in Figure 6.8b demonstrate a 1.51, 1.04 and a 0.97 fold increase in 
HSP90β release in the MV fraction from the PRG/C2 cell line with an average fold increase 
of 1.17. 
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Figure 6. 7 : Confirmation of the presence of HSP90α in MV’s prepared to validate the 
SILAC results. 
Western blot analysis was used to confirm the presence of HSP90α in MV’s and the remaining 
CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in identical 
conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) shows the 
densitometry results of the blots using a GS-800 calibrated densitometer (BIO-RAD). A, B 
and C represent biological replicates. 
 
 
A B C
97kDa
R
G
/C
2
R
G
/C
2
PR
G
/C
2
PR
G
/C
2
MV REM CM
R
G
/C
2
R
G
/C
2
PR
G
/C
2
PR
G
/C
2
MV REM CM
R
G
/C
2
R
G
/C
2
PR
G
/C
2
PR
G
/C
2
MV REM CM
Chapter 6  Results 
239 
(a) 
 
 
 
(b) 
HSP90beta
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
MV REM CM MV REM CM MV REM CM
A B C
Fo
ld
 C
ha
ng
e
RG/C2 PRG/C2
 
Adj volume 8.24 12.42 27.59 9.56 4.10 4.25 8.71 10.24 8.92 8.62 2.26 0.97
Fold change 1.00 1.51 1.00 0.35 1.00 1.04 1.00 1.18 1.00 0.97 1.00 0.43  
Figure 6. 8 : Confirmation of the presence of HSP90β in MV’s prepared to validate the 
SILAC results. 
Western blot analysis was used to confirm the presence of HSP90β in MV’s and the remaining 
CM (after MV preparation) from RG/C2 and PRG/C2 (5x106 cells) grown in identical 
conditions used in the SILAC experiments. Fig (a) shows the Western blots. Fig (b) shows the 
densitometry results of the blots using a GS-800 calibrated densitometer (BIO-RAD). A, B 
and C represent biological replicates. 
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6.7 Conclusions 
The aim of this Chapter was to validate the results of the SILAC experiments 
described in Chapter 5 using Western blot analysis. The Western blot results shown here for 
the proteins found to be elevated in the SILAC experiments demonstrate that they are not 
exclusively found in the MV fractions. As previously described in Section 1.8, the contents of 
MVs can be released shortly after secretion from the cell as demonstrated by Sidhu et al 
(Sidhu et al., 2004). The MV fractions collected in this study were collected after 24hr 
incubation. Figure 6.2a shows that EMMPRIN was predominantly present in the MV however 
all other proteins were found in both MV and REM CM fractions. This could be due to the 
incubation time for the MV collection used in these experiments.  
The Western blot results shown in this chapter also demonstrate the variability 
between biological replicate experiments. All the proteins investigated (apart from Annexin 
A2) were detected by Western blotting confirming their presence thereby supporting the MS 
results from Chapter 5. However, the density of the bands and the abundance ratio between 
the RG/C2 and PRG/C2 cell lines was variable between biological replicate experiments. 
Figure 6.9a demonstrates the average fold change in the Western blot experiments (as 
calculated by densitometry) and the variation between the triplicate experiments. This 
variation between replicate experiments was also observed in the SILAC data described in 
Chapter 5. Figure 6.9b demonstrates the average fold change (ASAPRatio) observed in the 
SILAC experiments compared to the densitometry results. The ASAPRatio values for each of 
the proteins were higher than the fold change values calculated from the densitometry results 
with an average ASAPRatio <1.50 for each of the six proteins. The densitometry results from 
the Western blot analysis demonstrate a >1.50 fold increase in AGR2, OLFM4, SBP1 and 
HSP90α in the PRGC2 cell line however, HSP90β and CEACAM5 demonstrated a <1.50 fold 
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Figure 6. 9 : Summary of results from the Western blot validation experiments and the 
comparison with the ASAPRatio from the SILAC experiments. 
(a) Bar chart to show the average fold change as calculated from the densitometry results 
from the Western blot validation experiments for the 6 proteins chosen to validate the SILAC 
results. (b) Bar chart to show the average ASAPRatio (calculated from all four SILAC 
experiments) compared to the average fold change calculated from the densitometry of the 
Western blot validation experiments.  
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increase. Considering the results of the SILAC experiments and the validation Western blot 
analysis, the proteins that showed the most potential that would warrant further investigation 
are AGR2, OLFM4, HSP90α and HSP90β. 
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Chapter 7 : Discussion 
7.1 Conclusions and Discussion 
Colorectal cancer (CRC) is the third most common cancer and the second most 
common cause of cancer related deaths in the UK (see Section 1.1). As shown in Figure 1.2e, 
the five-year survival rate for CRC if diagnosed at an early stage (i.e Dukes’ stage A) is 83% 
which is much higher than the survival rates if diagnosed at Dukes’ stage D (3%). However, 
only 11% of all CRC cases in the UK are diagnosed at Dukes’ stage A. Unfortunately, none 
of the currently used biomarkers are sufficient for routine screening for the early detection of 
CRC. The aim of this study was to identify potential biomarkers for the early detection of 
CRC using proteomic techniques. A cell model of early tumour progression (i.e. RG/C2 and 
PRG/C2) was used to investigate changes in the secreted protein profile. 
Chapter 3 describes how differentially secreted proteins in CM from both of these cell 
lines were initially investigated using 2DE. The proteins in CM from both cell lines were 
separated by 2D gel electrophoresis. Figure 3.3 illustrates the complexity of the secreted 
protein profile for both cell lines, especially one region of the gel that exhibited intense CBB 
G250 staining representing abundant proteins that demonstrated poor separation. This 
observation was reproducible in biological triplicate experiments and indicated that pre 
fractionation prior to gel electrophoresis would be required. 
The CM was then pre-fractionated by isolating MV from the CM. MV release is 
thought to play an important role in tumour progression and is thought to be a potential 
source of clinically useful biomarkers in the detection and diagnosis of cancer. As described 
in Section 1.5, MVs consist of two main sub-types, larger shedding vesicles and smaller 
exosomes. Shedding vesicles have been shown to contain membrane proteins which are 
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difficult to separate using 2DE. Also, the 2D gels shown Figure 3.3 demonstrate a poor 
reproducibility between biological replicates so therefore MVs were isolated from CM from 
both cell lines and separated using 1D electrophoresis. EMMPRIN is a protein that has 
previously been shown to be released in MVs by Sidhu et al and was used as a marker for 
MV isolation in this study. MVs were isolated from the CM from the RG/C2 and PRGC2 
using the method described by Sidhu et al and Western blot analysis confirmed the presence 
of EMMPRIN predominantly in the MV fraction and also showed an elevated secretion by 
the PRG/C2 cell line (Sidhu et al., 2004). However as described in Chapter 3, EMMPRIN 
could not be identified using MS based proteomics methods although its presence could be 
confirmed in multiple experiments. This could be due to the presence of higher abundance 
proteins that prevent the identification of EMMPRIN peptides. The CBB G250 stained 1D 
gel shown in Figure 3.7 demonstrated that the MV fraction contained distinct bands 
throughout the length of gel and not any regions of the gel with large diffuse bands of 
proteins that may mask the identification of other proteins (as was the case with the 2D gels 
shown in Figure 3.3). 
Based on the results shown in Chapter 3, the next aim was to isolate MV fractions 
from CM from both the RG/C2 and PRG/C2 cell lines and identify differentially secreted 
proteins. This would be achieved by separating the proteins by 1D electrophoresis, digesting 
them with trypsin and analysing the peptides by MS. In Chapter 4, the sensitivity of the LCQ 
Deca XPPLUS was investigated and the data analysis methods were optimized. The sensitivity 
of the instrument was investigated by analysing differing amounts of digested BSA. Table 4.1 
shows that BSA peptides could be detected at ~4 fmoles when the sample was digested in 
solution. This sensitivity was decreased (~250 fmoles) when the samples were first run on a 
1D gel and in-gel digestion was performed. Also, the sensitivities of using a CBB G250 or a 
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silver staining protocol were compared. Figure 4.1a showed that the silver staining protocol 
was more sensitive with the lowest amount of BSA detected as 31.25 fmoles compared to 250 
fmoles for the CBB G250 protocol. However as shown in Figure 4.1b, BSA peptides could 
only be detected by MS in >250 fmoles therefore the CBB G250 staining protocol was used 
in this study as the sensitivity provided by the silver staining would not be required because 
the differences in secretion would be detected by mass spectrometry. 
Next, the data analysis methods were optimized such as choice of database and data 
filter parameters. As described in Chapter 4, the human IPI database proved to be more useful 
for analysing large shotgun proteomic datasets compared to an NCBI database as it required 
less manual interpretation. Also, the optimal filter parameters that would be suitable for this 
type of database were determined as the following: Match = 4; Delta Cn = 0.100; Xcorr = 
1.00; Sp = 350; RSp = 5 and Percent ions = 50%. In the same dataset, these parameters were 
shown to identify more proteins compared to those that were routinely used in our lab 
without increasing the false positive rate. 
The aim of Chapter 5 was to isolate MVs from both the RG/C2 and PRG/C2 cell line 
and identify differentially secreted proteins using SILAC. The results from the initial SILAC 
experiment was analysed using the filter parameters optimized in Chapter 4 and the Xpress 
function in Bioworks Browser was used to calculate the abundance ratio of peptides between 
both experiments. Manual interpretation of the Xpress ratio and the peaks used by the 
software to calculate the ratios found that it could yield misleading results (see Figure 5.3 and 
Table 5.1). Alternative software that could be used to determine the abundance ratios more 
reliably and would not require time consuming manual interpretation needed to be used. The 
software utilized in this study was TPP which was used to analyse four separate SILAC 
experiments. The results for each were filtered using a threshold of protein probability >0.70 
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which yielded FDR values of 0.042-0.017 (4.2 – 1.7% false positive rate). All four 
experiments were then compared and 86 proteins were identified in multiple experiments and 
demonstrated similar ASAPRatios (abundance ratio) in each experiment (listed in Table 5.2). 
The aim of the final Chapter of this study was to validate the SILAC results described 
in Chapter 5 using Western blot analysis. Six proteins were chosen from the listed proteins in 
Table 5.2, these were: CEACAM5; AGR2; OLFM4; SBP1; HSP90α and HSP90β. MV 
fractions were prepared from both cell lines cultured under identical conditions to the SILAC 
experiments in biological triplicate and Western blot analysis was performed for each of 
these proteins alongside three proteins that were shown to have an average ASAPRatio ~1.00 
(i.e. HSC70, TACSTD1 and Annexin A1). The Western blots were able to confirm the 
presence of HSC70, TACSTD1, the positive control protein, EMMPRIN and all six 
validation proteins (see Figures 6.1-6.8). However, Annexin A1 could not be detected by 
Western blot analysis using the AbCam antibody described in Table 2.2a. Densitometry 
performed on all the Western blots confirmed an increase in secretion of the validation 
proteins by the PRG/C2 cell line although these increases were not as pronounced as the 
ASAPRatios calculated by the TPP software from the SILAC experiments (Figure 6.9b). 
The results of the Western blot analysis demonstrate that the proteins chosen for 
validation of the SILAC experiments do show an increase secretion in MVs from the PRG/C2 
cell line. Therefore, these proteins show potential as candidate markers of early tumour 
progression however, further work would be required to show that they are clinically useful. 
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7.2 Future Work 
7.2.1 Further Validation 
As described in Chapter 6, many of the proteins selected for validation were not 
predominantly detected in the MV fraction. Sidhu et al showed that MV can be short lived 
once released from the cells therefore releasing their contents into the surrounding media 
(Sidhu et al., 2004). This could explain why these proteins could also be detected in the REM 
CM fractions. Further time-course experiments would be required to determine whether these 
proteins would be predominantly detected in the MV fraction if shorter incubation times were 
used. Also, it would be interesting to investigate whether these incubation times are different 
for each protein and whether they are secreted in different MVs with different roles. This 
would also involve fractionating the MV fraction to isolate the two main sub types (i.e. 
exosomes and larger shedding vesicles) to determine which type of MV these proteins are 
secreted in. However the aim of this thesis was to discover potential secreted biomarkers for 
the detection of early stage diagnosis of CRC and the origin of these proteins is irrelevant for 
biomarker discovery but would be important for understanding the biology of these proteins 
and their importance in CRC. Also, as shown in Figure 3.7, there are areas of intense CBB 
G250 staining in the REM CM which could be investigated further as a potential source of 
markers. 
Table 5.2 shows 86 proteins that were selected from the SILAC results because they 
were all detected in multiple experiments with ASAPRatios calculated in multiple 
experiments and an ASAPRatio >1.50. Apart from those proteins investigated in Chapter 6, 
these have not yet been investigated further or validated using Western blot analysis. For 
some of these proteins, validation by Western blot analysis may not be possible as antibodies 
are not widely available. This could be resolved by producing antibodies in-house. 
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Alternatively, these results could be validated using another quantitative method by repeating 
these experiments using methods such as iTRAQ (see Section 1.2.4.4) using newer 
technology instruments such as the Thermo linear ion trap/Fourier transform ion cyclotron 
resonance LTQ/FT, Orbitrap mass spectrometers or the Bruker Maxis TOF/TOF to improve 
mass accuracy and resolution. 
7.2.2 Validation in Serum/Plasma 
Once these proteins have been validated further, they need to be investigated in 
serum/plasma samples to demonstrate quantifiable differences in healthy vs disease. This 
could involve performing Western blot analysis in pooled serum/plasma samples from 
healthy, early stage CRC and also in advanced stage disease to investigate whether the 
changes are stage specific. Enzyme-linked immunosorbent assays (ELISA) could also be 
used to compare the presence of specific proteins in panels of serum from healthy control 
patients and patients with early stage CRC. ELISA assays involve detecting a protein of 
interest in a sample using a specific antibody immobilized to a solid support. A second 
detection antibody covalently linked to an enzyme is then incubated with the sample. Then 
after several washes, the assay is developed using an enzyme substrate that is linked to a 
reporter molecule that can be used to produce a signal that can be measured. There are 
ELISA kits commercially available for CEACAM5 and HSP90α however, ELISA assays 
would need to be developed and optimized for AGR2, OLFM2, SBP1 and HSP90β. 
Once each of the single proteins have been validated, they could then be assessed for 
their use as a single biomarker or as part of a panel of biomarkers which could potentially 
increase the sensitivity and specificity. Candidate biomarker validation can be impeded by 
the cost of reagents such as the development of high-quality protein antibody assays which 
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may not be available for novel candidates. A high level of confidence in the candidates is 
required before spending too much time and money on developing an assay. 
One method to overcome this hurdle is Selected Reaction Monitoring or Multiple 
Reaction Monitoring/Stable Isotope Dilution MS (MRM/SID-MS) using ion trap and triple 
quadropole mass spectrometers (Kitteringham et al., 2009). Selected Reaction Monitoring 
(SRM) can be accomplished using triple quadropole mass spectrometers for quantitative 
proteomics. The first and third quadropoles act as filters to specifically select a pre-defined 
narrow m/z range for the precursor and the fragment ion. The second quadropole acts as a 
collision cell to induce fragmentation of the parent ion. These precursor/fragment ion pairs 
are referred to as transitions and are monitored over time to investigate the retention time and 
signal intensity of specific transitions. This mass selection at two levels offers high selectivity 
(Lange et al., 2008). 
SRM can be used to monitor a pre-defined set of proteins in a complex mixture. 
Previous knowledge is required to establish the optimal transitions to use. Firstly, the target 
proteins to be monitored needs to be determined. Secondly, peptides that produce good 
responses and uniquely identify the target protein need to be identified. These are referred to 
as proteotypic peptides or PTPs (Mallick et al., 2007). These assays take time and effort to be 
established but once set up, they can be used on various samples. This could be one method 
used to set up an assay to monitor a single or a panel of multiple biomarkers in a variety of 
samples (Lange et al., 2008). 
One of the main challenges to developing a SRM assays using triple quadropole mass 
spectrometers is finding the best peptides that are sequence specific or unique to that protein 
(i.e. proteotypic) and give sufficient signal intensity without using protein/peptide standards. 
Peptide selection relies upon previous data or computational prediction and candidate lists 
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can be long with the transition list being even longer. Thermo Scientific have developed 
intelligent SRM (iSRM) for use with their triple quadropole instruments (Thermo Scientific 
TSQ Vantage) which is able to quantify and simultaneously confirm the identity of target 
peptides. iSRM involves data-dependant SRM acquisition that monitors primary and 
secondary transitions for peptide sequence confirmation which is only triggered when the 
signal intensities of the primary transitions reach a threshold for a certain number of cycles. 
The target protein list generated from discovery phase experiments is used to generate a 
preliminary list of peptides and their transitions to develop an iSRM method. This method is 
then used to analyse a control sample containing these peptides and only those peptides 
exhibiting good responses are retained in the method whilst those that do not show a good 
response are removed from the method. This ensures that the cycle time is only being used to 
analyse peptides that will produce high quality results. 
MRM/SID-MS is a high throughput method that offers greater sensitivity and 
accuracy than methods used in the discovery phase and has the potential to target 30-100 
candidate markers within the same assay (Rifai et al., 2006). When the appropriate standards 
are used, MRM can provide absolute quantification as well as relative quantification and 
demonstrates a high specificity for the analyte. An ion fragment of interest is isolated in the 
first quad and fragmented by collision with a neutral gas in a collision cell (the second quad) 
and the mass of the resulting product ion is analysed in the third quadropole. Multiple ion-
product transitions can be monitored in a single assay when coupled to a liquid 
chromatographic elution method. SID-MS can increase the reliability of the quantification by 
comparing the signal from an endogenous species with a known concentration of an 
exogenous stable isotope species. This method has been successfully used to measure human 
growth hormone and prostate specific antigen in serum or plasma (Barnidge et al., 2004, S. L. 
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Wu et al., 2002) and also been used to quantify the levels of 53 high-abundance proteins in 
plasma (L. Anderson and Hunter, 2006). To detect lower abundance proteins, depletion of the 
high abundance proteins is required as described in Chapter 1. For those proteins that are at 
too low a level to detect by MRM, stable isotope standards and capture by anti-peptide 
antibodies (SISCAPA) can also be used to capture isotopically labeled and unlabelled target 
peptides to improve sensitivity and specificity (N. L. Anderson et al., 2004). Labeled and 
unlabeled peptides both bind to the antibodies therefore quantification is still possible. 
 
7.2.3 Proteomic Profiling of Whole Cell line 
Many cancer studies have compared datasets from similar studies using the same 
profiling technique but very few cancer studies have integrated the data from multiple data 
sets using different profiling techniques. Gene expression patterns could be compared with 
proteomic profiles to investigate any correlations. These are not necessarily associated with 
protein levels not reflected in the RNA level (S. Hanash, 2003). Comparing the data at the 
protein and RNA level in the same system could improve the understanding of tumour 
function. One such study investigated the gene expression levels in 60 human cancer cell 
lines (NCI-60) and also measured the expression levels of 52 cancer-related proteins in the 
same cell lines (Nishizuka et al., 2003). The study identified two markers that could be useful 
to distinguish colon from ovarian adenocarcinomas and also found that the level of structural 
proteins were highly correlated with the levels of the corresponding mRNAs. The same 
correlation was not observed for non-structural proteins. For this study, a global profile of the 
proteome for both the RG/C2 and the PRG/C2 cell line could be investigated using 
quantitative methods and compared with the gene expression profile for both cell lines. This 
would give a much wider view of the processes and the changes that occur during early 
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tumour progression in colorectal cancer and would provide an alternative approach to 
investigating the secretome. 
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